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1 Abstract 
 
Energy storage and consumption of the healthy human body are well geared to the needs 
under physiological conditions. Any disturbances in this balance can result in metabolic 
diseases such as obesity. A key feature of metabolic disorders is an abnormal lipid profile, 
as characterized by elevated serum triglycerides, elevated low density lipoprotein (LDL) 
cholesterol and reduced high density lipoprotein (HDL) cholesterol. These alterations can 
increase the risk for the development of type 2 diabetes or atherosclerotic cardiovascular 
diseases.  
In this study, the transcriptional co-factor transforming growth factor beta1-stimulated 
clone 22 D1 (TSC22D1) was identified as novel regulator of systemic cholesterol 
metabolism. Acute or chronic knockdown of TSC22D1 in livers of wild-type mice resulted in 
a significant decrease of serum HDL cholesterol and mildly elevated liver cholesterol. These 
changes are caused by a reduced expression of key genes involved in cholesterol efflux such 
as Apolipoprotein A1 (ApoA1), or transporters as ATP binding cassette protein A1 (ABCA1), 
ABCG5 and ABCG8. Interestingly, serum HDL cholesterol could be elevated by 
overexpression of hepatic TSC22D1 in wild type mice.  
Moreover, TSC22D1 expression was found to be differentially regulated in mouse models of 
opposing energy supply. Whereas levels of TSC22D1 transcripts were significantly reduced 
in states of energy wasting as in cancer cachexia, they were increased by energy surplus as 
under obese conditions.  
Along these lines, hepatic TSC22D1 expression was increased in ob/ob mice, which are 
highly resistant to the development of atherosclerosis due to their elevated HDL levels. 
Again, TSC22D1 knockdown significantly lowered serum HDL cholesterol and reduced 
expression of ApoA1, ABCA1, ABCG5 and ABCG8.  
Intriguingly, plasma concentrations of HDL/ApoA1 inversely correlate with the risk for 
atherosclerotic cardiovascular disease in humans. Thus, hepatic TSC22D1 transcription 
factor complex may represent an interesting new target for beneficial manipulation of HDL 
cholesterol levels.  
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2 Zusammenfassung 
 
Energieaufnahme und -verbrauch sind im gesunden menschlichen Körper unter 
physiologischen Bedingungen genau aufeinander abgestimmt. Jegliche Abweichungen von 
dieser Balance können in metabolischen Funktionsstörungen wie Fettleibigkeit resultieren. 
Ein klinisches Hauptmerkmal von metabolischen Erkrankungen sind Störungen im 
Serumlipidprofil, gekennzeichnet durch einen erhöhten Triglyzeridspiegel, erhöhte LDL- 
(low density lipoprotein) und reduzierte HDL-(high density liporotein) Cholesterinwerte. 
Diese Veränderungen sind Risikofaktoren für Typ 2 Diabetes oder atherosklerotische Herz-
Kreislauf-Erkrankungen.  
In dieser Studie wird gezeigt, dass der transkriptionelle Co-Faktor “transforming growth 
factor beta1-stimulated clone 22 D1” (TSC22D1) die Konzentration von zirkulierendem HDL-
Cholesterin reguliert. Akute oder chronische „Knockdown“-Studien mit TSC22D1 in Lebern 
von Wildtypmäusen führten zu einer deutlichen Verringerung des HDL-Cholesterins im Blut. 
Eine Erklärung hierfür bietet die signifikante Reduktion in der Genexpression von 
Schlüsselgenen im Cholesterintransport, wie Apolipoprotein A1 (ApoA1), „ATP binding 
cassette“ Protein A1 (ABCA1), ABCG5 und ABCG8. Im Gegensatz zum „Knockdown“-Effekt 
konnte die hepatische Überexpression von TSC22D1 den HDL-Cholesterinspiegel erhöhen.  
Weiterhin wurde gefunden, dass hepatisches TSC22D1 in Mausmodellen mit 
gegensätzlichem Energiestatus auch konträr exprimiert wird. Während die Expression bei 
Energieverlust, wie bei Krebskachexie, massiv reduziert ist, wird sie bei Energieüberschuss, 
wie bei Übergewicht, verstärkt.  
In diesem Zusammenhang wurde auch eine erhöhte Expression von TSC22D1 in ob/ob 
Mäusen beobachtet, die durch ihre erhöhten HDL-Cholesterinspiegel sehr resistent 
gegenüber Atherosklerose sind. Der leberspezifische „Knockdown“ von TSC22D1 konnte 
auch hier zirkulierendes HDL-Cholesterin verringern und die Expression von ApoA1, ABCA1, 
ABCG5 und ABCG8 reduzieren.  
Interessanterweise korrelieren in humanen Studien die HDL/ApoA1 Serumlevel negativ mit 
dem Risiko für atherosklerotische Herz-Kreislauf-Erkrankungen. Dieser Befund legt den 
Schluss nahe, dass TSC221 ein neues und attraktives therapeutisches Ziel zur Verbesserung 
des HDL-Cholesterinspiegels darstellt.  
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3 Introduction  
3.1 Metabolic homeostasis  
Under normal physiological conditions energy uptake and utilization are well geared to the 
body’s energy needs. This is referred to as metabolic homeostasis. Excessive uptake and 
storage of energy substrates or increased energy wasting can result in metabolic disorders. 
In order to maintain metabolic homeostasis it is crucial to understand the tight regulation 
of underlying molecular mechanisms and know the players which are in involved in keeping 
a healthy balance.  
 
3.2 Metabolic disorders 
3.2.1 Obesity  
In recent years obesity has become a new major health threat in developed as well as in 
developing countries. The World Health Organization (WHO) states that worldwide obesity 
has nearly doubled since 1980 (Fig 1) and the numbers are on the rise (WHO fact sheet No 
311, 2013).  
 
Fig 1: Emerging obesity. Incidence of obesity defined by a body mass index ≥ 30 in 1990 and most 
recent (2012). 
(Generated from global database on body mass index WHO.) 
 
The underlying causes for the emerging prevalence of obesity are diverse. Factors that can 
affect obesity are genetic predisposition, sedentary lifestyle and high energy intake (P.G. 
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Kopelman, 2000). Recent research also links the composition of the gut microbiota to 
obesity (V. Tremaroli and F. Backhed, 2012). 
Overweight and obesity are defined by a body mass index (BMI) of ≥25 or ≥30, respectively. 
Obesity is the fifth leading cause of death worldwide (WHO fact sheet No 311, 2013). This is 
due to the close relationship between BMI and increasing risks for several non-
communicable medical conditions such as type 2 diabetes, hypertension, coronary heart 
diseases and cholelithiasis (P.G. Kopelman, 2000). Furthermore, the risk for certain types of 
cancer as breast (R.E. Patterson et al., 2013), endometrial, cervical (W. Gu et. al., 2013) and 
colon cancer (M. Bardou et al., 2013) is increased in obese patients.  
In 2011 already more than 40 million children under the age of five were overweight (WHO 
fact sheet No 311, 2013), demonstrating the emerging need to discover new approaches 
for prevention or treatment of obesity.  
 
3.2.2 Metabolic syndrome 
The term “metabolic syndrome” describes a complex combination of metabolic disorders 
rather than a specific disease. The exact definition of this term is debated by experts 
worldwide as are the criteria which have to be met for the diagnosis of a metabolic (R.G. 
Thaman and G.P. Arora, 2013). In 1988, G.M. Reaven was the first who defined a 
constellation of metabolic derangements then known as syndrome X (G.M. Reaven, 1988). 
However, despite these controversies it is generally accepted that central obesity, insulin 
resistance or impaired glucose tolerance, dyslipidemia, a low-grade proinflammatory state 
and hypertension are key features of the metabolic syndrome (K.G. Alberti et al., 2009) (Fig 
2).  
Taken together, these factors are associated with an increased risk for the development of 
cardiovascular diseases (CVD) and type 2 diabetes (K.G. Alberti et al., 2009) or further 
comorbidities such as nonalcoholic fatty liver disease.  
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Fig 2: The metabolic syndrome. Schematic representation of possible causes, risk factors and 
consequences of the metabolic syndrome. The metabolic syndrome is a clustering of risk factors 
which can increase the development of type 2 diabetes and cardiovascular diseases. There is no 
fixed pathogenesis, all factors interact dynamically.  
 
Due to the complex nature of the metabolic syndrome, therapeutic intervention is difficult. 
Pharmacological treatment mostly targets individual components, mainly aiming to reduce 
the risk for CVD and type 2 diabetes. In addition, so-called life-style therapies including 
dietary changes and increased physical exercise are approaches to reduce obesity (H. Bays 
et al., 2006).  
Considering that in the US approximately 34% of all adults meet the criteria for the 
metabolic syndrome (R.B. Ervin, 2009), there is an ongoing search for new treatment 
strategies. 
 
3.2.3 Cachexia 
Whereas obesity is a disorder of energy surplus conditions, the energy balance can also be 
disturbed energy deprivation conditions such as cachexia. This multifactorial wasting 
disease is associated with either chronic or end-stage diseases as chronic obstructive 
pulmonary disease, chronic heart failure, infections, rheumatoid arthritis, tuberculosis, 
AIDS or cancer. Cachexia is associated especially with cancers of the gastrointestinal tract 
and the lung, and it accounts for up to 20% of all cancer related deaths (K. Fearon et al., 
2012). Even though there are no specified clinical criteria for diagnosis, cachectic patients 
are commonly recognized by severe weight loss, early satiety, weakness, impaired immune 
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function and reduced physical performance (M. Puccio and L. Nathason, 1997). Moreover, 
there are multiple metabolic alterations accompanying cachexia (Table 1).  
Up to now, cachexia cannot be cured; current treatments mainly focus on improving 
patients’ quality of life (S. Lucia et al., 2012). The only approved drugs available in Europe as 
progesterone, improve appetite and body weight but show no improvement of in muscle 
mass or survival (E. Tazi and H. Errihani, 2010). In order to find new approaches for treating 
cachexia, most studies have focused so far on the role of adipose tissue and skeletal 
muscle. However, recent studies indicate, that the liver, as an organ being crucial for overall 
energy homeostasis, needs to be taken into consideration as well (A. Jones et al., 2013, 
M.E. Martignoni at al., 2009).  
Table 1: Alterations in carbohydrate, lipid and protein metabolism in cancer cachexia 
Carbohydrate    Lipid  Protein 
↑ Hepatic gluconeogenesis  ↑ Adipose tissue lipolysis  ↑ Muscle protein breakdown 
↑ Cori cycle activity  ↓ Lipogenesis  ↑ Hepatic protein synthesis 
↓ Uptake of glucose into 
skeletal muscle 
 ↓ Whole-body lipid storage  ↓ Protein synthesis 
  Altered lipoprotein metabolism   
  Hyperlipidemia   
(summarized from M. J. Tisdale 2002, S. Lucis and D. H. Esper, 2005) 
↑: increase, ↓: decrease in the respective process 
 
3.3 The liver as a metabolic organ 
The liver is an organ with diverse functions. It integrates nutritional, neural and endocrine 
signals and it can thereby participate in carbohydrate, lipid and amino acid metabolism. It is 
the largest internal organ, with an average weight of roughly 1.5 kg in a healthy adult. As a 
heterogeneous organ the liver consists of different cell types with hepatocytes as the 
largest population, which make up 80% of the liver volume; the remaining cells are 
endothelial cells, hepatic stellate cells, immune reactive Kupffer cells, natural killer cells and 
other cells (W. Liu et al., 2011). The liver is supplied with blood and hence with nutrients, 
hormones or drugs by the portal vein.   
 
3.3.1 Hepatic lipid metabolism 
One major task of the liver is to balance the body’s blood sugar levels. But, other than 
contributing to glucose homeostasis, the liver is a key organ in regulating systemic lipid 
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metabolism. To maintain lipid homeostasis it can clear lipids from dietary sources, break 
down lipids for energy production or store lipids. Four sources supply the liver with fatty 
acids, namely a) hydrolysis of adipose tissue generating plasma non-esterified fatty acids, b) 
chylomicron remnants, c) cytoplasmic triglyceride stores and d) de novo lipogenesis (S. 
Tiwari and S. A. Siddiqi, 2012; J. Huang et al,. 2010). Uptake of fatty acids into the liver is 
mediated by transporters as CD36 or diffusion. Within the hepatocyte they bind to fatty 
acid binding proteins (FABP) and are either oxidized or processed to form neutral lipids. 
Oxidation takes place in mitochondria or in peroxisomes. During this process called β-
oxidation, fatty acids are broken down to acetyl-CoA, which is then fed into the TCA cycle to 
generate NADH. At high concentrations acetyl-CoA cannot completely be metabolized via 
the TCA cycle and is then utilized by incomplete β-oxidation, and can serve as an alternative 
energy source. Moreover, acetyl-CoA is a precursor in the synthesis of cholesterol (P. 
Nguyen et al., 2008). 
Acetyl-CoA, which can also be generated by breakdown of glucose is the precursor 
molecule for triglyceride (TG) synthesis as well. To this end, several chemical reactions form 
long chain fatty acids in the cytoplasm which can subsequently, be esterified with glycerol 
forming TGs. These are either stored in the liver or released into the circulation as part of 
very low density lipoprotein particles (VLDL) (J. Huang et al., 2010). 
 
3.3.2 Lipoproteins 
Triglycerides as well as cholesterol are water insoluble, thus, they are packed into 
lipoprotein particles to be transported through the blood stream. Lipoproteins are 
macromolecular complexes which vary in composition, size, density and function (Table 2). 
The hydrophobic core of the lipoprotein comprises TGs and cholesterol-esters (CE). The 
surface is covered by amphipathic phospholipids, free cholesterol and apolipoproteins. 
Apolipoproteins help to solubilize the core lipids and they are crucial scaffolds for 
interaction with lipid processing enzymes or transporters (H. N. Ginsberg et al., 2005) (Fig 
3).  
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Table 2: Physico-chemical characteristics of the major lipoprotein classes  
Lipoprotein Density (g/ml) Diameter (nm) Apolipoprotein 
component 
Lipid content (%) 
  TG            C              PL 
Chylomicron 0.95  75-1200 ApoB48, ApoE, 
ApoAI, ApoAII, 
ApoAIV, ApoCII, 
ApoCIII 
80-95 2-7 3-9 
VLDL 0.95-1.006 30-80 ApoB100, ApoE, 
ApoCII, ApoCIII 
55-80 5-15 10-20 
IDL 1.006-1.019 25-35 ApoB100, ApoE 20-50 20-40 15-25 
LDL 1.019-1.063 18-25 ApoB100 5-15 40-50 20-25 
HDL 1.063-1.21 5-12 ApoAI, ApoAII, 
ApoAV 
5-10 15-25 20-30 
adapted from: H.N. Ginsberg 2005  
VLDL: very low density lipoprotein, IDL: intermediate density lipoprotein, LDL: low density lipoprotein, HDL: 
high density lipoprotein, % lipid content indicates percentages of triglycerides (TG), cholesterol (C) and 
phospholipids (PL) within the respective lipoprotein class, the remaning part consists of apolipoproteins 
 
 
 
Fig 3: Schematic representation of the general structure of a lipoprotein.  
The surface of a lipoprotein is consisting of phospholipids, free cholesterol and apolipoproteins. Free 
cholesterol, cholesterol-ester and triglycerides are packed into the core. 
 
3.3.3 Exogenous lipid metabolism 
Dietary lipids mostly consist of TGs, additionally phospholipids, free fatty acids, cholesterol 
(in the form of cholesterol-esters) and fat soluble vitamins are present. In the stomach and 
the duodenum fats are broken down to fatty acids and free cholesterol by gastric and 
pancreatic lipase and are then solubilized by bile acids micelles. In this way they are 
transported into the enterocyte where they are re-esterified to TGs and cholesterol-ester 
and packed onto ApoB48. On their way through the plasma they recruit additional 
apoliproteins, e.g. ApoCII and ApoE from high density lipoprotein (HDL), forming now a 
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mature chylomicron. In the capillaries of adipose tissue and muscle, ApoCII activates 
lipoprotein lipase (LPL), which hydrolyzes the TG core to free fatty acids and glycerol. These 
can be taken up by fat cells and re-incorporated into TG for storage or used by muscle for 
energy generation. The cholesterol ester rich chylomicron remnants circulate back to the 
liver where ApoE enables removal by the liver. Uptake of remnants includes binding to LDL 
receptor, LDL receptor related protein (LRP), hepatic lipase (HL) and cell surface 
proteoglycans (Fig 4). 
 
3.3.4 Endogenous lipid metabolism 
The endogenous pathway refers to the hepatic secretion and metabolism of TGs and 
cholesterol-esters by very low density lipoproteins (VLDL), low density lipoproteins (LDL) 
and intermediate density lipoproteins (IDL) (Fig 4).  
One obligatory component of VLDL is apolipoprotein B (ApoB). ApoB occurs in two forms, 
ApoB100 and ApoB48, which consist of the N-terminal 48% of full length ApoB100 derived 
from editing ApoB100 mRNA. In humans, ApoB100 is secreted by the liver and ApoB48 
from the intestine; the mouse liver, however, secrets both Apo forms (M. Liu et al., 2011). 
VLDL assembly requires the action of microsomal transfer protein (MTP), which transfers 
triglycerides to the growing ApoB peptide. Regulation of VLDL-TG secretion is multifactorial. 
Factors that influence VLDL production are lipid availability, MTP levels, apolipoprotein 
availability or secretory vesicle trafficking. Once in the circulation VLDL acquires ApoE, 
ApoCII and ApoCIII. ApoCII activates LPL on the surface of peripheral tissues, which 
hydrolyzes TG into free fatty acid and glycerol for uptake in the cell. IDLs result from VLDL 
breakdown and are cleared by the liver via LDL receptors. The predominant remaining 
proteins are ApoB and ApoE. Further hydrolysis of TGs by hepatic lipase results in the 
formation of low density lipoproteins, where ApoB is the only apolipoprotein component 
and cholesterol-esters are the main lipid part. LDL can be cleared by the liver in a process 
mediated by ApoB and LDL receptors. LDL is often referred to as “bad cholesterol”, because 
it is considered to be atherogenic. LDL particles that are not cleared by the liver can 
accumulate in the subendothelial space. They can be oxidized and taken up by 
macrophages leading to the formation of so called lipid filled foam cells. Foam cells can 
aggregate within the arterial wall and subsequently form atherosclerotic plaques. If they 
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rupture a thrombus can form, consequently, blood flow is reduced, increasing the risk of 
infarctions in the heart, brain or other vital organs (H.N. Ginsberg, 2000). 
 
 
Fig 4: Schematic representation of exogenous and endogenous lipid metabolism.  
In the exogenous pathway dietary fat and cholesterol is packed into chylomicrons containing 
ApolipoproteinB48 (ApoB) in form of free cholesterol (C) und triglycerides (TG). During transport 
through the bloodstream chylomicrons mature, obtaining ApoCII (CII) and ApoE (E) from high density 
lipoproteins (HDL). In peripheral tissues, lipoprotein lipase (LPL) hydrolyses TGs and the remnants 
are taken up into the liver by LDL receptors. In the endogenous pathway TGs are secreted by the 
liver in form of ApoB containing very low density lipoprotein (VLDL). On the way through the plasma, 
VLDL obtains ApoE, ApoCII and ApoCIII (CIII). Hydrolysis by LPL leads to the formation of 
intermediate density lipoprotein (IDL) containing ApoB100 and ApoE. IDL is further hydrolyzed to low 
density lipoprotein (LDL) with ApoE as the sole lipoprotein. The cholesterol rich particle is taken up 
by the liver or extrahepatic tissues.  
B48/100: ApolipoproteinB48/100; C: cholesterol; CE: cholesterol-ester, TG: triglycerides; CII/III: 
ApolipoproteinCII/III; E: ApolipoproteinE; HDL: high density lipoprotein; VLDL: very low density lipoproteins; 
ILD: intermediate density lipoproteins; LDL: low density lipoproteins; LPL: lipoprotein lipase 
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3.3.5 HDL metabolism and reverse cholesterol transport 
The cholesterol in our diet comes exclusively from animal sources. It is important to 
maintain membrane fluidity; it is a precursor for bile acids, steroid hormones and vitamin 
D. All nucleated cells can synthesize cholesterol, but only hepatocytes can metabolize 
cholesterol and enable its secretion from the body. In a process called reverse cholesterol 
transport (RCT) cholesterol is transported from the periphery to the liver by HDL particles, 
taken up by the liver, secreted in the bile and finally via feces (R. Ross and J. A. Glomset, 
1973) (Fig 5). HDL levels in the serum are inversely associated with the risk of developing 
atherosclerosis (T. Gordon et al., 1977; S. Lewington et al., 2007) and hence HDL is also 
referred to as the “good cholesterol”.  
Formation of HDL particles begins with synthesis of ApoAI in the liver or the intestine. 
ApoAI proteins are the most abundant apolipoproteins in the HDL particle followed by 
ApoAII. The lipid poor nascent HDL acquires cholesterol and phospholipids from the liver, 
intestine or macrophages forming mature HDL. Transport is mediated by the membrane 
protein ATP-binding cassette protein A1 (ABCA1). Humans affected with Tangier disease, 
caused by a homozygous mutation in the ABCA1 gene, exhibit severe HDL deficiency (M. 
Marcil, 1999). Further important factors for reverse cholesterol transport are ABCG1, which 
also effluxes cholesterol to HDL, lecithin-cholesterol acetyltransferase (LCAT), which 
esterifies free cholesterol and cholesterol-ester transfer protein (CETP), which enables the 
transfer of cholesterol-esters from HDL to TG rich lipoproteins as VLDL. Mice naturally lack 
cholesterol-ester transfer protein (CETP) (Y.C. Ha and P. J. Barter, 1982), which can explain 
their high levels of plasma HDL as compared to humans. After conversion of VLDL to LDL, 
cholesteryl esters are finally removed from the circulation by LDL receptor mediated 
endocytosis. Scavenger receptor B1 (SR-B1) plays a major role in the uptake of HDL into the 
liver. Finally, ABCG5/8 heterodimers facilitate hepatobilary cholesterol transport for final 
excretion.  
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Fig 5: Schematic representation of HDL metabolism and reverse cholesterol transport in humans 
The liver or the intestine synthesize ApoA1 (A1), via transporters as ATP-binding cassette protein A1 
(ABCA1) nascent HDL acquires cholesterol (C), which is subsequently esterified by lecithin-cholesterol 
acetyltransferase (LCAT). Mature high density lipoprotein (HDL) is taken up by liver cholesterol is 
either converted to bile or directly excreted via transporters as such ABCG5/8. This process of 
cholesterol removal from the body is called reverse cholesterol transport (RCT). In HDL some 
cholesterol-esters (CE) are transferred from mature HDL to very low density lipoproteins (VLDL) in 
exchange for triglycerides (TG). VLDL particles are hydrolyzed to intermediate density lipoproteins 
(IDL) and low density lipoproteins (LDL) and taken up by receptors in the liver or further transported 
through the body for uptake by other tissues.  
A1/2: ApolipoproteinA1/2; C: cholesterol; LCAT: lecithin-cholesterol acetyltransferase; CE: cholesterol-ester, 
HDL: high density lipoprotein; ABC A1/G5/G8: ATP-binding cassette protein A1, G5, G8; VLDL: very low density 
lipoproteins; TG: triglycerides; ILD: intermediate density lipoproteins ; LDL: low density lipoproteins  
 
3.3.6 Dyslipidemia 
The metabolic syndrome is associated with an increased risk for CVD, which in turn is linked 
to lipid and lipoprotein abnormalities of insulin resistance (T. J. Chahil and H. N. Ginsberg, 
2006). Dyslipidemia describes a disorder that is marked by deregulated blood lipid content, 
as elevated serum TGs, low HDL cholesterol levels and normal or slightly elevated LDL 
cholesterol levels. In a state of insulin resistance there is an increased flux of free fatty acids 
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to the liver, resulting in the accumulation of TGs in the liver. This leads increased 
production and secretion of VLDL, leading to hypertriglyceridemia. If too much TGs 
accumulate steatosis (fatty liver) develops. Once in the serum, cholesterol-ester transfer 
protein (CETP) transfers TGs and cholesterol between VLDL and HDL or LDL. In the end this 
results in lower levels of HDL cholesterol and higher levels of small dense LDL particles. 
Furthermore, in state of insulin resistance clearance of VLDL and intestinal derived 
chylomicrons is impaired. This leads to prolonged plasma retention of VLDL and 
chylomicron remnants, which are in combination with low HDL levels particularly 
atherogenic (B. Klop et al., 2013).  
There are different strategies to treat dyslipidemia. One arm is lifestyle interventions, such 
as diet or physical activity (A.M. Haffner, 2003), the other arm is pharmacological 
treatment, such as statins or fibrates (H. E. Bays et al., 2013), which can help to reduce risk 
for developing atherosclerosis. CVDs are a major health burden; therefore, a thorough 
understanding of the molecular mechanisms of lipid metabolism is important to find novel 
approaches for prevention or treatment of dyslipidemia and its associated disorders. 
 
3.4 Transcriptional regulation by nuclear receptors 
3.4.1 Nuclear receptors 
Metabolic homeostasis happens on different levels. One level is the long-term overall 
metabolic homeostasis from birth during time of growth and development to adulthood, 
which includes adapting the energy intake to the body’s needs. The second level is the daily 
rhythm of fasting and feeding cycles, where one of the major aims is to keep the blood 
sugar balanced. Overall, these processes require a tight regulation, also to prevent 
metabolic disorders. One key aspect in this context is transcriptional regulation.  
The key concepts of regulating gene expression have been established in a bacterial system 
(F. Jacob and J. Monod, 1961). Their seminal work and many following studies found DNA 
binding transcription factors to occupy specific DNA sequences at control elements (cis-
elements) and to recruit and regulate the transcription apparatus.  
One well described class of transcription factors comprises nuclear receptors (NR), which 
are crucial for integrating signals from dietary, metabolic and endocrine pathways to 
control target gene expression. NRs are a superfamily of structurally-related ligand-
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dependent transcription factors. There are 48 known family members in humans and 49 
family members in rodents, out of which 37 are expressed in the liver (M. Downes and C. 
Liddle, 2008).  
All NR receptors exhibit common structural features (Fig 6), namely the highly variable N-
terminal activation domain (AF1), a central much conserved DNA binding domain (DBD), 
containing two zinc fingers and the C-terminal ligand binding domain (LBD). The LBD 
harbors a further activation domain (AF2), which is important for binding of ligands, such as 
steroid hormones, cholesterol or fatty acids, and for co-regulator recruitment (R.M. Evans, 
1988). 
Based on their ligand and DNA binding properties nuclear receptors can be subdivided into 
three different classes (D.J. Mangelsdorf et al., 1995). The first class of NR comprises the 
classical steroid receptors such as the estrogen (ER) or glucocorticoid receptors (GRs), 
which act as receptors for fat-soluble hormones and vitamins. A second class of NR 
comprises the so called adopted orphan receptors including the peroxisome proliferator-
activated receptors (PPARs) or liver X receptor (LXR), which are central regulators of lipid 
and glucose homeostasis and therefore, interesting molecular targets for drugs to treat 
hyperlipidaemia and type 2 diabetes (M. Downes and C. Liddle, 2008). The last class are the 
orphan receptors where no physiological or synthetic ligand have been discovered yet (D.J. 
Mangelsdorf et al., 1995). 
 
Fig 6: Schematic representation of nuclear receptor structure 
The primary and tertiary common domain structure of a nuclear receptor is depicted. It consist of 
the N-terminal ligand independent activation domain (AF-1), a central DNA binding domain (DBD), 
with 2 zinc finger motifs (ZN), a hinge region and the C-terminal ligand binding domain (LBD) with a 
further activation domain (AF-2). 
N: N-terminus; AF-1/2: activation domains; DBD: DNA binding domain; ZF: zinc fingers; C: C-terminus; LBD: 
ligand binding domain.  
 
3.4.2 The role of transcriptional co-regulators  
Nuclear receptors or transcription factors do not regulate transcription by themselves; they 
require co-regulators to modify and remodel chromatin structure and to recruit the 
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transcriptional machinery (J. N. Feige and J. Auwerx, 2007). Co-regulator complexes 
function either as co-activators or co-repressors, depending on their composition (Fig 7). As 
they cannot bind to DNA directly, they influence gene transcription by either recruiting 
further regulatory units, the reservoir for interacting partners comprises more than 200 
proteins (J. N. Feige and J. Auwerx, 2007), or they exert themselves post-translational 
modifications as phosphorylation, acetylation, ubiquitination and SUMOylation (M. 
Anbalagan et al., 2011).  
Two of the best described co-repressors are nuclear receptor co-repressor (NCoR) and 
silencing mediator of retinoic and thyroid hormone receptor (SMRT) (A.J. Horlein et al., 
1995; J.D. Chen and R. M. Evans, 1995), which interact with unliganded nuclear receptors. A 
further part of the NCoR/SMRT complexes are histone deacetylase (HDACs). Removal of 
acetyl residues from histone tails results in a condensed DNA structure, transcription is 
inhibited.  
Transcriptional activators either bind to histone acetyl transferases (HAT) or have intrinsic 
HAT activity (X. Liu et al., 2008). Acetylation of histones opens the DNA structure and makes 
it accessible for the transcriptional machinery (C. A. Johnson, 2000).  
One way to mediate the change between repression and activation of gene transcription is 
the exchange of co-activator and co-repressor complexes. One cofactor that has been 
described to be a so-called nuclear exchange factor is transducing beta like 1 (TBL1) (V. 
Perissi et al., 2004). Together with transducing beta like related 1 (TBL1) it has been 
established to be part of the NCoR/SMART, HDAC3, G-protein pathway suppressor-2 (GPS2) 
complex (M. G. Guenther, 2000; J. Li, 2000; J. Zhang, 2000). TBL1 and TBLR1 were described 
to recruit ubiquitin/19S proteasome units to the transcriptional complex, resulting in 
dismissal of SMRT-NCoR-HDAC3 complex and consecutive binding of co-activators (V. 
Perissi et al., 2004). Furthermore, TBL1 and TBLR1 have been shown to actively recruit co-
activators as RIP140 (V. Perissi et al., 2004).  
Our group described TBL1/TBLR1 as regulators of hepatic lipid metabolism (P. Kulozik et al., 
2011). In mice liver specific knockdown of TBL1 resulted in hepatic steatosis and 
hypertriglyceridemia. The increase in liver and serum TGs could be explained by reduced 
mitochondrial and peroxisomal fatty acid oxidation pathways and increased lipogenesis. 
Consistent with these findings, it was shown that TBL1 interacts with and activates PPARα. 
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This was the first implication that the TBL1/TBLR1 co-factor complex plays a critical role in 
liver metabolism.  
Altogether, transcriptional co-factors add another level of complexity to the regulation of 
metabolic balance. However, the discovery of so far unappreciated co-regulators may 
present new targets for the treatment of metabolic disorder. 
 
Fig 7: Schematic diagram of transcriptional repression or activation by nuclear receptors and co-
regulators. 
In case of repression nuclear receptor (NR) dimers are bound to response elements (RE) on the DNA. 
Well described co-repressor complexes contain nuclear receptor co-repressor (NCoR) and silencing 
mediator of retinoic and thyroid hormone receptor (SMRT), transducing beta like 1 (TBL1) and 
histone deacetylase 3 (HDAC3) and other factors (X, Y). These mediate histone deacetylation so that 
target gene transcription is switched off. Ligand binding leads to conformational changes in the NR 
dimer. Co-activator complexes containing histone acetylase (HAT) can bind. Chromatin is opened 
and target gene transcription is switched on.  
NCoR: nuclear receptor co-repressor; SMRT: silencing mediator of retinoic and thyroid hormone receptor; 
TBL1: transducing beta like 1; HDAC3: histone deacetylase 3; HAT: histone acetylase; X/Y: co-repressors; 
X*/Y*: co-activators 
 
3.4.3 Transforming growth factor beta stimulated clone 22D 1 as a novel co-regulator 
Transforming growth factor beta stimulated clone 22D 1 (TSC22D1) was first isolated from 
mouse osteoblastic cells in 1992 (M. Shibanuma et al., 1992). Prior to this study, TSC22D1 
has been identified in a screen to directly bind to transcriptional co-regulator TBL1 (PhD 
thesis, Allan Jones, Herzig Lab). It is a member of a family of 4 structurally related proteins 
named TSC22D1-TSC22D4 (H.A. Kester et al., 1999) conserved from Caenorhabditis elegans 
to humans (S. Gluderer et al., 2010.).  
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TSC22D1 expression in vitro is strongly but transiently induced by TGF-β stimulation (M. 
Shibanuma et al., 1992; T. Kawa-Uchi et al., 1995; R.A. Gupta et al., 2003) and it has been 
speculated that this is due to post-transcriptional regulations like an increase in mRNA 
stability (D. Uchida et al., 2003) or an enhanced TSC22D1 translation (M. Kato et al., 2010). 
Several studies describe TSC22D1 in the context of transcriptional regulation. TSC22D1 
contains a leucine zipper structure in mice (M. Shibanuma et al., 1992) and humans (P. Jay 
et al., 1996). However, it has no DNA binding domain as it lacks the basic region at the N-
terminus of the zipper. One study has shown that it can directly bind to the promoter of 
human C-type natriuretic peptide (CNP) and can as well enhance CNP promoter activity in a 
rat pituitary derived cell line (GH3) (S. Ohta et al., 1996). Most studies concerning the 
function of TSC22D1 in regulation of gene transcription indicate, however, that it is a 
transcriptional co-factor rather than a transcription factor. Fused to a heterologous-DNA 
binding domain it was described to activate transcription in a mammalian cell system (S. 
Hino et al., 2000). In this study activation only worked in CHO cells but not in two other cell 
lines. Another study with TSC22D1 fused to a heterologous-DNA binding domain reported 
repression of transcription (H.A. Kester, 1999). Interestingly, this repressive function was 
dependent on dimerization with TSC22D4. Moreover, TSC22D1 can directly interact with 
transcription factor Smad4 and increase its transcriptional activity in vitro (S.J. Choi et al., 
2005). Along these lines, TSC22D1 was to shown to interact with the transcription factor 
Tfe3 in co-immunoprecipitation studies (M. Kato et al., 2010) and enhance transcription. 
ChIP experiments displayed an increased occupancy of TSC22D1 at enhancer E-boxes of 
collagen type I alph-2 (Col1a2) through TGFbeta1 stimulation in primary mouse MC, 
strengthening the idea of TSC22D1 as a transcriptional co-factor. 
Regarding its function, some work on TSC22D1 indicates that it acts as a tumor suppressor. 
Downregulation of TSC22D1 enhanced growth of a human salivary gland cancer cell line (K. 
Nakashiro, 1998). Moreover, it has shown to be downregulated in human salivary gland 
tumors (K. Nakashiro, 1998) in a set of human brain tumors (K.O. Shostak et al., 2003) and 
in aggressive forms of astrocystic tumors (K.O. Shostak et al., 2003). Furthermore, several 
publications demonstrate that in cell culture models overexpression of TSC22D1 induces 
apoptosis (S. Ohta et al., 1997; S. Hino et al., 2000), presumably by a caspase 3 dependent 
pathway (J.H. Lee et al., 2008) or inhibits tumor cell growth by preventing proteosomal 
degradation of p53 (Y. Lu et al., 2007, C.H. Yoon et al., 2012). In the only in vivo study 
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published so far, TSC22D1-deficient mice were susceptible to tumorigenesis in a mouse 
model of chemically-induced liver tumors bearing active mutations of Ras/Raf (M. 
Nakamura et al., 2011), emphasizing the tumor suppressive function of TSC22D1. 
Up to date, there are no publications about a role of TSC22D1 in metabolism in general. 
Interestingly, its family member TSC22D4 has proven to be a critical molecular determinant 
of systemic lipid homeostasis and lipoprotein metabolism (A. Jones et al., 2013 and A. Jones 
unpublished work). Liver-specific ablation of TSC22D4 triggered hypertriglyceridemia 
through the induction of hepatic VLDL secretion. The fact that TSC22D1 and TSC22D4 can 
heterodimerize (H.A. Kester et al., 1999) and the observation that TSC22D1 interacts with 
another crucial regulator of hepatic lipid metabolism TBL1 (P. Kulozik et al., 2011 and PhD 
thesis Allan Jones, Herzig Lab), prompted us to hypothesize that hepatic TSC22D1 is a 
further novel regulator of liver metabolism.  
 
 
3.5 Aim of the study 
 
Given the previous work from this lab, the aim of this study was to elucidate the role of 
transcriptional co-factor TSC22D1 in liver metabolism. To this end, the regulation of hepatic 
TSC22D1 expression was to be analyzed in various mouse models of metabolic imbalance. 
Further, TSC22D1 knockdown and overexpression tools were to be generated. 
Subsequently, studies in relevant mouse models were to be performed to investigate 
TSC22D1 function in vivo. 
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4 Results 
4.1 TSC22D1 is a candidate transcriptional co-regulator 
4.1.1 TSC22D1 interacts with transcriptional co-factor TBL1 
Transcriptional co-factors play an important role in the regulation of metabolic processes, 
as previously demonstrated by studies from this lab (M. Berriel-Diaz et al., 2008; P. Kulozik 
et al. 2011; A. Jones et al., 2013; M. Rohm et al., 2013). One example is the transcriptional 
co-factor TSC22D4 (A. Jones et al., 2013), which was shown to be important for liver lipid 
handling. TSC22D4 was discovered in a luminescence-based mammalian interactome 
mapping (LUMIER) screen (PhD thesis Allan Jones, Herzig Lab) aiming to detect novel 
interaction partners of the transcriptional co-factor TBL1 (P. Kulozik et al., 2011) or TBLR1 
(M. Rohm et al., 2013), which are both regulators of lipid metabolism in liver as well as in 
fat. In this screen, also TSC22D1, which is known to dimerize with TSC22D4 (H.A. Kester et 
al., 1999), showed a strong interaction with TBL1 and TBLR1 (PhD thesis Allan Jones, Herzig 
Lab). Thus, we hypothesized that TSC22D1 might play a role in liver metabolism as well. As 
a first step, the interaction between TBL1 was verified by Flag-co-immuoprecipitation 
studies (Fig 8), whereas, the interaction with TBLR1 could not be verified. These results 
indicated that TSC22D4 and TSC22D1 have distinct interaction partners and therefore also 
distinct functions. The previously published interaction between TSC22D1 and TSC22D4 
(H.A. Kester et al., 1999) could be recapitulated as well. However, it was impossible to map 
the interaction between TBL1 and TSC22D1 by Glutathione-S-Transferase (GST)-pulldowns 
(data not shown).  
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Fig 8: TSC22D1 co-precipitates with TBL1 in Flag co-immunoprecipitation studies. Co-
immunoprecipitation studies, in HEK293 cells transfected with Flag-TSC22D1 and a vector encoding 
either the control Flag peptide, (A) Myc-TSC22D1 (B) HA-TBL1 or (C) HA-TBLR1. Affinity purification 
was performed with an anti-Flag antibody. Bound proteins were resolved by SDS-PAGE and 
subsequently detected by Western blotting with Myc, Flag, TBL1 and TBLR1 antibodies. Ip: Input; Ub: 
unbound; El: elution 
 
4.2 Hepatic TSC22D1 expression is altered by energy status 
4.2.1 Analysis of hepatic TSC22D1 expression in mouse disease models 
The mouse can serve as a good model system to study human diseases. Mice and men both 
have 3 million base pairs of DNA, which share about 85% similarity. The whole mouse 
genome has been sequenced in 2002 (R.H. Waterston et al., 2002). Metabolic, physiological 
and behavioral stresses can be tested in mouse models and the results can be compared 
directly with human clinical information (N. Rosenthal and S. Brown, 2007). Given the 
importance of TBL1 and TSC22D4 for hepatic lipid metabolism (P. Kulozik et al., 2011 and A. 
Jones et al., 2013) combined with the results from the co-immuniprecipitation study (Fig 8) 
we chose the liver as a target organ for this study. Prior work from this lab (P. Kulozik et al., 
2011 and A. Jones et al., 2013) has shown that TBL1 and TSC22D4 expression as such are 
altered in mouse disease models; therefore, we analyzed the expression of TSC22D1 in 
livers of mice challenged with different metabolic conditions.  
 
4.2.2 TSC22D1 expression is strongly downregulated by fasting 
Prolonged fasting results in a state of nutrient deprivation and energy wasting. As a result 
of falling blood sugar levels glucagon is secreted from the pancreas which signals to a 
variety of organs. In the liver, fasting signals cause glycogenolysis and gluconeogenesis, 
followed by the release of glucose. Additionally, fatty acids (FA) and glycerol are released 
from adipose tissue and taken up by the liver. In prolonged fasting, when glycerol stores 
are empty, free fatty acids are broken down for the generation of ketone bodies.  
In the postprandial state, blood sugar rises and subsequently, insulin signaling results in the 
uptake of glucose and lipids into the liver, adipose tissue or muscle. The FAs are packaged 
into lipoproteins for further transport throughout the body. Altogether, these processes 
underlie a tight regulation.  
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In order to see if hepatic TSC22D1 expression is altered by fasting signals, male and female 
C57BL/6 mice were fasted for 16 hours. After starvation, one group of mice was sacrificed 
immediately and the other mice were refed for 6 hours. Hepatic TSC22D1 mRNA expression 
was determined by quantitative PCR (qPCR) (Fig 9A). Levels of TSC22D1 expression were 
not gender dependent. Interestingly however, in the fasting state TSC22D1 mRNA levels 
were decreased by approximately 80%. In a further approach, male C57BL/6 mice were 
fasted for 24 hours one group of mice was sacrificed immediately and the other mice were 
fed for either 1, 6 or 24 hours (Fig 9B). Taking 24 hours of reseeding as the baseline value 
for TSC22D1 expression, TSC22D1 expression was 80-90% decreased after 24h fasting and 
returned to its baseline level 6 hours after refeeding. These results indicate that fasting 
signals might control TSC22D1 expression.  
 
Fig 9: TSC22D1 expression is strongly downregulated by fasting. A) TSC22D1 expression in male or 
female mice fasted for 16h and either directly sacrificed or refed for 6h. B) TSC22D1 expression in 
mice fasted for 8h or 24h hours and either directly sacrificed or refed for 1h, 6h or 24h. Liver mRNA 
levels were analyzed by qPCR. (n=5-7), (means ± SEM). (A-B) (**) indicates significance p≤0.01 to 6h 
fed, (B) (##) indicates significance p≤0.01 to 24h fed 
 
4.2.3 TSC22D1 expression is reduced in mice on a methionine and choline deficient diet 
Mice fed with a diet lacking methionine and choline (MCD) encounter dramatic weight loss, 
develop severe hepatic steatosis and have low serum TG levels (M.E. Rinella et al., 2008). 
To determine if TSC22D1 expression is altered in this model of energy wasting, hepatic RNA 
was isolated from mice fed either control diet or an MCD diet for 4 weeks. Subsequently, 
TSC22D1 mRNA expression was analyzed by qPCR (Fig 10). TSC22D1 mRNA levels were 
significantly reduced in mice on MCD diet compared to mice on the control diet. This 
suggests that the energy status can influence TSC22D1 expression. 
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Fig 10: TSC22D1 expression is reduced in mice on methionine choline deficient diet. TSC22D1 
expression in mice fed a methionine choline deficient diet (MCD) or a control diet. Liver mRNA levels 
were analyzed by qPCR. (n=4), (means ± SEM). (*) indicates significance p≤0.05 
 
4.2.4 TSC22D1 levels negatively correlate with weight loss in cachectic patients  
Cachexia is a multi-factorial disease characterized by massive wasting of adipose tissue and 
skeletal muscle mass (M.J. Tisdale, 2002). Further, cachexia causes hepatic dysfunction in 
the form of reduced VLDL secretion and hypoapolipoproteinemia (A. Jones et al., 2013). For 
this study we analyzed mRNA expression of TSC22D1 in liver biopsies from 10 patients with 
pancreatic cancer with or without cachecxia. Interestingly, body weight loss negatively 
correlated with TSC22D1 expression levels (Fig 11A and B).  
The C26 colon carcinoma model is a mouse model for tumor-induced cachexia. Tumor 
bearing mice suffer from severe weight loss mainly by adipose tissue and muscle wasting, 
they develop hyperglycemia (Y. Tanaka et al., 1990) and they exhibit reduced serum TG 
levels (A. Jones et al., 2013). To induce cancer cachexia, Balb/C mice were injected 
subcutaneously with 1.5 x 106 Colon26 adenocarcinoma cells. Mice were sacrificed 
approximately three weeks after tumor-cell injection with the on-set of cachexia, 
determined by body weight loss. Hepatic TSC22D1 mRNA levels were significantly reduced 
in the cachectic mice compared to healthy control mice (Fig 11C). As seen in the patient 
data (Fig 11B), TSC22D1 expression correlated with the degree of weight loss (Fig 11D). 
These results are in line with the observations that TSC22D1 expression is reduced in 
conditions of energy deprivation (Fig 9 and 10).  
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Fig 11: TSC22D1 expression correlates with the degree of cachexia in patients and mice.  
A) TSC22D1 expression in livers of pancreatic cancer patients with or without cachexia. Liver mRNA 
levels were analyzed by qPCR (n=5). (**) indicates significance p≤0.01 B) Pearson’s correlation of 
log(2) of TSC22D1 expression and body weight loss as % of initial weight in livers of pancreatic 
cancer patients. (n=10) C) TSC22D1 expression in male Balb C mice, injected with 1.5x 106 C26 mouse 
tumor cells and sacrificed with the onset of cachexia.  Liver mRNA levels were analyzed by qPCR (n ≥ 
6) (means ± SEM) (***) indicates significance p≤0.001 D) Pearson’s correlation of log(2)  of TSC22D1 
expression and body weight loss as % of initial weight at time of sacrifice. ▲ = control mice, ● = C26 
(E) Representative Western blot and quantification of liver extracts from same mice as in C. Protein 
was detected by TSC22D1 and β-actin (loading control) antibodies.  
 
4.2.5 TSC22D1 expression is increased in mice on a high fat diet 
Feeding mice a high fat diet over the course of several weeks results in weight gain, 
development of hyperglycemia, hyperinsulinemia, hypertension and an increased TG 
content in adipose tissue, serum and liver (R. Buettner et al., 2007). To address if high fat 
diet feeding influences TSC22D1 expression, livers of mice were analyzed, that were fed 
either a high fat diet containing 60% energy from fat or a control low fat diet containing 
10% energy from fat over a 9 week period. Mice on HFD gained significantly more weight 
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than mice on a LFD (data not shown). Hepatic TSC22D1 mRNA levels were analyzed by qPCR 
(Fig 12). TSC22D1 expression was 3 fold increased in mice on a HFD compared to control 
mice, indicating that TSC22D1 might be involved in the onset of obesity.  
 
 
Fig 12: TSC22D1 expression is increased in mice on a high fat diet. Mice were fed a control low fat 
diet (LFD) or a high fat diet (HFD). Liver TSC22D1 mRNA levels were analyzed by qPCR. (n=4), (means 
± SEM). (**) indicates significance; p < 0.01. 
 
4.2.6 TSC22D1 expression is increased in obese mice  
There are various monogenetic mouse models available to study obesity. Two of the most 
widely used mouse models are ob/ob or db/db mice, which harbor homozygous loss of 
function mutations in the genes for the satiety hormone leptin (ob) or its receptor (db). 
These mice suffer from obesity and its associated complications as hyperglycaemia, 
hyperinsulinemia and subsequently pre-diabetes (K. Kobayashi et al., 2000 and P. 
Lindstrom, 2007). In random fed db/db TSC22D1 expression levels were 3-fold increased as 
compared to control wild type mice (Fig 13A). Also, TSC22D1 gene expression was analyzed 
in 5, 9 and 13 week old ob/ob mice and age-matched control wildtype C57BL/6 mice (wt). 
Whereas TSC22D1 expression did not significantly change with age in the wt mice, from 
week nine on levels of TSC22D1 were about 3-fold increased in ob/ob mice compared to wt 
control mice (Fig 13B). These data indicate that TSC22D1 expression might be regulated by 
changes in signaling due to obesity. 
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Fig 13: TSC22D1 expression is increased in obese mice. A) TSC22D1 expression was determined in 
random fed db/db and C57BL/J (wt) mice. B) TSC22D1 expression was determined in, 9 or 13 week 
old ob/ob mice and control wt mice. Liver mRNA was analyzed by qPCR. (n=4-5), (means ± SEM). (*) 
indicates significance; p < 0.05. 
 
4.2.7 TSC22D1 expression is reduced in aged mice 
Aging is characterized by an overall impairment of cellular function, resulting in common 
metabolic, inflammatory, cardiovascular and neurodegenerative diseases. Pathways that 
are altered in aged mice include glucose and fatty acid metabolism and redox homeostasis 
(R.H. Houtkooper et al., 2011). In 22 month old mice which were refed for 6h after 24h of 
fasting TSC22D1 mRNA levels were 70% lower compared to refed 12 week old mice. 
Further, they did not exhibit down-regulation of TSC22D1 expression after fasting as seen in 
young mice (Fig 14). These results point towards an altered function of TSC22D1 in aged 
mice.  
 
 
Fig 14: TSC22D1 expression is reduced in old mice. TSC22D1 expression in 22 month old mice and 12 
week old mice which were fasted for 24h hours, one group was sacrificed directly and the other 
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group was refed for 6h. Liver mRNA was analyzed by qPCR. (n=5), (means ± SEM). (*) indicates 
significance p≤0.05 for nutritional status, (#) indicates significance p≤0.05 for age 
 
4.2.8 TSC22D1 expression is induced by TGF-beta1 in vivo and in vitro  
Signaling by the transforming growth factor TGF-β has various functions including the 
control of development, growth or function of diverse cell types (Y. Shi and J. Massague, 
2003). In vitro TSC22D1 expression was shown to be induced by TGF-β1 stimulation (M. 
Shibanuma et al., 1992, T. Kawa-Uchi et al., 1995, R. A. Gupta et al., 2003). We could 
recapitulate these findings in primary hepatocytes (Figure 15A), where expression started 
to increase 6h after stimulation and peaked after 24h. Furthermore, in vivo application of 
TGF-β1 to C57BL/6 mice increased hepatic TSC22D1 expression (Figure 15B). Interestingly, 
TGF-β1 levels correlate with obesity in mice (Figure 15C) and humans (H. Yadav et al., 
2011).  
 
Fig 15: TSC22D1 expression is induced by TGF-β1 stimulation. (A) TSC22D1 expression in primary 
hepatocytes after stimulation with 10 ng human recombinant TGF-β1 for the indicated time. Primary 
hepatocyte mRNA was analyzed by qPCR. (n=3), (means ± SEM). (B) TSC22D1 expression in C57BL/6 
mice injected with either PBS or 5µg human recombinant TGF-β1. Mice were sacrificed at indicated 
time points after injection. (n=4), (means ± SEM). (C) Serum TGF-β1 levels in ob/ob mice compared 
to wildtype control mice (wt). TGF-β1 levels were determined by ELISA. (n=4), (means ± SEM). (*) 
indicates significance p≤0.05 
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4.2.9 Summary of TSC22D1 expression data 
Altogether, we found hepatic TSC22D1 levels to be strongly altered in mouse models of 
metabolic disorders (Table 3). Whereas TSC22D1 expression was up-regulated in mouse 
models of obesity, it was strongly downregulated in models for wasting, cancer cachexia 
and upon fasting. These results point towards an important role of TSC22D1 in liver 
metabolism in different states of energy supply. 
Table 3: Summary of hepatic TSC22D1 expression under different metabolic conditions 
 
↑: indicates up-regulation, ↓ indicates down-regulation compared to respective controls 
 
4.3 Phenotypic analysis of TSC22D1 deficient C57BL/6J mice 
4.3.1 Adenoviral mediated knockdown of TSC22D1 in vivo  
Adenoviruses are commonly used as vectors to transfer exogenous DNA to cells or whole 
organs in vivo or in vitro. If adenovirus is injected into the tail vain it is transported through 
the capillary system into the liver. Thus, mainly liver cells get infected and other tissues are 
hardly affected by the transgene. In this study an adenoviral vector system was used to 
deliver short hairpin RNAs (shRNA) or a cDNA into the mouse liver. Adenoviral vectors can 
only be used for short term experiments, as the virus is cleared from the system after 
approximately 14 days. The ideal time point for phenotypic analysis has been shown to be 7 
days post infection (U. Lemke et al., 2008) and has thus been used for all adenovirus 
experiments described in this work.  
Specific shRNA sequences targeting TSC22D1 were cloned into the Invitrogen pENTR-DEST 
vector. Their knockdown efficiency was tested by co-transfecting Hepa1c1 cells with 
shRNAs targeting TSC22D1 or a scrambled control and a TSC22D1 overexpression construct. 
TSC22D1 depletion was analyzed by luciferase assay and Western blot (Fig 16). Sequence 
395 performed efficiently in both assays and was subsequently sub-cloned into the 
Invitrogen pAD-BLOCK-IT vector. This vector contains most of the viral genome, but lacks 
Mouse Model / Condition Regulation 
Fasting ↓ 
MCD diet ↓ 
Cachexia ↓ 
HFD ↑ 
db/db ↑ 
ob/ob ↑ 
TGFβ1 ↑ 
Aging ↑ 
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for safety reasons E1 and E3 genes which are required for viral replication. Adenovirus was 
propagated in HEK293A cells which express the missing genes in trans. Next, virus was 
purified by the cesium chloride method (U. Lemke et al., 2008) and the titer was 
determined for in vivo application.  
 
Fig 16: Cloning of adenoviral expression construct for TSC22D1 knockdown. A) HEK293A cells were 
transfected with plasmids containing the TSC22D1 sequence in frame with the luciferase coding 
sequence and co-transfected with plasmids expressing either a scrambled shRNA sequence (shNC) or 
different TSC22D1 targeting sequences (sh235-484). Luciferase activity is normalized to β-
galactosidase and plotted relative to control shRNA. (n=3), (means ± SEM). B)  HEK293A cells were 
transfected with plasmids overexpressing flag-tagged TSC22D1 and co-transfected with plasmids 
expressing either a scrambled shRNA sequence (NC) or different TSC22D1 targeting sequences 
(sh235-484) or nothing (-). Protein levels were analyzed by immunoblot using flag-antibody and 
VCP-antibody as loading control. Representative results from 3 experiments are shown.  
 
In order to investigate the effects of reduced TSC22D1 expression in livers of C57BL/6J 
mice, 2 x 109 viral particles expressing either a scrambled shRNA sequence (shNC), or the 
sequence targeting the TSC22D1 (shD1) mRNA were administered via tail vein injection. 
Over the time of the experiment, mice were housed in a TSE phenotyping system for indirect 
calorimetry. Mice were kept at 22°C with free access to food and water. Six days post injection 
animals were fasted for 24 hours. Then, half of the mice were sacrificed directly and the other 
group was refed for 6h. TSC22D1 knockdown efficiency was assessed at mRNA level by qPCR 
and at protein level by Western blot (Fig 17A-B). As also seen before (Fig 9), TSC22D1 
expression was strongly downregulated by fasting.  
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Fig 17: ShRNA mediated knockdown of TSC22D1. (A) TSC22D1 expression in C57BL/6J mice treated 
with control or TSC22D1 shRNA adenovirus. Mice were fasted for 24h and one group was directly 
sacrified and the other was refed for 6h. Liver mRNA levels were determined by qPCR. (B) 
Representative Western Blot of liver extracts from same mice as in A, using TSC22D1 (D1) or actin 
(loading control) specific antibodies. (means ± SEM). (*) indicates significance p≤0.05 
 
4.3.2 TSC22D1 deficiency does not alter body or liver weight 
To asses if TSC22D1 knockdown affects body weight, mice were weight prior to injection and 
during the course of the experiment. There was no difference detectable between the TSC22D1 
knockdown group and the control group. After 24h fasting, both groups lost approximately 15% 
of their body weight. After 6h refeeding, the TSC22D1 depleted animals gained slightly less 
weight, which was 10% of their body weight (Fig 18A). During dissection of the mice, liver and 
abdominal fat weight was determined, which remained unchanged by TSC22D1 knockdown (Fig 
18B-C). Moreover, indirect calorimetry revealed no differences in oxygen consumption (Fig 18D). 
Also respirator exchange ration (RER), which is an indicator for preferences in substrate 
(lipid/carbohydrate) utilization, was similar in both experimental groups (Fig 18E). 
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Fig 18: Body, liver and abdominal fat weight are not affected by TSC22D1 knockdown. A) Body 
weight of mice treated with control (shNC) or TSC22D1 shRNA (shD1) adenovirus. Mice were fasted 
for 24h and one group was directly sacrified and the other was refed for 6h. (B) Liver weight of same 
mice as in A. Weight was determined after dissection. (C) Abdominal fat weight in same mice as in 
A. Weight was determined after dissection. (D) Oxygen consumption in same mice as in A, as 
determined by indirect calorimetry. (E) Respiratory exchange ratio in same mice as in A, as 
determined by indirect calorimetry. (n=5) (means ± SEM) 
 
4.3.3 Hepatic glycogen and blood glucose are not affected by TSC22D1 knockdown 
In the fed state, excess glucose is stored in the liver in the form of glycogen, whereas in the 
fasting state the glycogen is broken down to maintain normoglycemia. As TSC22D1 is 
downregulated in the fasted state, we wanted to asses if that influences the emptying or 
refilling of liver glycogen stores or blood glucose levels. However, there was no difference 
between both groups neither in the fasted nor in the fed state (Fig 19).  
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Fig 19: Glycogen and blood glucose are unaltered by TSC22D1 knockdown. (A) Blood glucose of 
mice treated with control (shNC) or TSC22D1 shRNA (shD1) adenovirus. Mice were fasted for 24h 
and one group was directly sacrified and the other was refed for 6h. (B) Hepatic glycogen of same 
mice as in A. (n=5) (means ± SEM) 
 
4.3.4 TSC22D1 knockdown significantly reduces serum triglycerides  
In order to investigate if TSC22D1 knockdown in the liver alters the levels of circulating non-
esterified free fatty acids (NEFA), ketone bodies and triglycerides, these parameters were 
measured in mouse serum using commercially available colorimetric assays. 
Hydrolysis of triglycerides by hormone sensitive lipase liberates NEFAs and glycerol. After 
uptake into hepatocytes, they can be used for energy production, re-packaged into 
triglycerides for secretion or storage or converted to ketone bodies. In the fasting state, 
serum NEFA levels are elevated due to increased breakdown of adipose tissue to meet the 
energy demands (M. Lafontan and D. Langin, 2009). In the present experiment, NEFA levels 
were up-regulated by fasting as expected but not affected by TSC22D1 knockdown (Fig 
20A).  
In case of prolonged fasting, the brain blood glucose levels are not high enough to supply 
the brain with energy, and ketone bodies can serves as an alternative energy source. The 
liver is the only organ that can produce ketone bodies as a by-product of beta-oxidation 
(H.A. Krebs et al., 1999). In this experiment, the level of serum ketone bodies was higher in 
the fasted state as expected but remained unaffected by TSC22D1 knockdown (Fig 20B).  
Most of the fats digested by humans are triglycerides. They can be stored and as well as 
synthesized by fat and liver cells. In case of energy deprivation hormonal signaling as by 
epinephrine results in the breakdown of triglycerides to free fatty acids, which can be used 
for energy production.  
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In the fasting state, serum TGs were below the detection limit in both experimental groups. 
Interestingly, however, in the fed state serum TGs were significantly lower (60%) in 
TSC22D1 deficient mice (Fig 20C). These results hint at a role of TSC22D1 in lipid 
metabolism. As the liver can also store excessive triglycerides, hepatic TG levels were 
analyzed by lipid isolation and oil-red-o staining (Fig 20D). TSC22D1 knockdown did not 
alter liver lipid levels. Interestingly, fasting liver cholesterol levels were significantly 
increased by TSC22D1 knockdown (Fig 20E).  
 
 
Fig 20: Serum triglycerides are significantly reduced by TSC22D1 knockdown. (A) Serum non-
esterified free fatty acids (NEFA) in C57BL/6J mice treated with control or TSC22D1 shRNA 
adenovirus. Mice were fasted for 24h and one group was directly sacrified and the other was refed 
for 6h. (B) Serum ketone bodies in the same mice as in A. (C) Postprandial serum triglycerides (TG) in 
same mice as in A. Triglycerides in the fasted group were below the detection limit. (D 
Representative liver cryosections from same mice as in A. Lipids were stained red using Oil Red O. (E) 
Liver cholesterol from same mice as in A (means ± SEM). (*) indicates significance p ≤0.05 
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4.3.5 TSC22D1 deficient mice have reduced circulating VLDL triglycerides and HDL 
cholesterol 
As triglycerides and cholesterol are water-insoluble, they are transported as part of 
lipoproteins through the blood stream. Triglycerides are mainly associated with very low 
density lipoproteins (VLDL) whereas cholesterol is transported by low densitiy (LDL) and 
high density (HDL) lipoproteins (H. N. Ginsberg et al., 2005).  
As a significant decrease in serum TG levels was observed in mice after TSC22D1 
knockdown, we analyzed the different lipoprotein species in regard to their TG and 
cholesterol content. For this purpose, total serum was fractionated by fast protein liquid 
chromatography on a Superose 6 10/300 GL column. According to their size, VLDL particles 
are collected first, followed by LDL and finally HDL particles.  
Indeed, the observed decrease in serum TGs in the fed mice could be attributed to the VLDL 
fraction, as the corresponding peak (fraction number 21) was significantly lower than in the 
control group (Fig 21A).  
Cholesterol is mainly transported in HDL particles. Cholesterol is a component of cellular 
membranes and serves as a substrate for the production of hormones and bile acids. In the 
fasted state the peak corresponding to HDL particles (fraction 36) was nearly gone in the 
shTSC22D1 treated group compared to the control group. In the refed state the peak was 
only mildly reduced (Fig 21B). 
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Fig 21: TSC22D1 knockdown lowers circulating VLDL triglycerides and HDL cholesterol. Lipoprotein-
associated serum triglyceride (TG) and cholesterol levels as measured by fast protein liquid 
chromatography (FPLC). Serum from 24 hour fasted (B) or 6 hour refed (A and C) mice treated with 
either control or TSC22D1 shRNA adenovirus was pooled and applied to a Superose 6 10/300 GL 
column; shown are concentrations of triglycerides (A) and cholesterol (B and C) (n=5).  
 
4.3.6 TSC22D1 knockdown alters gene expression of key genes involved in VLDL 
assembly and HDL cholesterol metabolism  
To determine the mechanism responsible for the reduction in serum VLDL triglycerides and 
HDL cholesterol, lipoprotein lipase (LPL) activity in white adipose tissue, VLDL uptake and 
secretion and gene expression was analyzed.  
4.3.7 TSC22D1 knockdown does not affect LPL activity in white adipose tissue 
Lipoprotein lipase (LPL) is the rate-limiting enzyme for the hydrolysis of TGs from 
chylomicrons or VLDL particles. It is expressed in heart, adipose tissue and muscle and sits 
on the periphery of these tissues. The hydrolysis of a triglyceride molecule yields three fatty 
acids and a molecule of monoglycerol. These products are taken up by the tissues locally 
and serve different purposes. A reduced activity in adipose tissue LPL leads to an 
accumulation of VLDL triglycerides in the blood stream (H. Wang and R. H. Eckel, 2009). As 
serum VLDL triglycerides were significantly reduced in TSC22D1 knockdown mice, we 
wanted to determine if LPL activity was increased. To this end, the enzyme was isolated 
from white adipose tissue. A subsequent activity assay was performed using radiolabeled 
glyceryl tri-[14C] oleate. No significant changes were observed in LPL activity upon TSC22D1 
knockdown (Fig 22) revealing that LPL activity is not responsible for the decrease in VLDL 
triglyceride levels.  
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Fig 22: LPL activity is not affected by TSC22D1 knockdown. White adipose tissue LPL activity was 
determined in C57BL/6J mice injected with control or TSC22D1 shRNA adenovirus. Mice were fasted 
for 24h and one group was directly sacrified and the other was refed for 6h. (n=3-5), (means ±SEM) 
 
4.3.8 Hepatic TG release is not changed upon TSC22D1 knockdown 
To investigate the rate of TG production, a Tyloxapol assay was performed. Tyloxapol is a 
non-ionic detergent which upon injection results in complete inhibition of LPL. (S. Mandard 
et al., 2006). Inhibition of LPL continually leads to an accumulation of VLDL particles 
released from the liver into the blood stream over time. For this experiment, wt C57BL/6J 
mice were injected via tail vein with 2 x 109 viral particles expressing either a scrambled 
shRNA sequence (shNC), or the sequence targeting the TSC22D1 (shD1) mRNA. On day 6 
after injection, mice were fasted for 16 hours and then injected with 20% w/v Tyloxapol. 
Blood was drawn at specific time points and TG levels were determined colorimetrically (Fig 
23). Even though serum TG levels were slightly higher 50 and 100 min after Tyloxapol 
injection, there was no significant difference between both experimental groups at the final 
time point. Thus, TSC22D1 knockdown does not alter hepatic TG release.  
 
 
Fig 23: TSC22D1 knockdown does not alter VLDL secretion by the liver. Serum TG levels after 
tyloxapol injection in control or TSC22D1 shRNA adenovirus injected wild-type C57BL/6J mice. (n=6), 
(means ± SEM).  
 
4.3.9 TSC22D1 knockdown increases VLDL triglyceride clearance 
Apolipoprotein B is the main apolipoprotein of VLDL and it is present as one molecule per 
lipoprotein particle (H. N. Ginseberg et al., 2005). Thus, the determination of the amount of 
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ApoB directly yields the amount of VLDL particles. Excessive VLDL particles as occurring 
after a meal are cleared by the liver to prevent accumulation in the blood stream. In order 
to investigate if the clearance of VLDL particles is affected by TSC22D1 knockdown, a VLDL 
clearance assay was performed. To this end, mice were fasted for 4 hours and injected with 
purified human VLDL via the tail vein. Blood was taken at distinct time points and human 
apolipoprotein B (ApoB) levels in the serum were determined via enzyme-linked 
immunosorbent assay (ELISA) (Fig 24A), for human ApoB. In this experiment, VLDL 
clearance was significantly increased in TSC22D1 knockdown mice, which is in line with the 
observed phenotype. Further, Western blot analysis of livers from wild-type C57BL/6J mice 
injected with control or TSC22D1 shRNA adenovirus showed increased levels of ApoB in the 
liver of TSC22D1 knockdown mice (Fig 24B). As ApoB needed to enable clearance of VLDL 
from the blood, higher abundance of AboB protein in the liver are in accordance with 
higher clearance.  
 
Fig 24: TSC22D1 knockdown increases VLDL triglyceride clearance. Clearance of human ApoB from 
serum of control or TSC22D1 shRNA adenovirus injected C57BL/6J mice. 20μg of human VLDL were 
injected into each animal and serum samples were taken at the indicated time points. Human ApoB 
levels were determined by human-specific ELISA (n=5) (means ± SEM) Two Way ANOVA RM. (B) 
Representative Western blot of liver extracts from C57BL/6J mice injected with control (shNC) or 
TSC22D1 shRNA adenovirus. Protein was detected using ApoB and VCP (loading control) antibodies. 
n=3 
4.3.10 TSC22D1 knockdown leaves pFoxo1 levels unchanged  
Forkhead box (Fox)O1 is a transcription factor that has been shown to be a regulatory 
factor in VLDL metabolism. It can transcriptionally activate microsomal triglyceride transfer 
protein (MTP), which is required for VLDL assembly (A. Kamagate et al., 2008). FoxO1 is 
inactivated by Akt-mediated phosphorylation. In regards to the observed reduction in VLDL-
TGs by TSC22D1 ablation, FoxO1 and Akt levels in the liver were analyzed by Western 
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blotting. Neither total Akt or phosphorylated Akt nor FoxO1 or phosphorylated FoxO1 levels 
were altered upon TSC22D1 knockdown (Fig 25) indicating that FoxO1 is not responsible for 
the observed phenotype.  
 
 
Fig 25: TSC22D1 knockdown does not alter pFoxo levels. Representative Western blots of liver 
extracts from C57BL/6J mice injected with control (shNC) or TSC22D1 shRNA adenovirus. Protein was 
detected by (A) Akt, pAkt and VCP antibodies,(B) FoxO1, pFoxO1 and β-actin (loading control) 
antibodies.n=3  
4.3.11 TSC22D1 knockdown decreases expression of genes involved in cholesterol 
metabolism and VLDL synthesis 
Knockdown of TSC22D1 resulted in decreased serum VLDL triglycerides and HDL 
cholesterol. It was likely that expression of genes involved in lipid or cholesterol 
metabolism were altered to account for the observed phenotype. Quantitative real time PCR 
was used to analyze a panel of putative target genes for changes in gene expression (Fig 26). 
The investigated genes are grouped according to the functions or metabolic pathway they are 
involved in. A short description of their hepatic function is listed in Table 4.  
Table 4: List of analyzed genes involved in hepatic lipid and cholesterol metabolism  
Gene Name  Abbreviation Function Pathway regulated / 
cellular function 
Liver X Receptor LXR Transcription factor regulating 
cholesterol, fatty acid and glucose 
metabolism. 
 
 
Nuclear Receptors  
Peroxisome proliferator-
activated receptor alpha   
PPARα Transcription factor regulating hepatic 
lipid metabolism  
ATP-citrate lyase ACLY Acetyl CoA synthesis   
 
Lipogenesis 
Fatty acid synthase FANS Fatty acid elongation 
Stearoyl-CoA desaturase-1 SCD1 Production of desaturated fatty acids 
Fatty acid binding protein  FABP1 Binding of long chain fatty acids 
Angiopoietin-like 3 and 4 ANGPTL3/4 Inhibition of lipoprotein lipase and 
endothelial lipase 
 
LPL-Activity 
Scavenger Receptor B1 SRB1 HDL Receptor  
 
 
 
Low density lipoprotein 
receptor-related protein 1 
LRP1 Apolipoprotein E acceptor 
Low-Density Lipoprotein LDLR Apolipoprotein B receptor 
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Receptor  
Lipoproteins/Receptor/
Transporter 
Lipolysis-stimulated 
lipoprotein receptor 
LSR Receptor for triglyceride-rich 
lipoproteins 
Cluster of Differentiation 
36 
CD36 Uptake of long-chain fatty acids 
Apolipoprotein B ApoB Primary apolipoprotein of VLDL 
Tribbles homolog 1 TRIB1 Regulator of VLDL Production  
 
 
TG/VLDL synthesis and 
assembly 
diacylglycerol O-
acyltransferase 1 and 2  
DGAT1/2 Catalyzationof the formation of 
triglycerides from diacylglycerol and 
Acyl-CoA. 
Perilipin 2 PLIN2 Associated to lipid droplets  
Microsomal triglyceride 
transfer protein 
MTTP Lipoprotein assembly  
Lipin1 LPIN1 Involved in VLDL production 
Fat specific protein 27 FSP27 Associated to lipid droplets 
Cell death-inducing DNA 
fragmentation factor A-
like effector B 
CIDEB Associated to lipid droplets 
ATP-binding cassette 
transporter ABCA1 
ABCA1 Mediation of cholesterol and 
phospholipid efflux  
 
 
 
 
 
Cholesterol 
Metabolism 
ATP-binding cassette sub-
family G member 1 
ABCG1 Transport of cholesterol into 
endosome 
ATP-binding cassette sub-
family G member 5 and 8 
ABCG5/8 Excretion of sterols into bile 
Apolipoprotein A1/2 APOA1/2 Major protein components of HDL 
Lecithin-cholesterol-
acyltransferase 
LCAT Conversion of free cholesterol into 
cholesteryl ester 
Phospholipid transfer 
protein 
PLTP Transfer of phospholipids from 
triglyceride-rich lipoproteins to HDL 
Results 
 
 
39 
 
Fig 26: TSC22D1 knockdown results in decreased expression of key genes involved in cholesterol 
metabolism. TSC22D1 expression in C57BL/6J mice treated with control or TSC22D1 shRNA 
adenovirus. Mice were fasted for 24h and one group was directly sacrificed (Panel A) or refed for 6h 
Results  
 
 
40 
(Panel B). Liver mRNA levels of depicted genes (Table 2) were analyzed by qPCR. (n=5) (means ± 
SEM). (*) indicates significance; p < 0.05; (**)p < 0.01 
 
Firstly, gene expression analysis (Fig 26) revealed that most of the observed changes in 
gene expression occurred in the postprandial state. In the fed state, nuclear receptor LXR 
was slightly down-regulated, whereas PPARα was slightly up-regulated. Expression of key 
genes involved in lipogenesis as fatty acid synthase was not altered. Also expression of 
ANGPTL3 and 4, which inhibit lipoprotein lipase were unchanged, which is in line with the 
results of LPL activity measurement (Fig 22). When it comes to lipid metabolism, receptors 
for lipoproteins and their receptors play an important role in mediating the transport and 
uptake of lipids. Expression of LSR, which is a receptor for the TG-rich lipoproteins, was 
down-regulated as well as CD36 which mediates the uptake of long chain fatty acids. 
Moreover, genes involved in key steps in TG and VLDL synthesis and assembly as DGAT1 
and 2 or MTTP were significantly down-regulated by TSC22D1 knockdown. Genes for key 
mediators of cholesterol metabolism as ABCA1 which mediates cholesterol efflux, or 
ABCG1 which is responsible for cholesterol transport, were significantly less expressed in 
TSC22D1 knockdown animals as compared to control mice. In the fasted state, only PPARa 
was slightly up-regulated and expression of ApoA1 was nearly fully blunted. Altogether, 
these results are in line with the observed phenotype regarding decreased levels of VLDL-
triglycerides (Fig 21A) and decreased levels of HDL-cholesterol (Fig 21B) in TSC22D1 
knockdown animals compared to control mice particulary during fasting.  
 
4.4 Overexpression of TSC22D1 increases circulating VLDL triglycerides and 
HDL cholesterol 
As we observed that short term knockdown of TSC22D1 resulted in significant decrease of 
circulating VLDL triglycerides and HDL cholesterol, we wanted to investigate if 
overexpression of TSC22D1 could reverse that phenotype. For this purpose, an adenovirus 
encoding the TSC22D1 cDNA sequence in frame with the Flag peptide under the control of 
the constitutively active CMV promoter was cloned and produced. 
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4.4.1 Overexpression of TSC22D1 in fasted and refed mice  
For the overexpression study, 1x109 infectious units of either TSC22D1 overexpression 
virus, or an empty control virus incorporating the CMV promoter were injected via tail vein 
into C57BL/6J mice. As endogenous TSC22D1 expression is altered by fasting, 6 days after 
infection half the mice were fasted for 24h and sacrificed directly, whereas the other half 
was refed for 6h.  
Overexpression in the liver was analyzed by qPCR and Western blotting (Fig 27A-B). In the 
fasted as well as in the refed state, TSC22D1 was significantly overexpressed. Other than 
expected, TSC22D1 overexpression was higher in the fasted than in the refed state, which 
does not match the endogenous regulation. This is probably due to an activation of the 
CMV promoter by fasting signals, which has been observed in other experiments before 
(unpublished observation Maria Rohm, Allan Jones Herzig Lab). In order to see if TSC22D1 
overexpression was tissue specific, TSC22D1 levels were determined in abdominal fat (abd), 
inguinal fat (ing), kidney and gastrocnemius muscle (GC). Expression in these tissues was 
not changed by TSC22D1 overexpression in liver (Fig 27C). 
 
Fig 27: Hepatic overexpression of TSC22D1 in fasted and refed mice. TSC22D1 expression in 
C57BL/6J mice treated with control or TSC22D1 overexpression adenovirus. Mice were fasted for 16h 
and directly sacrificed or refed for 6h. (A) Liver mRNA levels of TSC22D1 were analyzed by qPCR. (B) 
Western blot of liver extracts from representative mice using TSC22D1 and β-actin (loading control) 
antibodies. n=3 (C) TSC22D1 expression in liver, abdominal fat (abd), inguinal fat (ing), kidney or 
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gastrocnemius muscle (GC) in the fasted state in same mice as in A. (means ± SEM, n=7). (**) 
indicates significance p<0.01 
 
4.4.2 TSC22D1 overexpression does not alter body or liver weight 
To asses if TSC22D1 overexpression affects body weight, mice were weight before injection 
and during the course of the experiment. There was no difference between the TSC22D1 
overexpression group and the control group. After 24h fasting both groups lost 
approximately 15% of their body weight. After 6h refeeding both experimental groups 
gained back 10% of their body weight (Fig 28A). During dissection of the mice, liver and 
abdominal fat weight were determined, which remained unchanged by TSC22D1 
overexpression (Fig 28B-C).  
 
Fig 28: Body, liver and abdominal fat weight are not affected by TSC22D1 overexpression. (A) Body 
weight (B) liver and (C) abdominal fat weight of mice treated with control (NC) or TSC22D1 
overexpression (D1) adenovirus. Mice were fasted for 24h and one group was directly sacrified and 
the other was refed for 6h. n=7 (means ± SEM)  
 
4.4.3 Hepatic glycogen and blood glucose are not affected by TSC22D1 overexpression 
Knockdown of TSC22D1 did not affect hepatic glycogen and blood glucose (Fig 19), as expected 
there were also no differences in blood glucose levels observed between TSC22D1 
overexpressing and control mice neither in fasted nor in the fed state (Fig 29A). For hepatic 
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glycogen, levels could only be determined in the fed animals, also blood glucose levels were 
unchanged (Fig 29B).  
 
Fig 29: Glycogen and blood glucose are unaltered by TSC22D1 overexpression. (A) Blood glucose 
and (B) hepatic glycogen in mice treated with control (NC) or TSC22D1 overexpression (D1) 
adenovirus. Mice were fasted for 24h and one group was directly sacrified and the other was refed 
for 6h. (n=7) (means ± SEM) 
 
4.4.4 TSC22D1 overexpression alters circulating VLDL triglycerides and HLD cholesterol 
levels  
The strong phenotype regarding serum parameters including circulating VLDL TGs in 
TSC22D1 knockdown mice prompted us to analyze the same parameters in TSC22D1 
overexpressing mice.  
As in the knockdown experiment, levels of circulating NEFAs and ketone bodies were 
unchanged (Fig 30A-B). Levels of circulating TGs were reduced in the fasted state but 
unaltered in the refed state (Fig 30C). Liver triglycerides were unchanged as well (Fig 30D).  
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Fig 30: Serum parameters are unchanged by TSC22D1 overexpression. (A) Serum non-esterified 
free fatty acids in C57BL/6J mice treated with control (NC) or TSC22D1 (D1) overexpression 
adenovirus. Mice were fasted for 24h and one group was directly sacrified and the other was refed 
for 6h (B) Serum ketone bodies in the same mice as in A. (C) Serum triglycerides in same mice as in A. 
(D) Liver triglyceride (TG) content in same mice as in A. (n=5) (means±SEM)  
 
FPLC analysis allows rapid separation by size and purification of the different lipoprotein 
fractions present in the serum. This allows a more detailed analysis of the serum lipid 
composition (W. Marz et al., 1993). In this study, FPLC analysis revealed a significant 
elevation in the VLDL peak in mice overexpressing TSC22D1 in the fasted state as compared 
to the control mice and also a mild elevation in the VLDL peak in the fed state (Fig 31A-B). 
Cholesterol levels in the fasting state were unchanged whereas in the refed state TSC22D1 
overexpression resulted in an elevated HDL peak (Fig 31C-D). These results are opposing to 
the effects seen by TSC22D1 knockdown, which strengthens the idea that TSC22D1 is 
involved in regulating levels of serum VLDL and HDL. 
 
Results 
 
 
45 
 
Fig 31: TSC22D1 overexpression increases circulating VLDL triglycerides and HDL cholesterol. 
Lipoprotein-associated serum triglyceride (TG) and cholesterol levels as measured by fast protein 
liquid chromatography (FPLC). Serum from 24 hour fasted or 6 hour refed mice treated with either 
control or TSC22D1 overexpression adenovirus was pooled and applied to a Superose 6 10/300 GL 
column; (A) TGs fasted, (B) TGs fed, (C) cholesterol fasted, (D) cholesterol fed. (n=5) 
 
4.4.5 TSC22D1 overexpression significantly induces ABCG1 expression 
In order to see if TSC22D1 overexpression changes the expression of genes that were 
affected by TSC22D1 knockdown (Table 4 and Fig 26), mRNA levels were analyzed by qPCR 
(Fig 32A-B). As observed before (Fig 26A), in the fasted state gene expression was not 
changed (Fig 30A). In the fed state, TSC22D1 overexpression resulted in a significant 
increase of FSP27 expression, which is opposite of what was detected in the case of 
TSC22D1 knockdown. For DGAT1 and 2 it is less clear, as DGAT1 expression is unregulated, 
whereas DGAT2 is down-regulated. Regarding the genes involved in cholesterol 
metabolism, ApoA1 and A2 expression was surprisingly down-regulated. Nevertheless, 
ABCG1 expression, which is a key factor for cholesterol shuttling, is up-regulated, which is 
in line with the FPLC results (Fig 31) and opposite of what is seen for TSC22D1 knockdown 
(Fig 21).  
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Fig 32: TSC22D1 overexpression induces FSP27 and ABCG1 expression. TSC22D1 expression in 
C57BL/6J mice treated with control or TSC22D1 cDNA adenovirus. Mice were fasted for 24h and one 
group was directly sacrificed (Panel A) or refed for 6h (Panel B). Liver mRNA levels of depicted genes 
(Table 4) were analyzed by qPCR. (n=5), (means ± SEM). (*) indicates significance; p < 0.05; (**)p < 
0.01 
 
4.5 Chronic knockdown of TSC22D1 results in reduced HDL cholesterol  
4.5.1 Chronic hepatocyte specific TSC22D1 knockdown 
As the short term knockdown as well as overexpression of TSC22D1 affected lipid 
metabolism, we wanted to confirm these results in an independent system. To investigate 
if chronic knockdown results in a similar phenotype as the short-term knockdown, a miRNA 
targeting TSC22D1 was cloned in an AAV vector system. Adenoviruses can only be used for 
short-term experiments as they are cleared from the body by the immune system. Adeno-
associcated viruses (AAV) do not evoke an immune-response and hence, can be used for 
long term knockdown experiments (N. Chirmule et al., 1999). Furthermore, the AAV 
serotype that was used (AAV2/8) was designed to preferentially infect hepatocytes and the 
inserted mRNA was under the control of the hepatocyte-specific LP1 promoter, which is not 
active in other liver cells such as Kupffer cells (P. Kulozik et al., 2011). Specific miRNA 
sequences targeting TSC22D1 were cloned into the Invitrogen pcDNA6.2-GW/EmGFP-miR 
vector. Their knockdown efficiency was tested by co-transfecting Hepa1c1 cells with 
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miRNAs targeting TSC22D1 or a scrambled control and a TSC22D1 overexpression 
construct. TSC22D1 depletion was analyzed by luciferase assay and Western blot (Fig 33A-
B). Sequence 4.2, performed efficiently in both assays and was subsequently sub-cloned 
into the pdsAAV-LP1-EGFPmut AAV (P. Kulozik et al., 2011). The plasmids encoding the 
miRNA constructs were contransfected into HEK293T cells with the pDGΔVP helper plasmid 
(D. Grimm et al., 1998) and a mutated p5E18-VD2/8 expression vector (G.P. Gao et al., 
2002) encoding AAV2 rep and a mutated AAV8 cap protein. The generated virus particles 
were purified via Iodixanol gradient and titered for in vivo application.  
 
 
Fig 33: Cloning of AAV miRNA expression construct for long term TSC22D1 knockdown. (A) 
HEK293A cells were transfected with plasmids containing the TSC22D1 sequence in frame with the 
luciferase coding sequence and co-transfected with plasmids expressing either a scrambled miRNA 
sequence (miNC) or different TSC22D1 targeting sequences. Luciferase activity is normalized to β-
galactosidase and plotted relative to control miRNA. (n=3), (means ± SEM). (B)  HEK293A cells were 
transfected with plasmids overexpressing flag-tagged TSC22D1 and co-transfected with plasmids 
expressing either a scrambled miRNA sequence (NC) or different TSC22D1 targeting sequences (1.3-
4.2) or nothing (-). Protein levels were analyzed by immunoblot using flag-antibody and VCP-
antibody as loading control. Results from 3 independent experiments are shown. 
 
4.5.2 TSC22D1 expression is significantly reduced in a chronic knockdown experiment 
C57BL/6N mice were injected with 5x1011 viral particles into the tail vein. Mice were kept 
for 34 days and sacrificed in a random fed state. TSC22D1 expression was analyzed by qPCR 
(Fig 34A) and Western blot (Fig 34B). TSC22D1 mRNA and protein levels were significantly 
reduced. In order to see if chronic TSC22D1 knockdown was tissue specific, TSC22D1 levels 
were determined in abdominal fat (abd), inguinal fat (ing), kidney and gastrocnemius 
muscle (GC). Expression in these tissues was not changed by miRNA mediated TSC22D1 
knockdown in the liver (Fig 34C). 
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Fig 34: AAV mediated TSC22D1 knockdown. TSC22D1 expression in C57BL/6N mice treated with 
control (NC) or TSC22D1 overexpression (miD1) AAV. (A) Liver mRNA levels of TSC22D1 were 
analyzed by qPCR. (B) Western blot and quantification of liver extracts from representative mice 
using TSC22D1 and β-actin (loading control) antibodies.(n=3) (C) TSC22D1 expression in liver, 
abdominal fat (abd), inguinal fat (ing), kidney or gastrocnemius muscle (GC) in same mice as in A. 
(means ± SEM, n=7). (***) indicates significance; p<0.001 
 
4.5.3 Long-term TSC22D1 knockdown reduces liver weight  
During the course of the experiment different weight parameters and blood glucose 
concentration were monitored. 25 days after injection mice were challenged with 24h 
fasting to see if fasting glucose was changed. There was no difference between the groups 
(Fig 35A). After sacrifice, abdominal fat and liver weight was measured. Interestingly, 
whereas body weight was not changed, TSC22D1 knockdown mice showed a slightly 
reduced liver weight, which could be correlated to TSC22D1 expression (Fig 35D-E). 
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Fig 35: Chronic TSC22D1 knockdown reduces liver weight. (A) Blood glucose of mice treated with 
control (miNC) or TSC22D1 miRNA (miD1) AAV. Mice were fasted for 24h refed for 6h, (B) body 
weight, (C) abdominal fat weight (D) and liver weight after sacrifice (E) Pearson’s correlation of 
log(2) of TSC22D1 expression and liver weight. n=5 (means ± SEM) (*) indicate significance p < 0.05 
 
4.5.4 HDL cholesterol is reduced by chronic TSC22D1 knockdown 
As short term knockdown of TSC22D1 as well as its overexpression, altered the serum 
profile regarding VLDL triglycerides and HDL cholesterol, this effect was analyzed in more 
detail. Different to the other two studies the mice were in a random fed state at the time of 
sacrifice. Serum NEFAS were unchanged, whereas, ketone bodies were reduced in the 
TSC22D1 knockdown animals compared to control mice (Fig 36A-B). Circulating TGs were 
not altered, and liver TGs were slightly but not significantly reduced (Fig 36C-D). As seen 
before by acute knockdown (Fig 20) liver cholesterol levels were significantly increased in 
TSC22D1 depleted mice as compared to control mice (Fig 36E).  
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Fig 36: Serum ketone bodies are reduced by long term TSC22D1 knockdown. (A) Serum non-
esterified free fatty acids in BL56C/6N mice treated with control (miNC) or TSC22D1 miRNA AAV 
(miD1). Mice were sacrified in refed state. (B) serum ketone bodies, (C) serum triglyceride, (D) liver 
triglyceride (TG) content, (E) liver cholesterol content in same mice as in A. (n=5) (means±SEM)  
 
To characterize the lipoprotein fractions we again performed an FPLC analysis. In contrast 
to acute TSC22D1 knockdown, the VLDL TG peak was unchanged (Fig 37A). However, we 
observed again a 25% reduction in the HDL cholesterol peak (Fig 37B). This is in line with 
the results from the acute knockdown study (Fig 20) and the hypothesis that TSC22D1 plays 
a role in regulating levels of circulating HDL cholesterol.  
 
Fig 37: Long term TSC22D1 knockdown lowers circulating HDL cholesterol. Lipoprotein-associated 
serum triglyceride (TG) and cholesterol levels as measured by fast protein liquid chromatography 
(FPLC). Serum from random fed mice treated with either control (miNC) or TSC22D1 miRNA AAV 
(miD1) was pooled and applied to a Superose 6 10/300 GL column; (A) TGs (B) cholesterol (n=5).  
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4.5.5 Chronic knockdown of TSC22D1 alters expression of key cholesterol metabolism 
genes 
Chronic TSC22D1 knockdown reduced HDL cholesterol but left VLDL TGs unaltered (Fig 37A-
B). In order to investigate if that can be explained by changes in gene expression, we 
performed qPCR analysis on genes involved in VLDL assembly and cholesterol metabolism 
(Table 4). Other than for the short term knockdown (Fig 26) chronic TSC22D1 ablation did 
not change expression of DAGT1 or 2 or MTTP (Fig 38A). Again, however, genes involved in 
cholesterol metabolism as ApoA1 or ABCG5 and 8 were significantly down-regulated in 
TSC22D1 knockdown mice as compared to control mice (Fig 38B). These results are in line 
with the FPLC analysis (Fig 37).  
 
 
Fig 38: Chronic TSC22D1 knockdown alters expression of cholesterol metabolism genes. TSC22D1 
expression in C57BL/6N mice treated with control or TSC22D1 AAV. Liver mRNA levels of depicted 
genes involved in (A) VLDL assembly, (B) cholesterol metabolism (Table 4) were analyzed by qPCR. 
(n=5) (means ± SEM). (*) indicates significance; p < 0.05; (**)p < 0.01 
 
In order to get a comprehensive analysis of changes in gene expression by chronic TSC22D1 
ablation, microarray analysis was performed using RNA extracts isolated from the livers of 
control or TSC22D1 deficient mice. As seen from the hierarchical heat map (Fig 39A), the 
four groups were very homogenous but distinct from one another. In total, more than 1600 
genes were differentially regulated. The volcano plot (Fig 39B) shows all genes on the 
microarray, all genes above the threshold are considered as significantly altered in 
expression (p < 0.05). Genes shown on the left are less expressed and on the right more 
expressed in the TSC22D1 knockdown mice as compared to negative control mice. The 
volcano plot indicates, that TSC22D1 knockdown up- as well as downregulates a 
comparable amount of genes. As expected, TSC22D1 was among the most strongly down-
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regulated genes. Furthermore ABC transporters, as ABCA1, or apolipoproteins as ApoA4, 
which is a part of HDL cholesterol were among the down-regulated genes. Gene set 
enrichment analysis (GSEA) was performed to find groups of genes that are regulated 
together. Among the top regulated pathways were steroid synthesis and PPAR signaling, 
but also pathways as cytosolic DNA-sensing pathway or TGFbeta signaling. Microarray 
analysis proved that hepatocyte specific TSC22D1 knockdown changes the expression of a 
large set of genes. It did not give new insight, however, in regards to the observed 
cholesterol phenotype.  
 
 
Results 
 
 
53 
Fig 39: Gene expression profiling of C57BL/6J mice treated with control or TSC22D1 AAV. (A) 
Hierarchical heat map cluster of the samples, (B) Volcano Plot of control vs. TSC22D1 miRNA treated 
animals.The red arrow indicates TSC22D1. (n=4) 
4.6 Effects of TSC22D1 knockdown in cultured cells 
Next, we wanted to see if TSC22D1 ablation can as well change the expression of some of 
the genes involved in cholesterol metabolism in a cell culture model. For this purpose, 
Hepa1c1 cells, a mouse hepatoma cell line, were infected with either control or TSC22D1 
shRNA adenovirus and harvested 48h post transfection. Gene expression was analyzed by 
qPCR (Fig 40). TSC22D1 mRNA levels were reduced by 80%. Hepa1c1 cells do not express 
ABCG1 and ABCG8, nevertheless, ABCG5 and ApoA1 mRNA levels were reduced by 
TSC22D1 knockdown, which is in line with the results seen in vivo (Fig 38B).  
 
 
Fig 40: TSC22D1 knockdown reduces ApoA1 expression. Expression of genes involved in cholesterol 
metabolism (Table 4) in Hepa1c1 cells infected with either control (shNC) or TSC22D1 shRNA 
expressing adenovirus at an MOI of 500. mRNA levels were analyzed by qPCR. (n=3-4) (means ± 
SEM). (*) indicates significance; p < 0.05;  
 
4.7 TSC22D1 knockdown reduced HDL cholesterol in a mouse model of 
obesity 
TSC22D1 expression was shown to be up-regulated in mouse models of obesity, such as 
ob/ob mice (Fig 12A). These mice have a mutation in the leptin gene (Y. Zhang et al., 1994). 
Furthermore, they exhibit increased levels of cholesterol (P. Hahn, 1980). Having in mind 
the reduction of HDL cholesterol by TSC22D1 knockdown in wildtype C57BL/6J mice, we 
expected that TSC22D1 knockdown also reduces cholesterol in ob/ob mice.  
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4.7.1 TSC22D1 can be efficiently knocked down in ob/ob mice 
The AAV system was used to deliver control or TSC22D1 specific miRNAs to knockdown 
TSC22D1. For this purpose, mice were injected with 5x1011 viral particles into the tail vein 
and housed for 3 weeks, body weight and blood glucose were monitored. On day 20 after 
injection mice were fasted for 24h, one group was sacrificed directly and the other was 
refed for 6h. Liver TSC22D1 mRNA levels were determined by qPCR (Fig 41A) and Western 
blot analysis (Fig 41B). TSC22D1 mRNA and protein level were significantly lower in the 
miD1 group compared to the control group. Also, in the control group TSC22D1 expression 
was down-regulated by fasting again.  
 
Fig 41: AAV mediated TSC22D1 knockdown. (A) TSC22D1 expression in ob/ob mice treated with 
control (NC) or TSC22D1 overexpression (miD1) AAV. Mice were fasted for 24h and either directly 
sacrificed or refed for 6h. Liver mRNA levels of TSC22D1 were analyzed by qPCR. (B) Western blot of 
liver extracts from representative mice using TSC22D1 and β-actin (loading control) antibodies. 
(n=7), (means ±SEM), (*) indicates significance p<0.05 and (**) p<0.01 for genotype and (#) 
indicates significance p<0.05 for nutritional status 
 
4.7.2 Body weight, blood glucose and liver weight are unaltered by TSC22D1 
knockdown in ob/ob mice 
As already observed in the previous experiments, body weight and liver or abdominal fat 
weight were not changed (Fig 42A-C). It should be noted, that the blood sugar 
concentration was in a physiological range in all groups and under all conditions (Fig 42D), 
which indicates that the ob/ob mice were not yet in a diabetic state.  
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Fig 42: No change of body weight, blood glucose or liver weight by TSC22D1 knockdown. (A) Body 
weight of ob/ob mice treated with control (miNC) or TSC22D1 miRNA (miD1) AAV. Mice were fasted 
for 24h and sacrificed or refed for 6, (B) abdominal fat weight, (C) liver weight and (D) blood glucose. 
n=7 (means ± SEM) (*) 
 
4.7.3 HDL cholesterol is reduced by TSC22D1 knockdown in ob/ob mice 
Based on the other three studies, serum parameters were analyzed for the fasted and the 
fed state. Serum NEFAS, ketone bodies and serum TGs were unchanged (Fig 43A-C). Livers 
of ob/ob mice contained a lot of lipid droplets, but fat content was not changed by 
TSC22D1 knockdown as shown by liver lipid isolation and Oil-red-o staining (Fig 43D). As 
observed before (Fig 36) cholesterol was increased in livers of fed TSC22D1 knockdown 
mice as compared to control mice (Fig 43E).  
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Fig 43: No change in circulating TGs by TSC22D1 knockdown in ob/ob mice. Ob/ob mice were 
treated with control (miNC) or TSC22D1 miRNA AAV (miD1). Mice were fasted for 24h, one group 
was sacrified directly and the other refed for 6h. (A) Serum non-esterified free fatty acids (NEFA), (B) 
serum ketone bodies, (C) serum triglycerides, (D) liver triglyceride (TG) as shown by representative 
Oil-red-O staining of cryosections and (E) liver cholesterol. (n=7) (means±SEM), (*) indicates 
significance p<0.05 
  
The FPLC analysis of circulating VLDL-TGs or HDL-cholesterol revealed no difference in VLDL 
TGs in fasted or refed animals (Fig 44A-B). However, a substantial reduction in fasting HDL 
and LDL cholesterol and a slight reduction of HDL cholesterol in the fed state by TSC22D1 
knockdown could be shown (Fig 44C-D). This data is in line with the results of the prior 
studies of acute and chronic TSC22D1 knockdown.  
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Fig 44: TSC22D1 knockdown in ob/ob mice lowers circulating HDL cholesterol. Lipoprotein-
associated serum triglyceride (TG) and cholesterol levels as measured by fast protein liquid 
chromatography (FPLC). Serum from 24h fasted or 6h refed ob/ob mice treated with either control 
(miNC) or TSC22D1 miRNA AAV (miD1) was pooled and applied to a Superose 6 10/300 GL column; 
(A) fasting TGs, (B) fed TGs, (C) fasting cholesterol and (D) fed cholesterol (n=7).  
 
4.7.4 TSC22D1 knockdown can decrease expression of cholesterol metabolism linked 
genes in ob/ob mice 
As hypothesized, TSC22D1 knockdown in ob/ob mice could reduce HDL cholesterol (Fig 44). 
Again, we analyzed expression of genes involved in VLDL assembly and cholesterol 
metabolism (Table 4) by qPCR. Expression of MTTP, DGAT1/2 and FSP27 (Fig 45A-B) was not 
altered. For the panel of genes involved in cholesterol metabolism different genes were 
altered depending on the feeding status of the mice (Fig 45A-B). In fasted animals, ABCA1 
and LCAT and PLTP showed reduced expression in TSC22D1 ablated mice as compared to 
controls. In the fed state, as seen before (Fig 26, 28 and 38) expression of ApoA1 and 2 and 
ABCG51, 5 and 8 was significantly reduced. The expression data is in line with the previous 
results and strengthens the idea of TSC22D1 as a mediator of cholesterol metabolism.  
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Fig 45: TSC22D1 knockdown reduces expression of cholesterol metabolism genes. TSC22D1 
expression in C57BL/6J mice treated with control or TSC22D1 cDNA adenovirus. Mice were fasted for 
24h and one group was directly sacrificed (Panel A) or refed for 6h (Panel B). Liver mRNA levels of 
depicted genes (Table 4) was analyzed by qPCR. (n=7) (means ± SEM). (*) indicates significance; p < 
0.05; (**)p < 0.01 
 
4.8 Comprehensive overview of all conducted mouse experiments  
A summary of phenotypes and biochemical parameters resulting from acute or chronic 
TSC22D1 knockdown or overexpression in the liver of wild-type or ob/ob mice is shown in 
Table 5. 
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Table 5: Summary of phenotypic changes in mice with altered hepatic TSC22D1 expression 
 
Abd: abdominal fat; NEFA: non esterified fatty acids; Ketone: ketone bodies; TG: triglycerides; Glc: glucose; C: 
cholesterol; Gly: Glycogen: FPLC: fast protein liquid chromatography; VLDL: very low density lipoprotein; HDL: 
high density lipoprotein; KD: knockdown; OE: overexpression, -: no change; ↓ reduced levels;  ↑ increased 
levels both as compared to control mice; ud: undetectable; nd: not determined  
Mouse 
 Strain 
TSC22D1 
 Status 
Nutritional 
Status 
Weight Serum Liver FPLC Expression of key 
genes Body Abd Liver NEFA Ketone TG Glc TG C Gly VLDL HDL 
C57BL/6 KD acute Fast - - - - - ud - - ↑ ud ↓↓ ↓↓ ↓APOA1 
C57BL/6 KD acute Fed - - - - - ↓↓ - - - - ↓↓ ↓ ↓DGAT1/2, MTTP, 
TRIB1, PLIN2, 
CIDEB, FSP27, 
ABCA1, ABCG1, 
ABCG8, APOA2 
C57BL/6 OE acute Fast - - - - - ↓ - - nd ud ↑↑ -  
C57BL/6 OE acute Fed - - - - - - - - nd - ↑ ↑↑ ↑DGAT2, FSP27, 
ABCG1, PLTP, ↓ 
APOA1, APOA2 
C57BL/6 KD 
chronic 
Fed - - ↓ - ↓↓ - - - ↑ - - ↓↓ ↓APOA1, ABCG5/8 
ob/ob KD 
chronic 
Fast - - - - - - - - - nd - ↓↓ ↓ABCA1 
ob/ob KD 
chronic 
Fed - - - - - - - - ↑ nd - ↓ ↓APOA1, APOA2, 
ABCG1, ABCG5/8 
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5 Discussion 
5.1 TSC22D1 regulates systemic HDL cholesterol metabolism 
Cardiovascular diseases (CVDs) are the leading cause of death worldwide. In 2008 an 
estimate of 17.3 million people died from CVDs, and the numbers are on the rise (WHO fact 
sheet No 317, 2013). Prevention of atherosclerosis requires life style changes, but several 
drugs have also been developed with statins representing the most widely used group. 
They are HMG-CoA reductase inhibitors which work primarily by reducing LDL cholesterol 
levels, as elevated serum LDL levels are shown to be atherogenic. Nevertheless, HDL 
cholesterol remains a predictor for cardiovascular events in statin treated patients besides 
their LDL levels (H. Soran et al., 2012). Further, various studies in humans present an 
inverse correlation between plasma concentrations of HDL, and the risk for atherosclerotic 
cardiovascular disease (G.F. Lewis and D.J. Rader, 2005). 
 
5.1.1 TSC22D1 knockdown alters cholesterol efflux by changes in gene expression 
In the present study we found that TSC22D1 has a promoting effect on systemic HDL 
cholesterol levels in mice (Table 5). Although mice are highly resistant to atherosclerosis; 
they represent a good and widely used model system to study HDL cholesterol metabolism 
in vivo, especially because of their high levels of HDL (J. Jawien et al., 2004). It has to be 
noted, that mice and humans have different blood profiles when it comes to cholesterol. 
Humans carry about 75% of their plasma cholesterol in LDL, mice, however, carry most of 
their cholesterol in form of HDL (J. Jawien et al., 2004). FPLC analysis showed a reduction of 
HDL cholesterol in an acute as well as in a chronic TSC22D1 loss of function experiment (Fig 
21 and 37) in C57BL/6 mice. Overexpression of TSC22D1 could in turn elevate plasma HDL 
cholesterol (Fig 31). We explain these findings by changes in gene expression of some key 
genes in the cholesterol metabolism pathway, which will be discussed in the following.  
Apoliprotein A1 is the most abundant apoliprotein in the human plasma and it is secreted 
by the liver and the intestine. Like HDL, ApoA1 plasma concentration is inversely correlated 
to atherosclerosis (G.F. Lewis and D. J. Rader, 2005). Mice lacking ApoA1 have significantly 
lower plasma HDL cholesterol levels (A. S. Plump et al., 1997), reflecting our findings with 
TSC22D1 ablated mice showing lower expression of ApoA1 (Table 5). As ApoA1 levels are 
mainly transcriptionally regulated (S. Malik, 2003), reduced expression of ApoA1 by 
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TSC22D1 knockdown would then translate to lower levels of serum ApoA1. However, 
serum analysis for ApoA1 levels has not been performed so far.  
ATP binding cassette transporter 1 (ABCA1) is often described as the most important 
mediator for the efflux of cholesterol from macrophages to HDL in the reverse cholesterol 
transport. Patients with Tangier disease, who carry a mutated and thus defective ABCA1, 
have very low plasma HDL (M. Maricil et al., 1999). ABCA1 expressed in hepatocytes is 
involved in the generation of HDL particles (E. Tarling et al., 2013). Thus, liver specific 
ABCA1 deficiency reduces serum HDL by 80% (J. Y. Lee and J.S. Parks, 2005). In the present 
study, ABCA1 expression in TSC22D1 ablated mice was decreased as compared to control 
mice (Table 5), indicating that this may contribute to the reduced levels of HDL cholesterol 
in these mice and increased liver cholesterol.  
Additionally, expression of ABCG5 and/or 8 is reduced by TSC22D1 knockdown (Table 5). 
ABCG5 and 8 are expressed in liver as well as in intestine and they function as a 
heterodimer in efflux of plant sterols. It was shown that ABCG5/8 knockout mice (ABCG5/8-
/-) fed a normal chow diet containing 0.02% cholesterol, had highly reduced serum 
cholesterol levels compared to control mice (L. Yu et al., 2002). These mice exhibited 
however reduced liver cholesterol, which is contradicting the increased hepatic cholesterol 
content of TSC22D1 ablated mice (Table 5). This discrepancy may possibly be explained 
through the observed decrease of ApoA1 expression, which might reduce HDL efflux and 
thereby result in higher cholesterol levels in the liver. ABCG5/8-/- mice have higher 
cholesterol concentrations in their gallbladder (L. Yu et al., 2002). The excretion of 
cholesterol into bile is important for cholesterol excretion out of the body and thus limits 
the reuptake of cholesterol by the intestine. In our studies the cholesterol content of the 
bile was not measured. The decrease in ABCG5/8 gene expression hints at a reduction of 
bile cholesterol in TSC22D1 ablated mice compared to control mice.  
In summary, TSC22D1 knockdown seems to specifically alter cholesterol efflux as presented 
in Fig 46. Apparently, cholesterol efflux from the liver mediated by the ABCA1 transporter is 
reduced as is ApoA1 expression, resulting in a decreased HDL particle formation. 
Furthermore, reduction of the levels of ABCG5/8 results in lowered transport of cholesterol 
to the intestine. Uptake appears to be unaffected as indicated by unchanged expression of 
scavenger receptor B1 (SR-B1) (Table 5), the major HDL receptor (S. Acton et al., 1996). 
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Fig 46: Altered cholesterol metabolism by reduced TSC22D1 expression. Hepatic knockdown of 
TSC22D1 in wild-type as well as in ob/ob mice specifically alters expression of genes involved in 
cholesterol efflux. Lower expression of hepatic ABCA1 results in decreased cholesterol efflux from the 
liver. Additionally, reduced ApoA1 expression decreases HDL particle formation. Finally, lower levels 
of ABCG5/8 reduce transport of cholesterol into the intestine for re-shuttling or final secretion from 
the body. Uptake of HDL into the liver or particle maturation is presumably not altered.  
A1/2: ApolipoproteinA1/2; C: cholesterol; LCAT: lecithin-cholesterol acetyltransferase; CE: cholesterol-ester, 
HDL: high density lipoprotein; ABC A1/G5/G8: ATP-binding cassette protein A1, G5, G8; TG: triglycerides 
The part of the cholesterol metabolism which is directly affected by reduced TSC22D1 expression is mareked 
with a red dotted line.  
 
ApoA1, as well as ABCG5 and 8 are also expressed by the intestine, where they play a 
substantial role in regulating system cholesterol homeostasis. TSC22D1 expression levels in 
intestine have been shown to be even higher than in the liver (P. Jay et al., 1996). Given the 
putative function of TSC22D1 to regulate expression of ApoA and ABCG5/8, it would be 
very interesting to analyze the effect of TSC22D1 knockdown in the intestine. One can 
speculate that a combined ablation of TSC22D1 liver and intestine function would have an 
even higher impact on systemic cholesterol homeostasis. We cannot rule out that TSC22D1 
exerts its function in a tissue specific manner, as is the case for TBL1 and TBLR1 which are 
expressed in various different tissues including liver and white adipose tissue and both play 
a major role in regulating liver lipids (P. Kulozik et al., 2011). Nevertheless, only TBLR1 not 
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TBL1 acts on lipolysis in white adipose tissue. (M. Rohm et al., 2013, and M. Rohm PhD 
thesis, Herzig Lab) 
We made an interesting observation regarding cholesterol metabolism and the regulation 
of TSC22D1. Apparently, regulation of TSC22D1 expression by fasting or feeding signals is 
impaired in aged mice (Fig 14). It has been described that cholesterol efflux is impaired with 
aging (H. Berrougui, et al. 2007) and also concentrations of ApoA1 decrease with age (H. 
Berrougui and A. Khalil, 2009). Hence, it is tempting to speculate, that a decrease in the 
expression levels of TSC22D1 correlates with impairment of cholesterol regulation in aging.  
5.1.2 Overexpression of TSC22D1 increases HDL cholesterol  
Currently, we cannot explain why overexpression of TSC22D1 leads to an increase in HDL 
cholesterol. When it comes to gene expression analysis (Fig 32), we saw a reduced 
expression of ApoA1 as also seen before in case of TSC22D1 knockdown. Expression of 
phospholipid transfer protein (PLTP) was slightly increased, a gene that was not affected by 
acute TSC22D1 ablation. PLTP is responsible for the transfer mainly of phospholipids from 
VLDL to HDL particles. A recent publication demonstrated that liver specific overexpression 
of PLTP resulted in an increase in non-HDL cholesterol and VLDL-TGs, rather than in HDL 
cholesterol. These findings regarding cholesterol levels are not in line with our study. 
Interestingly, however we saw a similar increase in VLDL-TG levels (Fig 31). Another gene 
upregulated by hepatic TSC22D1 overexpression, was ABCG1, which is responsible for the 
efflux of cholesterol to already lipid rich HDL. Liver-specific overexpression of ABCG1 
resulted in decreased serum HDL rather than increased levels as seen in our study. Further 
analysis is required to explain the HDL cholesterol phenotype seen by TSC22D1 
overexpression, including PLTP enzyme activity or ApoA1 protein abundance.  
5.1.3 TSC22D1 knockdown in a mouse model of obesity  
Given the promoting effect of TSC22D1 on systemic HDL cholesterol levels in C57BL/6 mice, 
we hypothesized that the observed upregulation of TSC22D1 under obesity conditions (Fig 
12-13) reflects a counter-regulatory mechanism to maintain high levels of HDL cholesterol. 
Compared to C57BL/6 mice ob/ob mice exhibit an abnormal blood profile they show higher 
levels of HDL as well as less dense HDL particles and LDL, both appearing as a shoulder on 
the HDL peak in an FPLC analysis and are referred to as HDL1/LDL (own observation and 
D.L. Silver et al., 1999). Interestingly, we could see that chronic knockdown of TSC22D1 
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resulted in significantly reduced levels of HDL cholesterol and also lowered the HDL1/LDL 
shoulder in ob/ob mice (Fig 44). As observed before, TSC22D1 knockdown in ob/ob mice 
resulted in a decreased expression of ABCA1, ApoA1, ABCG5 and 8 (Fig 45). Additionally, 
expression of ApoA2 was reduced. It is the second most abundant Apoliporotein on HLD 
particles, and interestingly, it is especially high expressed in ob/ob mice (D.L. Silver et al., 
1999). Due to the increased levels of HDL cholesterol, ob/ob mice are protected against 
atherosclerosis as compared to C57BL/6 mice (M.R. Plummer A. H. Hasty., 2008). Our data 
indicate that TSC22D1 might be involved in such a protection mechanism. 
5.1.4 Liver TSC22D1 expression is reduced in a mouse model of atherosclerosis  
LDL receptor knockout mice (LDLR-/-) represent one of the most used mouse models for 
studies regarding atherosclerosis. They present low levels of HDL and increased levels of 
LDL and develop atherosclerosis on a high cholesterol diet (J. Jawien, 2004). LDL and as well 
as VLDL levels are further increased in streptozotocin-induced (STZ) type 1 diabetic mice 
(R.K Vikramadithyan et al., 2005 and unpublished observation K. Genreith, Herzig Lab). 
Diabetes exaggerates development of vascular lesions in these mice. Interestingly, we 
found hepatic TSC22D1 levels significantly reduced in livers of STZ treated LDLR-/- mice, as 
compared to non-diabetic LDLR-/- controls (own observation, data not shown). 
Furthermore, liver TSC22D1 mRNA levels tended to negatively correlate with the degree of 
plaque formation in STZ treated or non-treated LDLR-/- mice (own observation, data not 
shown). These findings strengthen the idea that TSC22D1 plays a role in atheroprotection. 
In this respect, it would be highly interesting to see if hepatic TSC22D1 overexpression in 
LDLR-/- mice would help to normalize the blood profile by increasing HDL cholesterol and 
thus, decrease atherogenic plaque formation.  
5.1.5 Atherosclerosis and TGFbeta 
TSC22D1 expression was initially found to be induced by TGFbeta1 in mouse osteoblastic 
cells (M. Shibanuma et al., 1992). We could recapitulate this finding in vitro in primary 
hepatocytes (Fig 15) as well as in vivo, where systemic introduction of TGFbeta induced 
hepatic TSC22D1 expression. It has recently been shown that systemic TGFbeta levels were 
elevated in obese patients (H. Yadav et al., 2011) and obese mice (Fig 15 and H. Yadav et 
al., 2011), which interestingly is in accordance with higher TSC22D1 expression in ob/ob 
mice. Intriguingly, there is evidence that TGF beta is anti-atherogenic. It has been shown 
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that there is an inverse relationship between serum TGFbeta levels and the development of 
atherosclerosis (N.N. Singh D.P. Ramji, 2006). Serum levels of TFGbeta were found to be 
severely reduced in advanced atherosclerosis (D. J. Grainger et al., 1995). TSC22D1 
knockdown resulted in decreased levels of HDL cholesterol, which is a risk for development 
of atherosclerosis. It is tempting to speculate that there is a correlation between low 
TGFbeta levels in atherosclerosis, low levels of TSC22D1 expression and reduced 
atheroprotection by reduction of HDL cholesterol.  
5.1.6 Beyond cholesterol  
There are several other important aspects prompting to understand HDL metabolism. HDL 
has a lot of additional functions apart from its importance as the “good cholesterol”, as it is 
termed in the laymen press (C. Mineo, 2013). For instance, HDL and its component ApoA1 
can promote insulin secretion by pancreatic beta cells (S. J. Peterson et al., 2008). Other in 
vivo studies suggest, that HDL can bind and neutralize bacterial lipololysaccharide (LPS) and 
thereby prevent proinflammatory gene expression (H. Soran et al., 2012). There is also 
evidence that HDL can enhance endothelial cell proliferation, which is important an 
important response to vascular injury (C. Mineo, 2013). The present study did not consider 
a role of TSC22D1 for HDL besides cholesterol metabolism. But these few examples 
demonstrate that it might be worthwhile to have a look beyond cholesterol. 
 
5.2 TSC22D1 as a transcriptional co-regulator 
Transcriptional regulators represent critical checkpoints in the regulation of liver energy 
homeostasis, as exemplified by several nuclear receptor co-factors, e.g. peroxisome 
proliferator-activated receptor co-activator (PGC) 1, receptor interaction protein (RIP) 140 
and transducing beta-like (TBL1) (J.N. Feige and J. Auwerx, 2007; P. Kulozik et al., 2011, M. 
Berriel Diaz et al., 2008).  
In the present study, we could demonstrate with co-immunoprecipitation studies that 
TSC22D1 indeed interacts with TBL1 (Fig 8). This interaction, however, could neither be 
recapitulated nor further mapped by GST-pulldowns. These findings indicate that TBL1 and 
TSC22D1 do not interact directly but may be associated in a complex with several other 
proteins. This assumption could be experimentally verified by immunoprecipitation of 
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TSC22D1 directly from liver tissue and subsequent analysis using mass spectrometry to 
identify endogenous interaction partners.  
Other than TSC22D4, TSC22D1 did not co-immuoprecipitate with TBRL1, which early on 
indicated that TSC22D1 and TSC22D4 might be present in different complexes and thus, will 
also have different functions in liver metabolism. Previous studies on the common 
Drosophila melanogaster TSC22D precursor bunched also indicated that TSC22D4 and 
TSC22D1 may at least in part have antagonizing effects in regard to cell proliferation (X. Wu 
et al., 2008; S. Gluderer et al., 2008). This data is in line with our findings from gene 
expression analysis for TSC22D1 and TSC22D4. Whereas TSC22D1 expression is reduced in 
states of energy deprivation and increased in energy surplus situations (Table 3) TSC22D4 is 
regulated in the opposite direction (A. Jones, PhD thesis, Herzig Lab).  
TSC22D1 has to be present in the nucleus to act as a transcriptional co-factor. However, a 
nuclear localization signal is missing (M. Shibanuma et al., 1992; S. Ohta et al., 1997) but a 
nuclear export signal (NES) is present at its N-terminus (P. Jay et al., 1996). As the molecular 
weight of human as well as rodent TSC22D1 is about 16-18 kDa (P. Jay et al., 1996; M. 
Shibanuma et al., 1992) and intracellular proteins of 50 kDa or less can freely permeate 
through micropores in the nuclear membrane (J.E. Hinshaw et al., 1992). TSC22D1 may 
nevertheless be able to enter the nucleus. Additionally, translocation of TSC22D1 from the 
cytoplasm to the nucleus has been implicated, as flag-tagged TSC22D1 was present in the 
cytoplasm under steady-state conditions and Ras activation could induce nulear 
translocation (M. Nakamura et al., 2011). 
The intracellular localization of TSC22D1 in hepatocytes is presently unknown. Recently, a 
Western blot analysis detected TSC22D1 in the nuclear, but not in the cytoplasmic fraction 
of liver lysates (own observation). This preliminary observation requires a more in depth 
analysis to draw sound conclusion regarding the localization of TSC22D1. Furthermore, it 
would be interesting to see if its subcellular localization is altered under different metabolic 
conditions.  
5.2.1 TSC22D1 and LXR? 
We consider TSC22D1 to be a transcription co-regulator, nevertheless, we did not perform 
studies so far to determine DNA binding interaction partners. Based on its role in liver 
Discussion 
 
 
67 
metabolism, we assume that TSC22D1 would interact with a nuclear receptor because 
nuclear receptors are pivotal for integrating nutritional, metabolic and endocrine signals.  
In respect to the changes in gene expression seen by TSC22D1 knockdown (Table 5), liver 
receptor X (LXR) would be a likely candidate. There are two LXRs, LXRalpha, which is highly 
expressed in metabolic active tissues as liver, white adipose tissue or macrophages and LXR 
beta which is ubiquitously expressed (A. C. Calkin and P. Tontonoz, 2012). LXR functions as 
an obligate heterodimer with retinoid X receptor (RXR). Activation of gene transcription 
requires ligand binding. LXR can be activated by cholesterol derivatives as oxysterols (B. A. 
Janowski et al., 1996) or by synthetic agonists. Thus, direct target genes of LXR include 
genes involved in reverse cholesterol transport, cholesterol uptake, cholesterol absorption 
and secretion. Indeed, in our study TSC22D1 knockdown resulted in decreased expression 
of ABCA1 and ABCG5/8, which are direct targets of LXR (J. J. Repa et al., 2000). Along these 
lines, acute knockdown of TSC22D1 in C57BL/6 mice, as well as chronic TSC22D1 ablation in 
ob/ob mice, reduced expression of cholesterol 7 alpha hydroxylase (Cyp7a) (own 
observation). Cyp7a is the key enzyme in the conversion of cholesterol to bile acid, and is a 
further LXR target gene. It would be interesting to see if the presence of TSC22D1 can alter 
LXR activity and if so, under which conditions this occurs. Luciferase promoter assays could 
be conducted to address this question. A putative model for TSC22D1 function is shown in 
Fig 46. 
 
 
Fig 47: Putative TSC22D1 action on nuclear receptor LXR. 
LXR/RXR dimer and their co-repressor complex are bound to the DNA and transcription is repressed. 
Upon ligand binding conformational changes are induced and co-activator complexes can bind and 
activate target gene transcription e.g. of ABCA1 transcription. TSC22D1 (D1) protein is part of the 
co-activator complex. In case TSC22D1 levels are reduced, as by knockdown or by fasting, activation 
is less efficient and target gene transcription is reduced.  
LXR: liver X receptor; RE: response element; RXR: retinoid X receptor; ABCA1: ATP binding cassette protein A1; 
D1: TSC22D1  
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As discussed before, Apolipoprotein A1 expression was also shown to be reduced by 
TSC22D1 knockdown (Table 5). ApoA1 is not a direct target gene of LXR. Interestingly, 
however, ApoA1 is a farnesoid x receptor (FXR) target, which as LXR also heterodimerizes 
with RXR, indicating that TSC22D1 might act on RXR in combination with LXR rather than on 
LXR alone.  
In rodents, synthetic LXR ligands can inhibit the development of atherosclerosis, in part by 
upregulating expression of ABCA1, ABCG1, ABCG5/8 and thus lowering liver and serum 
cholesterol levels. Still, LXR agonist treatment also induces genes involved in fatty acid and 
TG regulation as FASN or ANGPTL3, resulting in high TG levels (J.R. Schultz, 2000) which 
limits a pharmacological success of LXR agonists. Intriguingly, in our study lipogenic gene 
expression was unaltered (Fig 26, 38 and 45). It is tempting to speculate that TSC22D1 
action might regulate the expression of a subset of LXR target genes beneficial for 
atheroprotection. Nuclear receptors exert different functions depending on their co-
repressor or activator complexes. Thus, these co-factors represent an interesting platform 
for the development of drugs, which alter expression of only a specific subset of genes thus 
limiting side effects.  
 
5.3 Open questions 
TSC22D1 seems to very specifically affect cholesterol metabolism, as indicated by the 
performed in vivo studies. Physiological parameters as body weight, blood glucose or serum 
non-esterified fatty acids remained mostly unchanged by manipulations in TSC22D1 
expression levels (Table 5). Nevertheless, analysis of all presented data leaves some 
obvious open questions.  
We observed a strong reduction of postprandial serum TGs upon acute TSC22D1 
knockdown (Fig 20). This reduction was due to a decrease in VLDL, as shown by FPLC 
analysis. In line with that, VLDL TGs were elevated by acute TSC22D1 overexpression (Fig 
21). Gene expression analysis revealed that some key genes involved in TG metabolism as 
microsomal triglyceride transfer protein (MTTP) or diaglyceride acetyltransferases 1 and 2, 
were downregulated by TSC22D1 knockdown. Additionally, acute TSC22D1 knockdown 
resulted in increased clearance of VLDL, whereas TG secretion was not altered (Fig 24). 
However, in chronic knockdown of TSC22D1 alterations in VLDL TG levels could not be 
Discussion 
 
 
69 
recapitulated (Fig 37). We cannot rule out that over time TSC22D1 function for TG 
metabolism can be compensated by other unknown factors. A similar phenomenon has 
been observed for TSC22D4 depletion which results in high serum and liver TG levels, this 
effect is, however, lost over time (A. Jones, Phd thesis, Herzig Lab). A time course study to 
monitor the effects of TSC22D1 knockdown could provide experimental evidence in that 
direction.  
Hepatic TSC22D1 expression was shown to be altered by the energy status (Table 3). Our 
findings about TSC22D1 function in cholesterol metabolism provide evidence that 
upregulation of TSC22D1 in an obese situation might help to maintain HDL levels. Another 
aspect of TSC22D1 regulation is the downregulation of TSC22D1 expression in situations of 
energy deprivation as cachexia or fasting. In fasting there is no uptake of exogenous 
cholesterol and thus less transport throughout the body required for final excretion. At 
least expression of ABCA1 and ApoA1 in control mice was reduced by fasting as well (Fig 16, 
32 and 45). Interestingly, in cachectic mice HDL cholesterol is slightly reduced (A. Jones et 
al., 2013), which cannot be explained so far. In cancer cachexia, cholesterol metabolism is 
of course not important in regards to atherosclerosis. Nevertheless, as mentioned before, 
HDL has more functions as being anti-inflammatory (C. Mineo, 2013) and cholesterol itself 
is important as a part of cell membranes or precursor of steroid hormones. The function of 
hepatic TSC22D1 in situations of energy deprivation requires further experimental analysis, 
which will help to understand the importance of TSC22D1 for systemic HDL metabolism.  
 
5.4 Conclusions 
In summary, we could demonstrate that hepatic TSC22D1 expression is found to be 
differentially regulated in mouse models of opposing energy supply. Intriguingly, we have 
identified hepatic TSC22D1 as a novel regulator of systemic cholesterol metabolism. Acute 
or chronic knockdown of TSC22D1 in livers of wild-type and obese mice resulted in a 
marked decrease of serum HDL cholesterol. Overexpression of TSC22D1, on the contrary, 
increased HDL cholesterol. TSC22D1 is a putative transcriptional co-regulator. Indeed, 
TSC22D1 ablation resulted in a significantly decreased expression of key genes involved in 
cholesterol efflux, namely ApoA1, ABCA1 and ABCG5/8. These changes can at least in part 
explain the observed reduction in serum HDL (Fig 46). HDL/ApoA1 plasma concentrations 
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inversely correlate with the risk for atherosclerotic cardiovascular disease. Thus, hepatic 
TSC22D1 transcription factor complex may represent an interesting new pharmaceutical 
target for manipulation of HDL cholesterol levels.  
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6 Methods 
6.1 Molecular Biology 
6.1.1 Transformation of Eschericha Coli 
Top 10, XL-1 blue and Sure2 chemical competent E. coli strains were transformed by chemical 
transformation. 50 µl of competent cells were thawed on iced. Either 0.1-1 µg plasmid DNA or 1-5 
µl of ligation reaction was added and cells were incubated for 20-30 min on ice. Following a heat 
shock for 45 s at 42°C, 250 µl LB- (for TOP 10 and XL-1 blue) or SOC- (for Sure2), medium was added. 
Cells were kept for 30-60 min at 37°C in a table top shaker with 300 rpm. After the incubation 
period, 100-200 µl of cell suspension was spread on Agar-plates containing the required antibiotic. 
Plates were incubated at 37°C overnight for bacterial growth and stored at 4°C. 
6.1.2 Bacterial liquid cultures 
Small scale liquid cultures 
Single colonies were inoculated into 5 ml LB medium supplemented with the appropriate antibiotic. 
The cultures were incubated over night at 37°C under vigorous shaking (~160 rpm). 
 
Larger scale liquid cultures 
Depending on the required DNA yield, 200-2000 ml cultures were inoculated with a small scale 
liquid culture that had been pre-incubated for 5-8h. The cultures were incubated over night at 37°C 
under vigorous shaking (~160 rpm). 
6.1.3 Preparation of plasmid DNA from Eschericha Coli 
Small scale plasmid preparation (Mini Prep) 
Plasmid preparation from small scale bacterial liquid cultures was performed using the Qiaprep 
Plasmid Miniprep Kit provided by Qiagen following the manufacturer’s instruction. The DNA was 
eluted with 50 μl H2O. Plasmid DNA was stored at -20°C. 
 
Large scale plasmid preparation (Maxi or Mega Prep) 
Plasmid preparation from large scale bacterial liquid cultures was performed using the PureLink 
HiPure Plasmid Maxiprep Kit provided by Invitrogen or the Qiaprep Plasmid Megaprep Kit provided 
by Qiagen following the manufacturer’s instruction. The DNA was eluted with 200 μl H2O or 800 µl 
of H2O, respectively. Plasmid DNA was stored at -20°C. 
6.1.4 Purification of plasmid DNA  
For the purification of plasmid DNA phase trap A tubes (Peqlab) were used. 800 µl 
phenol/chlorophorm/isoamylalcohol (25:24:1) was added to 1 ml plasmid DNA in a phase trap tube. 
The sample was inverted and centrifuged for 10 min at 13000 rpm. The aqueous phase was 
transferred to a fresh phase trap tube. 800 µl chloroform was added and the sample was inverted 
again and centrifuged for 10 min at 13000 rpm. The aqueous phase was transferred to a new 2 ml 
Eppendorf tube and 700 µl Isopropanol and 100 µl Sodium acetate (3M, pH 5.2) was added. The 
sample was centrifuged for 10 min at 13000 rpm. After removal of the supernatant, the DNA pellet 
was washed once with 70 % Ethanol and centrifuged for another 10 min at 13000 rpm. The pellet 
was dried and the DNA was dissolved in 800 µl H20. 
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6.1.5 Preparation of genomic DNA from liver tissue samples 
Liver tissue was digested in 500 μl proteinase K lysis buffer containing 0.5 mg/ml proteinase K for 3 
hrs at 60°C and overnight at 56°C, shaking. Genomic DNA was extracted by phenol chloroform 
extraction adding 500 μl phenol/chlorophorm/isoamylalcohol (25:24:1), vortexing and 
centrifugation at 13.000 rpm, 4°C, 10 min. The upper phase was transferred to a new tube and the 
extraction step was repeated. The upper phase was transferred to a new tube and 500 μl 
chloroform were added. After spinning, DNA was pelleted by adding the upper phase to 500 μl 
isopropano, vortexing and incubation at -20°C for 1 h, followed by spinning at 13.000 rpm, 4°C, 45 
min. Pellet was washed with 75% ethanol, dried, and resuspended in 100 μl TE buffer. Complete 
resuspension was accomplished by incubation for 2 h at 60°C. Genomic DNA was stored at 4°C until 
use. 
6.1.6 Determination of DNA concentration 
DNA concentrations were determined by using the NanoDrop ND-1000 spectrophotometer. The 
concentration was determined by measuring the absorption at 260 nm wavelength, contamination 
with salts or proteins was assessed by measuring the absorbance spectrum between 220 and 300 
nm. A 1.5 μl DNA sample was used for each measurement 
6.1.7 DNA sequencing 
Plasmids were sequenced by the company LGC genomics (Berlin). 
6.1.8 PCR  
DNA from plasmids, cDNA or a genomic DNA was amplified by polymerase chain reactions using a 
thermocycler (PTC 200) and Phusion polymerase (Finnzymes). The primers used are listed in the 
material section.  
A typical PCR rection is shown below:  
 
Amount   Final concentration  
5X Phusion polymerase buffer   10 μL    1 X  
10 mM dNTP mix    1 μL    0.2 mM  
Forward primer (100 μM )   1μL    2 μM  
Reverse primer (100 μM)   1 μL    2 μM  
DNA Template        ~ 5 ng  
Phusion polymerase   1 μL    2 U  
Double distilled water    ad 50 μL 
 
A typical PCR reaction was programmed as followed: 
Step     Temperature   Time  
1. Denaturation    95°C    30 sec  
2. Denaturation    95°C    10 sec  
3. Primer annealing    55 – 65°C   30 sec  
4. Extension     72°C    60 sec  
5. Go to 2        30x  
6. Extension     72°C    5-10 min  
7. Hold      4°C   ∞ 
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The annealing temperature was adjusted depending on the length and G/C content of the primers. 
The extension time was adjusted depending on the size of the desired PCR product.  
6.1.9 Purification of PCR fragments  
DNA from PCR reactions was purified using the QIAquick PCR purification kit provided by Qiagen 
following the manufacturer’s instructions. DNA was eluted in 30 μl H2O. Alternatively, fragments 
were purified by gel extraction as described. 
6.1.10 Agarose gel electrophoresis 
DNA fragments were separated by agarose gel electrophoresis using 1-2% agarose and 1 μg/ml 
ethidium bromide in TBE. DNA samples were mixed with 1x Orange G loading dye and separated at 
80-100 V. Gel pictures were taken under UV light (254 nm) with the Gel imager (Intas). 
6.1.11 Gel extraction of DNA 
DNA fragments were excised from agarose gels under a UV lamp using a scalpel and purified using 
the QIAquick Gel Extraction Kit, according to the manufacturer’s instructions. 
6.1.12 DNA restriction 
DNA restriction was performed by using restriction enzymes (10-20 U per µg DNA) and 
corresponding buffer provided by New England Biolabs. Reactions were incubated at the required 
temperatures for 1-12 h.  
6.1.13 DNA ligation 
Ligation of insert and vector DNA was performed using a T4 DNA ligase (NEB or Fermentas). The 
molar ratio of insert to vector was adjusted to 3:1 applying the following formula:  
ng insert = (100 ng vector x bp insert / bp vector) x 3  
1 U enzyme was used in 1x ligase buffer for the ligation reactions according to the manufacturer’s 
protocol. The reactions were performed in 20 μl total volume and incubated for 2-12 h at room 
temperature. After the ligation reaction, the enzyme was heat inactivated (10 min 65°C).  
6.1.14 RNA isolation  
RNA isolation from cell culture samples 
Adherent cells were treated according to experimental needs. The medium was removed and the 
cell monolayer was washed once with sterile PBS. The buffer was aspirated and 800-1000 µL 
Qiazol™ Lysis reagent was added per well. The cells were released from the plate using a pipette 
and transferred into DNase/RNase-free reaction tubes, in which they were incubated for 5 min at 
room temperature. The samples were vortexed vigorously, until all cells were solubilised. The 
obtained cell lysates were stored at -80°C or immediately used for RNA isolation, as described 
below. 
RNA isolation from tissue samples 
20-50 mg of snap frozen tissue were transferred into a 2 ml RNase/DNase-free reaction tube 
containing a stainless steel bead. 1 ml of Qiazol™ Lysis (Qiagen) reagent was added directly. The 
samples were lysed using the TissueLyser™ for 30-60 s at a frequency of 30 Hz. Lysates were 
incubated at room temperature for 5 min to release nucleoprotein complexes before they were 
transferred, excluding the stainless steel bead, into a fresh 1.5 ml RNase/ DNase-free safe-lock tube. 
Subsequently, 200 μl of chloroform was added. Mixtures were vigorously inverted 15 times and 
then centrifuged for 30 min at 13,000 rpm. The upper aqueous solution, containing the RNA, was 
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carefully transferred into a fresh reaction tube containing 500 μl of iso-propanol and incubated at 
room temperature for 10 min, followed by a 10 min centrifugation step at 12,000 rpm. The 
supernatant was aspirated and the pellet was washed once with 1 ml of 75% ethanol. The solvent 
was discarded, and the remaining ethanol was removed using a pipette. The pellet was briefly air-
dried and re-solubilised in water (30-50 μl). To increase solubilisation, the RNA solution was 
incubated at 55-60°C for 10 min. The samples were stored at -80 
For microarray analysis, RNA isolated using Qiazol™ Lysis reagent was purified using the RNeasy 
Mini purification kit provided by Qiagen. RNA was transferred to into a fresh reaction tube 
containing 525 μl of 100 % ethanol. RNA was then purified following the manufacturer’s instruction. 
The optional DNA digestion step was included. RNA was eluted in 30-50 µl H2O.  
6.1.15 Determination of RNA concentration 
RNA concentrations were determined by using the NanoDrop ND-1000 spectrophotometer. The 
concentration was determined by measuring the absorption at 260 nm. In parallel, the ratio 260 
nm/280 nm was detected in order to determine protein impurities in the samples. 
6.1.16 cDNA Synthesis 
For synthesis of complementary DNA, 800-2000 ng of RNA was used. cDNA synthesis was 
performed using the cDNA synthesis kit (Fermentas) following the manufacturer’s instructions. 
After completion, cDNA samples were diluted 10-fold in RNase free water and stored at -20°C. 
6.1.17 Quantitative PCR 
5 μl of the diluted cDNA samples obtained from reverse transcription, see above, were used for 
quantitative PCR. A master mix was prepared containing 10 μl TaqMan Gene Expression Assay 
Supermix, 4.5 μl DNase/RNase free water and 0.5 μl TaqMan probe per individual reaction. Water 
was used as a negative control and samples containing no reverse transcriptase served as controls 
for genomic DNA contamination. 20 μl PCR reactions were transferred per well onto a MicroAmp 
Optical 96 well reaction plate. All reactions were performed as technical duplicates. Quantitative 
PCR was performed using the StepOnePlus Real Time PCR System (Applied Biosystems). 
6.1.18 Gene expression profiling 
Gene expression profiling was performed with RNA extracted from livers with knockdown or 
overexpression of TSC22D1 and respective control livers, depending on the experiment in fasted, 
refed or random fed state. 
Total RNA was extracted using TRIzol method according to manufacturer’s protocol (Invitrogen Life 
Technologies). cDNA synthesis was performed using the SuperScript Choice System (Invitrogen Life 
Technologies, Invitrogen Corporation) according to manufacturer’s protocol. Biotin-labeled cRNA 
was produced using ENZO BioArray HighYield RNA Transcript Labeling Kit. Standard protocol from 
Affymetrix (Santa Clara, CA) with 3.3 μL of cDNA was used for the in vitro transcription (IVT). 
Cleanup of the IVT product was done using CHROMA SPIN-100 columns (Clontech, USA). 
Spectrophotometric analysis was used for quantification of cRNA with acceptable A260/A280 ratio 
of 1.9 to 2.1. After that the cRNA was fragmented using Affymetrix defined protocol. Labeled and 
fragmented cRNA was hybridized to Affymetrix Mouse430_2 microarrays for 16 hrs at 45° C using 
Affymetrix defined protocol. Microarrays were washed using an Affymetrix fluidics station 450 and 
stained initially with streptavidinphycoerytherin. For each sample the signal was further enhanced 
by incubation with biotinylated goat anti-streptavidin followed by a second incubation with 
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streptavidinphycoerytherin and a second round of intensities were measured. Microarrays were 
scanned with Affymetrix scanner controlled by Affymetrix Microarray Suite software. 
Microarry processing and statistical analysis 
Gene expression profiling was performed using arrays of Mouse430_2 -type from Affymetrix (Santa 
Clara, CA, USA). cDNA and cRNA synthesis and hybridization to arrays were performed according to 
the recommendations of the manufacturer. A Custom CDF Version 14 with Entrez based gene 
definitions was used to annotate the arrays. The Raw fluorescence intensity values were normalized 
applying quantile normalization. Differential gene expression was analysed based on loglinear 
mixed model ANOVA (W. P. Hsieh, 2003; J. Roy, 2007), using a commercial software package SAS 
JMP7 Genomics, version 4, from SAS (SAS Institute, Cary, NC, USA). A false positive rate of a=0.05 
with FDR correction was taken as the level of significance.  
The overrepresentation analysis (ORA) is a microarray data analysis that uses predefined gene sets 
to identify a significant overrepresentation of genes in data sets (A. Subramanian et al., 2005; T. 
Manoli et al., 2006). Pathways belonging to various cell functions such as cell cycle or apoptosis 
were obtained from public external databases (KEGG, http://www.genome.jp/kegg/). A Fisher's 
exact test was performed to detect the significantly regulated pathways. Gene Set Enrichment 
Analysis (GSEA), was used to determine whether defined lists (or sets) of genes exhibit a statistically 
significant bias in their distribution within a ranked gene list (see 
http://www.broadinstitute.org/gsea/for details (A. Subramanian et al., 2005). Pathways belonging 
to various cell functions such as cell cycle or apoptosis were obtained from public external 
databases (KEGG, http://www.genome.jp/kegg/). 
 
6.2 Cell Biology 
6.2.1 Cell culture conditions 
All experiments with eukaryotic cells were performed under sterile conditions. Cells were cultivated 
at 37°C, 5% CO2 and 95% humidity. All media and additives were warmed to 37°C prior to use. Cells 
were cultivated in 6-well, 12-well, 24-well, 96-well, chamber slides 10 cm or 15 cm cell culture 
dishes. A list of the media used for cell culture experiments is shown in tabel 6.  
Media used for cell culture and virus experiments 
Name Medium Serum  Antibiotic Further additives 
HEK293  DMEM 10% FCS 1% P/S  
HEK293A  DMEM 10% FCS 1% P/S 1% NAA 
HEK293T  DMEM 10% FCS 1% P/S 1% NAA 
HEK293A virus titration DMEM 2% FCS 1% P/S 1% NAA 
Hepa1c1 DMEM 10% FCS 1% P/S  
Freeze medium DMEM 20% FCS  10% DMSO 
 
6.2.2 Thawing of cells  
Eukaryotic cells were stored in liquid nitrogen tanks in 1 ml aliquots containing about 1*106 cells in 
freeze medium. Following thawing at 37°C, cells were carefully mixed with 10ml pre-warmed 
culture medium and centrifuged for 3 min at 2000 rpm, to remove DMSO. The pellet was 
resuspended in 10 ml medium. Those 10 ml were distributed to two 15 cm tissue culture plates (3 
ml and 7 ml) containing 25 ml culture medium.  
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6.2.3 Cultivation of Human Embryonic Kidney (HEK), HEK293A and HEK293T cells 
HEK 293 cells were maintained and propagated in Dulbecco’s Modified Eagle Medium with high 
glucose (DMEM), 10 % fetal calf serum (FCS) and 1 % penicillin/ streptomycin. HEK293A and 
HEK293T cells also required 1 % Non-Essential Amino Acids (NAA). Cells were passaged by the factor 
1:10 – 1:20 two times per week.  
For passaging, the cells were first washed in 1x PBS and then washed from the plate with 10 ml of 
culture medium. Cells were pelleted by centrifugation at 2000 rpm for 3 min and subsequently 
resuspended in 10 ml fresh medium and distributed to 15 cm plates. Cells were split by the factor 
1:10 – 1:20 two times per week.  
6.2.4 Cultivation of Hepa1c1 mouse hepatoma cells 
Hepa1c1 cells were maintained and propagated in DMEM containing 10 % FCS, 1 % penicillin / 
streptomycin and 1% NAA. For passaging, the cells were first washed in 1x PBS and trypsinized, then 
the detached cells were resuspended in 10 ml of fresh medium. Cells were pelleted by 
centrifugation at 2000 rpm for 3 min and subsequently resuspended in 10 ml fresh medium. Cells 
were split by the factor 1:10 two times per week 
6.2.5 Determination of cell number 
To determine the cell count and viability for subsequent seeding of cells or for cell numer assays the 
Countess® automated Cell Counter (Life technologies) was used. According to the manufactures 
protocol, 10 μl of sample was mixed with 10 μl of trypan blue, and pipetted into Countess® 
chamber slide and inserted into the machine. 
6.2.6 Transient transfection of HEK cells 
Transfection with calcium phosphate  
Cells were seeded 24 h prior to transfection and transfected at 60-80% confluency. DNA was mixed 
with 0.25 M CaCl2 and the same volume of 2x BBS, the amounts used are listed in table. After 15-20 
min at RT, the mixture was added to the cells in fresh medium. Medium was changed 12 h after 
transfection. Experiments were performed 48-72 hrs after transfection. 
 
Format Cell number DNA CaCl2 2x BBS 
6-well plate 2x 105 100 ng -1 μg 100 μl 100 μl 
12-well plate 1x 105 100 ng -1 μg 80 μl 80 μl 
Lipofectamin 2000 
For higher transfection efficiency HEK293 cells were transfected with Lipofectamine 2000 
transfection reagent (Invitrogen). 3 μl of the reagent were added to 250 μl of serum free Opti-MEM 
medium. The mixture was combined with DNA which was diluted in the same medium, and the 
mixture was incubated at RT for 20 min to allow complex formation. The DNA/Lipofectamine 
complexes were added dropwise to the cells in antibiotic-free medium. Medium change to the 
normal culture medium was performed the following day. 
6.2.7 Transient transfection of Hepatoma cells 
Hepa1c1 were transfected using polyethylenimine (PEI) reagent, a substance with low cytotoxicity 
For transfection with the PEI method cells were plated at a concentration of 1.4x105 cells/ml on a 
12-well plate one day prior to transfection. The amount of PEI needed was calculated with respect 
to the amount of DNA that was used for the individual transfection. Generally, 8 μl of PEI were 
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applied per μg of DNA. Per well a maximum of 1.5 μg DNA could be used. Each condition was done 
at least in duplicates. 
The following mixes were prepared as followed: 
Mix1: DNA xμl; yμg 
Water add ½ total of volume mix1 
NaCl ½ total of volume mix1 
 
Mix2: PEI (8μl/μg DNA) 
Water add ½ total of volume mix2 
NaCl ½ total of volume mix2 
(total volume at least 16 μl x μg DNA) 
 
After preparation Mix 2 was added to Mix1 and incubated for 10 min at RT. In the meantime, 
medium of the cells was changed. Afterwards, the mixture was added drop wise to the cells. After 
incubation of cells for 24h hours at 37°C the medium was changed. Cells were harvested 48 hours 
post-transfection. 
6.2.8 Luciferase assay 
The luciferase assay is one form of reporter gene assay. It was used to determine the promoter 
activities of the transfected reporter gene vectors. The enzyme Luciferase catalyzes the oxidation of 
its substrate luciferin in the presence of ATP and Mg2+. By formation of the product molecule 
oxyluciferin light is produced which can be measured. Under experimental conditions the amount of 
emitted light is proportional to the amount of luciferase in the cell lysate, which gives conclusions 
about the promoter activity. 
Transfected cells were harvested 48 h post transfection. Medium was removed and the cells were 
washed with PBS. Then 150 μl harvest buffer was added and the cells were shaken on a vortex 
device at the lowest strength about 20-30 min to allow detachment of cells from dish. Following, 
the cell-lysate was transferred into an Eppendorf tube and centrifuged at 13.000 rpm for 3 min at 
4°C to sediment cell debris. The supernatant was transferred into a new Eppendorf tube and stored 
at -20°C until subjected to the luciferase reporter knockdown assay. 
For the assay 30 μl of cell lysate from transfected cells were transferred into one well of a black 96-
well-plate. The lysate was diluted with 100 μl assay buffer and the plate was placed into a 
luminometer (Mithras 940 Luminescence). The automatic injection of 100μl luciferin buffer per well 
started the reaction. Light emission was measured at a wavelength of 569nm. Assay buffer was 
used as control. Triplicates were done and each value was normalized against β-galactosidase 
values. 
For determination of transfection efficiency the reactions were co-transfected with the pCMV-β-
galvector, which constitutively expresses β-galactosidase. The measured β-galactosidase activity 
directly correlates with the amount of DNA incorporated during transfection. As a substrate ortho-
nitrophenyl-β- galactopyranosid (ONPG) was provided with the assay buffer, prior to use 13.5 μl 
beta-mercaptoethanol was added per 5 ml. For the assay 50 μl cell lysate and 50 μl buffer per well 
was added to a 96-well plate. The plate was incubated until the samples developed a clear yellow 
color. The absorption was measured at 405 nm, which is the maximum absorption of the ortho-
nitrophenylat ion.  
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6.2.9 Infection of cells with adenovirus 
1-2x 105  HEK293 or 2-4x104 Hepa1c1 cells were seeded on 6- or 12-well plates or 2.4x104 Hepa1c1 
cells on chamber slides and infected with different amounts of adenovirus 6-12 h after plating. 
MOIs of 10-500  were used depending on the experiment. fibroblasts. The desired amounts of virus 
were diluted in DMEM culture medium and added to the cells. Cells were incubated 24-72 h until 
harvest.  
6.2.10 Primary hepatocyte experiments  
Primary mouse hepatocytes were isolated and cultured as described (U. Klingmueller et al., 2006). 
Male 8-12 week old C57Bl/6J mice were anesthetized by intraperitoneal injection of 5 mg 10% 
ketamine hydrochloride / 100 mg body weight and 1 mg 2% xylazine hydrochloride / 100 mg body 
weight. After opening the abdominal cavity, the liver was perfused with HANKS I buffer via the 
portal vein for 5 min at 37°C and subsequently with HANKS II buffer for 5-7 min until disintegration 
of the liver structure could be observed. The liver capsule was removed and the cell suspension was 
filtered through a 100 μm mesh. Cells were washed and, subsequently, viability of cells was 
determined by trypan blue staining. 500,000 living cells / well were seeded on collagen I-coated 6- 
or 12-well plates. Cells were infected with recombinant adenoviruses (multiplicity of infection = 
100) 24 hours after seeding and harvested for mRNA analysis 48 hours later. 
 
6.3 Virus Biology 
6.3.1 Cloning of adenoviruses 
The BLOCKiT™ Adenoviral RNAi Expression System was used to generate adenoviruses expressing 
shRNA sequences against murine TSC22D1 as well non-specific shRNAs. Oligonucleotide sequences 
were chosen using Invitrogen’s RNAi Designer tool. Forward and reverse oligonucleotides against 
the target gene sequence were annealed and cloned into the pENTR™/U6 vector according to the 
manufacturer’s instructions. The resulting constructs were recombined with the pAd/BLOCK-iT™ 
DEST vector, which contains the adenovirus serotyp 5 DNA, but lacks the E1 and E3 genes that are 
required for viral replication. The viral vector containing the shRNA sequence was linearized by 
restriction digest using the enzyme PacI and transfected into HEK 239A cells using Lipofectamine 
reagent according to the manufacturer’s instructions. HEK293A cells express the viral E1 and E3 
genes necessary for viral outbreak, allowing the virus to expand in this cell line. Viral plaques 
appeared 6 to 10 days after transfection and cells started to detach from the cell culture dish. Once 
about 70% of cells were floating, they were harvested. The same procedure was used to generate a 
virus overexpressing TSC22D1. The TSC22D1 cDNA was cloned into a pENTR vector harbouring the 
CMV promoter and subsequently recombined with the pAd/BLOCK-iT™ DEST vector. An empty 
adenovirus was used as a negative control in over expression experiments. 
6.3.2 Adenovirus harvest 
HEK293A cells were harvested, when 70-90% were rounded up and had detached from the plate. 
Remaining adherent cells were washed of the plate with the medium from the plate. The medium 
was collected from twenty 15 cm cell culture plates per virus and centrifuged for at 2,000 rpm for 
10 min. The supernatant was discarded and the cell pellet was resuspended in 3 ml PBS-TOSH 
buffer. The cell suspension was stroed at -80°C. The virus was released from the cell, by three freeze 
and thaw cycles. For that, the cell suspension was thawed at 37°C with vigorous vortexing and then 
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frozen in liquid nitrogen. After cell lysis the mixture was centrifuged at 3,000 rpm for 5 min, to 
remove cell debris. The supernatant containing the crude virus lysate was used for purification by 
cesium chloride gradient or for further infection of HEK293A cells.  
6.3.3 Adenovirus purification using cesium chloride gradient 
Cesium chloride (CsCl) gradient centrifugation is a type of density gradient centrifugation for the 
purification of viral particles. Confluent HEK293A on twenty 15 cm cell culture dishes were infected 
with crude virus lysate or purified adenovirus (1 μl per plate) and grown until 70-80% of the cells 
were rounded and lost adhesion, then they were harvested and lysed as described before. PBS-
TOSH was added to the crude lysate to a final volume of 20 ml. All solutions were adjusted to pH 
7.2. The first gradient was layered with 9 ml 4.4 M CsCl, 9 ml 2.2 M CsCl and 20 ml virus in PBS-
TOSH. After ultracentrifugation (2 hrs, 4 °C, 24,000 rpm, SW28 rotor) a clear virus band was visible. 
The virus band was removed by piercing the tube with a 5 ml syringe. To the obtained virus (3-
3.5ml) the same volume of saturated CsCl was added. The second gradient was layered with 6-7 ml 
virus in CsCl, 2 ml 4.4 M CsCl und 2 ml 2.2 M CsCl. Following the second ultracentrifugation (3 hrs, 4 
°C, 35,000 rpm, SW40Ti rotor) the virus band was removed by syringe in the smallest possible 
volume and dialysed twice against PBS-glycerol, 1 hour and over night at 4°C. 10% glycerol was 
added to the purified virus and aliquots were stored at -80°C. 
6.3.4 Virus Titration using the Tissue Culture Infectious Dose 50 (TCID50) method 
The Tissue Culture Infectious Dose 50 (TCID50) assay was used to titrate adenovirus. For that 
purpose, 104 HEK293A cells were seeded in 100 μl virus titration medium in each well of a 96 well 
plate and infected with decreasing amounts of virus after 2-4 hrs of adhesion. Serial dilutions of the 
virus from 10-7 to 10-14 were prepared in titration medium and added to the cells. Double 
measurements were performed for each virus. 10-12 days after infection and incubation at 37°C the 
plaques were counted using a microscope and the titer was calculated by the following formula:  
T = 10 1+(s-0.5) x 10 pfu / ml  
(s = sum of positive wells starting from the 10-1 dilution; 10 positive wells per dilution = 1) 
6.3.5 Cloning of AAV 
The BLOCKiT™ Pol II miR RNAi Expression System was used to generate adeno-associated viruses 
expressing miRNA sequences against murine TSC22D1 as well non-specific miRNAs. Oligonucleotide 
sequences were chosen using Invitrogen’s RNAi Designer tool. Forward and reverse 
oligonucleotides against the target gene sequence were annealed and cloned into the pcDNA6.2-
GW/EmGFP-miR vector according to the manufacturer’s instructions. Following, they were 
transferred into the previously described double stranded pdsAAV-LP1-EGFPmut AAV vector (P. 
Kulozik et al., 2011) using the restriction enzymes BglII and SalI. The plasmids encoding the miRNA 
constructs were contransfected into HEK293T cells with the pDGΔVP helper plasmid (D. Grimm et 
al., 1998) and a mutated p5E18-VD2/8 expression vector (G.P. Gao et al., 2002) encoding AAV2 rep 
and a mutated AAV8 cap protein (aa 589-592: QNTA to GNRQ). 
6.3.6 AAV production 
For virus production, HEK293T cells from six 80-90% confluent 15 cm plates were suspended in 
1100 ml medium. 1,000 ml of the cell suspension was transferred to a 10x cell-stack chamber and 
100 ml were transferred to a 1x-cell stack chamber (control chamber for analysis under the 
microscope). 24 h after plating, the cells were approximately 70-80% confluent and were 
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transfected with the plasmids encoding the viral genes using the PEI method in the amounts stated 
below.  
Plasmid       Amount  
AAV-miRNA expression vector     436 μg  
p5E18 VD2/8 helper plasmid    550 μg  
pDGΔVP helper plasmid     1579 μg  
 
Once the cell monolayer was approximately 90% confluent, cells were washed with PBS, before 
they were released from the plate using 10 ml (1x cell stack) or 100 ml (10x cell stack) trypsin-EDTA 
for 5 min at 37°C. Fresh medium was added (40 ml or 350 ml respectively) and the cells were 
transferred to a 50 ml falcon tube, or a 500 ml conical tube. The chambers were washed with PBS 
and used for a second round of transfection. Cells were centrifuged at 2,000 rpm for 10 min. The 
supernatant was removed and the pellets were resuspended in 8 ml lysis-buffer containing 150 mM 
NaCl and 50 mM Tris-HCL, pH 8.5. The lysates were transferred into 15 ml falcons, vortexed, snap-
frozen in liquid nitrogen and stored at -80°C. 
6.3.7 AAV purification 
AAV lysates were thawed at 37°C under vigorous vortexing and then centrifuged at 3,500 g for 10 
min. The supernatant was collected and the pellets were resuspended in 4 ml lysis buffer and snap-
frozen. The freeze-thaw cycle was repeated three times. The final pellet was solubilised using a 
sonicator in a water bath at 48 W for 1 min. The pooled suspension was then digested with 
benzonase (50 U/ml) for 30 min at 37°C. This solution was then centrifuged at 4°C and 3,500 g for 
10 min. The virus was stored at -80°C until further use.  
 
1st Iodixanol gradient  
Purifying virus by iodixanol gradient leads to a separation of packed and unpacked AAV capsids, as 
they migrate differentially upon ultracentrifugation. The first gradient, ranging from 15% iodixanol 
to 40% iodixanol, was prepared on top of the viral solution in a Beckman Quickseal tube using a 
Pasteur pipette, as described below. 
 
Layer (from top to bottom)    Component  
15 %-iodixanol dilution (7 ml)    1.75 ml OptiPrep  
5.25 ml PBS-buffer 2  
25 %- iodixanol dilution (5 ml)    2.08 ml OptiPrep  
2.29 ml PBS-buffer 1  
12.5 μl phenol red (0.5 %)  
40 %- iodixanol dilution (4 ml)    2.67 ml OptiPrep  
1.33 ml PBS-buffer 1  
60 %- iodixanol dilution (4 ml)    4 ml OptiPrep  
10 μl phenol red (0.5 %)  
Virus (18 ml) 
 
PBS-buffer 1: 1x PBS     PBS-buffer 2: 1x PBS  
1 mM MgCl2      1 mM MgCl2  
2.5 mM KCL      2.5 mM KCL  
1 M NaCl 
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About 1 ml of space was left above the gradient. Tubes were sealed and centrifuged in a 50.2 Ti 
rotor at 50,000 g and 10°C for 2 hours. Four gradients were run for each virus (two rounds; harvest 
and wash). After centrifugation, the 40% iodixanol layer (~3.5 ml) was carefully collected by 
inserting a 5 ml syringe from underneath. The viral suspension was pooled and stored at -80°C.  
 
2nd Iodixanol gradient  
The viral suspension resulting from the first gradient was filled up to 25 ml with lysis buffer. The 
second gradient was prepared by underlayering, as described below. 
 
Layer (from top to bottom)    Component  
 25 %- iodixanol dilution (5 ml)    2.08 ml OptiPrep  
2.29 ml PBS-buffer 1  
12.5 μl phenol red (0.5 %)  
40 %- iodixanol dilution (4 ml)   2.67 ml OptiPrep  
1.33 ml PBS-buffer 1 
60 %- iodixanol dilution (4 ml)    4 ml OptiPrep  
10 μl phenol red (0.5 %)  
Virus (25 ml)  
 
PBS-buffer 1:  1x PBS    PBS-buffer 2:  1x PBS  
1 mM MgCl2     1 mM MgCl2  
2.5 mM KCL     2.5 mM KCL  
1 M NaCl  
 
The gradient was then further processed as described for the first gradient. 
 
Virus concentration  
The viral solution was concentrated using a VivaSpin concentrator. The solution was consecutively 
centrifuged at 3,000 rpm and 10°C for 3-6 min until a final volume of about 1 ml.  
6.3.8 AAV titration 
Viral DNA was isolated by mixing 5 μl of virus suspension with 5 μl H2O and 10 μl 2M NaOH. The 
mixture was incubated at 56°C for 30 min and the reaction was then neutralized by adding 10 μl 2M 
HCL. After adding 970 μl H2O, the titer was determined by qPCR using an EGFP standard curve. 
 
6.4 Biochemistry 
6.4.1 Preparation of nuclear extracts from liver tissue samples 
For extraction of nuclear fractions about 50 mg frozen liver samples was grinded in Dounce 
homogeniser for 15 strokes with 1 ml of lysis buffer (50 mM Tris pH 7.2, 250 mM Sucrose, 10 mM 
KCL, 1 mM EDTA, 10 mM NaF, 2 mM Na3VO4, 1 mM DTT, 1 x Protease Inhibitor Cocktail (Sigma, 
Heidelberg, Germany), 1 x Phosphatase Inhibitor II (Sigma, Heidelberg, Germany). Homogenates 
were rotated end over end at 4°C for 30 min after which they were centrifuged at 4°C for 30 min at 
1000g. The pellet was dissolved in 500µl lysis buffer (50 mM Tris pH 7.2, 25% glycerol, 420 mM 
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NaCl, 1.5 mM MagCl2, 10 mM NaF, 1 mM DTT, 1 x Protease Inhibitor Cocktail,  1 x Phosphatase 
Inhibitor II, 0.1 % SDS, 1 % NP-40. Pellets were dissolved by grinding with a pestle. Homogenates 
were rotated end over end at 4°C for 30 after which they were centrifuged at 4°C for 30 min at 
9000g. 
6.4.2 Determination of Protein Concentration 
Protein concentrations were determined using the BCA kit (Pierce) following the manufacturer’s 
instructions. If SDS concentration of the samples was higher than 0.1 %, protein concentration had 
to be determined using the 2D-Quant kit (Amersham Biosciences) following the manufacturer’s 
instructions. All measurements were performed in duplicates within the linear range of the BSA 
standard curves (0.1-2 mg/ml). 
6.4.3 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Immunoblotting 
Protein samples in SDS sample buffer were loaded onto 6-15 % SDS-polyacrylamide gels and blotted 
onto nitrocellulose membranes or PVDF membranes using a wet blot system. PVDF membranes 
were activated with methanol prior to use. Blotting was performed at 70 V for 60 minutes or at 80V 
for 70min in transfer buffer. Membranes were subsequently blocked by incubation in 5% milk or 5% 
BSA dissolved in PBS-T or TBS-T for 1 hour. Specific primary antibodies diluted in milk or BSA, 
according to the manufacturer’s recommendations, were incubated with the membranes overnight 
at 4°C. The membranes were washed with PBS-T or TBS-T the next day and incubated with the 
secondary antibody conjugated to horse radish peroxidase (HRP) at a dilution of 1:5,000 for 1 hour. 
To detect specific bands the enhanced chemiluminescence system (ECL) Western Blotting Detection 
Reagent was applied. The chemiluminescent signal produced by the blots was detected with the 
ChemiDoc detector (BioRad). Exposure times differed based on the quality of specific antibodies 
and protein concentrations. 
6.4.4 Co-Immunoprecipitation 
Hepa 1c1 cells were cotransfected with a HA-TBL1, Myc-TBLR1 or an empty Flag vector in 
combination with a Flag-TSC22D4 vector. Subsequently, cells were lysed with lysis buffer containing 
protease and phosphatase inhibitors and centrifuged at 13,000 rpm, 4°C, 15 min. The supernatant 
was incubated with anti-FLAG M2 Agarose for 2 hours at 4°C and washed vigorously to remove 
unspecific binding. Precipitated proteins were eluted using excess Flag peptide. The 
immunoprecipitates were subsequently analyzed by Western blot as described.  
6.4.5 GST-pulldown 
GST-pulldown experiments were performed to map the interaction of TSC22D1 with TBL1. TBL1  
protein was purified from bacteria using a GST-tag and TSC22D1 protein was in vitro transcribed 
and translated in the presence of radiolabeled methionine. Full length and truncated GST fusion 
proteins were produced in BL21 cells and affinity purified using glutathione sepharose. In vitro 
transcription/translation was performed using the TNT T7/T3 quick coupled 
transcription/translation system according to the manufacturer's instructions. GST and in vitro 
translated full length and truncated proteins were incubated at 4°C overnight. After extensive 
washing, GST-precipitated proteins were separated by SDS-PAGE and detected by autoradiography. 
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6.4.6 Isolation of Hepatic Triglycerides 
Lipids were extracted from frozen and pulverized liver tissue using chloroform/methanol (2:1 v/v). 
About 100 mg (the exact weight was noted) of frozen, pulverized liver were transferred into a 2 ml 
tube containing 1.5 ml chloroform/methanol and a steel bead. The tissue was homogenized using a 
tissue lyzer for three times 30 s at a frequency of 30 Hz. For the lipid extraction, samples were 
incubated on a rotating wheel at room temperature for 20 min. Samples were centrifuged at 13,000 
rpm for 30 min at RT and 1m of the supernatants were transferred to fresh tubes. The organic layer 
was mixed 200µl with 0.9% sodium chloride and the aqueous solution was carefully discarded. The 
solution was centrifuged for 5 min at 2000 rpm. 750 μl of the lower organic layer were transferred 
to a fresh tube and stored at -80°C. For lipid resuspension 40 μl of triton-X 100/chloroform (1:1 v/v) 
was pipetted into fresh tubes and 200µl of the organic lipid sample was added. The reagents were 
mixed and the solvent was evaporated overnight using a speed vac. The residue containing the 
hydrophobic contents of the liver was resuspended in 2000 μl water and stored at -20°C until 
further use. 
6.4.7 Determination of Free Fatty Acid Levels  
Free Fatty Acids were determined in serum samples using a colorimetric assay from WAKO (NEFA 
kit) following the manufacturer’s instructions. 4 μl of serum samples were measured in duplicates. 
A standard curve was determined using a dilution series of oleic acid. OD-values were determined 
at 540 nm.  
6.4.8 Determination of Glycerol Levels  
Glycerol content of serum was measured using a calorimetric assay. The Free Glycerol component 
of the serum TG determination kit from Sigma was used for this assay. 4 μl of serum or 20 μl of 
supernatants were transferred to a 96well plate, 100 μl Free Glycerol Reagent were added and 
glycerol levels were measured at 540 nm against a glycerol standard. 
6.4.9 Determination of Triglyceride Levels  
TG levels were determined by separating TGs into one glycerol and three fatty acid molecules and 
measuring the glycerol using a colorimetric assay. The serum TG determination kit from Sigma was 
used for this assay. 4 μl of isolated hepatic TG or 4 μl of serum were transferred to a 96well plate. In 
order to determine a blank value, 100 μl Free Glycerol Reagent were added to each well and the 
plate was incubated at 37°C for 5 min. Free glycerol levels were measured at 540 nm. In a second 
reaction (assay), 100 μl TG Reagent were added. This mixture contains the enzyme lipase, which 
catalyses the release of fatty acids from TGs. Plates were incubated at 37°C for 5 min and measured 
at 540 nm. TG content (TG-bound glycerol) was determined by subtracting the free glycerol (blank) 
from the second measurement of total glycerol (assay). 
6.4.10 Determination of Cholesterol Levels  
Liver or serum cholesterol concentrations were determined using a total cholesterol determination 
kit (Randox Laboratories) following the manufacturer’s instructions. 4 μl of each sample were mixed 
with 100μl assay reagent and incubated at 37°C for 5 min. The optical density was measured at 492 
nm and the sample concentration was determined using a standard curve resulting from a serial 
dilution of cholesterol (200 mg/dl; provided with the kit).  
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6.4.11 Serum TGF-beta 1 measurement  
Serum TGF-beta 1 level was determined using the Mouse Quantikine ELISA Kit provided by R&D 
Systems. Activated serum samples were diluted 1:100 the rest of the assay was performed 
according to manufacturer’s instruction. The TGF-beta 1 level was measured at 450 nm and the 
sample concentration was determined using a standard curve.  
6.4.12 Determination of Blood Glucose Levels  
Blood glucose levels were determined using a drop of blood obtained from the tail vein and an 
automatic glucose monitor (One Touch, Lifescan).  
6.4.13 Isolation of hepatic glycogen 
Liver glycogen was extracted from snap frozen and pulverized liver tissue. About 45-55 mg of tissue 
(exact values were noted down) were added to a 2 ml Eppendorf tube containing a stainless steel 
bead and 500 µl 30% Potassium Hydroxide. The tissue was homogenized using a tissue lyzer for 
three times 30 s at a frequency of 30 Hz. The solution was transferred into new tubes and incubated 
at 95°C for 1 h. For precipitation of the glycogen 1.4 ml of 95% ethanol was added and the tubes 
were placed at -20°C for at least 20 min. Following, the samples were centrifuged for 20 min at 
3000 g and the remaining glycogen pellet was washed with 1ml 95% ethanol. The glycogen pellets 
were dissolved in 250 µl H2O for 30 min at 37°C.  
For measuring liver glycogen content the dissolved glycogen was digested with amyloglucosidase. 
For that purpose 50 µl of the glycogen solution were mixed with of 250 µl of a 10-20 Units/ml 
amyloglucosidase solution (amyloglucosidase in sodium acetate). The mix was incubated at 37°C 
overnight with shaking. The sample was neutralized by adding 6 µl of Potassium Hydroxide.  
Liver glycogen was measure using the Glucose (HK) assay kit provided by Sigma-Aldrich. The assay 
was performed with 20 µl of glycogen digest according to the manufacturer’s instructions. For fed 
mice digests were diluted 1:4 prior to assaying. The glucose liver sample concentration was 
determined using a glucose standard curve. 
6.4.14 Fast protein liquid chromatography (FPLC)  
FPLC was used to separate serum proteins according to their size. The FPLC set-up consisted of a 
Superose 6 10/300 GL column (GE Healthcare), a fraction collector and an ÄKTA FPLC System 
(Amersham). During separation, a liquid phase, containing the mixture to be fractionated was 
pumped over a stationary resin of cross-linked agarose beads with varying surface structure. Certain 
proteins subsequently eluted at specific times in specific fractions. A pool of 200 μl serum plus 100 
µl PBS, from 4 animals, was injected into the machine, diluted in 25 ml PBS and fractionated into 
500 μl fractions. 40 μl of each fraction were subsequently used for cholesterol and TG analysis using 
the TG Liquicolor (Human GmbH, Germany) and Cholesterol determination kit (Randox, UK) 
respectively. Distinct VLDL and HDL peaks could be observed in specific fractions. 
 
6.5 Histochemistry  
6.5.1 Hemotoxylin and Oil red O 
During preparation of liver tissue, slices were embedded Tissue Tek OCT compound and shock 
frozen in liquid nitrogen. 5 μm cryosections were cut and fixed in Baker’s formol. Neutral lipids and 
TGs were stained with oil red O and nuclei were counterstained with hematoxylin. 
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6.6 Animal experiments 
6.6.1 General procedures 
The animals were housed according to international standard conditions with a 12 hrs dark, 12 hrs 
light cycle and regular unrestricted diet if not stated otherwise. Animal handling and 
experimentation was performed in accordance with NIH guidelines and approved by local 
authorities (Regierungspräsidium Karlsruhe). Blood was taken after cervical dislocation. Organs 
including liver, kidney, fat pads, and gastrocnemius muscles were collected, weighed, snap-frozen in 
liquid nitrogen and used for further analysis 
6.6.2 Obesity models  
8-12 week old ob/ob or db/db or mice were obtained from Charles River Laboratories (Brussels, 
BEL) and maintained on a 12 hrs light-dark cycle with regular unrestricted diet. In high-fat diet 
experiments, C57Bl6 mice were fed a high-fat diet (45% or 60% energy from fat, New Brunswick, 
USA) or low-fat control diet (10% energy from fat, New Brunswick, USA) for a period of 12-20 
weeks.  
6.6.3 Colon26 murine cachexia model  
For tumor induction in cachexia models, 1.5x 106 Colon 26 cells in PBS were injected 
subcutaneously into 10 week old Balb/c mice (Charles River Laboratories, Brussels). Control mice 
were injected with PBS. Mice were sacrificed approximately 2 weeks after injection. 
6.6.4 Methionine/choline deficiency studies 
For a methionine/choline deficiency study, mice at the age of 10 weeks were fed the MCD diet for 4 
weeks (Research diets) before sacrifice. 
6.6.5 Fasting and Refeeding  
For an extensive fasting and refeeding study, male C57Bl6 mice at the age of 13 weeks were used. 
Different groups of mice were fasted for 8 hrs, 24 hrs and 48 hrs, respectively, and subsequently 
refed for 1 hr, 6 hrs or 24 hrs before the sacrifice. 
6.6.6 Adenovirus injections 
For studies with knockdown of TSC22D1 by shRNA, 1-2 x109 plaque-forming units per recombinant 
adenovirus were administered via tail vein injection into male C57Bl6 at the age of 9-11 weeks. For 
studies with over expression of TSC22D1, 1x109 plaque-forming units per recombinant virus were 
administered via tail vein injection into male C57Bl6 at the age of 10 weeks .In each experiment, 5 
animals received identical treatments. Fasting was standardly conducted for 24 h and refeeding for 
6 h. 
6.6.7 AAV injections 
For studies with knockdown of TSC22D1 by miRNA, 5 x109 virus paricles per recombinant AAV were 
administered via tail vein injection into male C57Bl6 at the age of 9-11 weeks. In each experiment, 5 
animals received identical treatments. Fasting was standardly conducted for 24 h and refeeding for 
6 h. 
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6.6.8 TGF-beta injections  
For TGFbeta experiments, C57Bl/6 mice were injected intravenously with either 150 µl PBS or 5 µg 
human recombinant TGFbeta1 in 150 µl PBS and organs were taken 2, 8 or 24 h after injection. 
6.6.9 Blood serum  
Blood serum was obtained by incubation of blood samples at room temperature for 30 min and 
subsequent centrifugation for 1 hr at 3,000 rpm, 4°C. The serum (upper phase) was transferred to a 
new tube and stored at -80°C. 
6.6.10 VLDL clearance  
Blood was drawn from a fasted individual and human VLDL was isolated by ultracentrifugation as 
described (125). 3.5 ml serum were put in a polyallomer tube (SW40Ti) and mixed with 1.39 g KBr, 
over-layered with 3x2.8 ml of a NaCl/KBr solution (D= 1.063, 1.019 and 1.006 g/ml) and run for 18 
hours at 40,000 rpm. 20 μg of human VLDL were injected into each animal and serum samples were 
taken at 2, 10, 30, 60 and 120 min. Human ApoB-100 levels were measured using a human-specific 
ApoB ELISA. For the ELISA, a primary coating antibody generated against human ApoB-100 (mAb47, 
kindly supplied by J. Witztum, University of San Diego, USA), at a concentration of 2 μg/well and a 
secondary biotinylated polyclonal antibody raised in goat against human ApoB at a concentration of 
4 μg/well in 1.5% BSA/TBS/0.1% tween were used. To prevent non-specific binding, plates were 
blocked with 1.5% BSA/TBS/0.1% tween. Samples were diluted 25-fold. Absorbance was read 30 
min after addition of TMB and termination of the reaction with 2 M H2SO4 at 450 nm (P.H. Groot, 
1991). 
6.6.11 VLDL release  
VLDL production was determined after tyloxapol injection as described (S. Mandard, 2006). 
Tyloxapol is a Lipoprotein Lipase (LPL) inhibitor, meaning that, after administration, any secreted 
VLDL particles could not be cleared from the blood stream. One day before the experiment, 
tyloxapol was dissolved in saline to obtain a 20% w/v solution. Six C57BL/6J mice per group were 
fasted overnight for 16 hours. On the following day, before administration, 40μl of blood was drawn 
from each mouse by cutting the tip of the tail. The tyloxapol (20%) volume (in μl) applied per mouse 
was approx. 3 times that of the weight of the mouse in grams; i.e. a 25 g mouse received 75 μL of 
the 20% solution. Specified amounts were administered via the tail vein and 40 μL blood samples 
were taken every 50 min for 2.5 hours. The mice were sacrificed after 300 min. The serum TG values 
were determined and plotted against the time. 
 
6.7 Human subjects 
Normal liver tissue samples were obtained by open liver biopsy from 30 patients, 15 with and 15 
without cachexia, who underwent surgery for pancreatic ductal adenocarcinoma as described 
previously (M. E. Martignoni, 2009). The study was approved by the local ethics committee of the 
University of Heidelberg, Germany. All patients gave preoperative written informed consent for the 
use of their samples. 
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6.8 Statistical Analysis  
For each experiment means ± SEM were determined. Statistical analyses were performed using 
student’s t-test in one-factorial designs. Correlation was determined using Pearson’s correlation 
coefficient; F-test was applied to determine significance. For multifactorial study designs, Two-way 
ANOVA and TWO-way ANOVA RM were used when appropriate. Holm-Sidak post hoc was applied 
when significant differences were found with an overall significance level = 0.05. 
7 Material 
7.1 Solutions and Buffers 
All buffers were diluted in H20, unless otherwise stated. 
Name  Component  
2xBBS 280 mM NaCl  
50 mM BES  
1.5 mM Na2HPO4 pH 6.95  
2x SDS sample buffer  
 
120 mM Tris /HCl pH 6.8  
4% SDS  
20% glycerol  
200 mM DTT  
0.01% bromphenol blue  
5x SDS sample buffer  
 
250 mM Tris/HCl pH 6.8  
0.5 M DTT  
10 % SDS  
50 % glycerol  
0.01% bromphenol blue  
Block buffer  
 
1x PBS  
0.1% Tween 20  
5% milk powder  
CoIP Lysis buffer  
 
20 mM HEPES/KOH pH 7.4  
125 mM NaCl  
0.5 mM EDTA  
0.1% NP-40  
10% Glycerol  
Coomassie stain  
 
4 parts Coomassie Colloidal 
Blue  
1 part Methanol  
Destain for Coomassie stained 
gels  
25% Isopropanol  
10% Acetic acid  
Gly-Gly buffer  
 
25 mM Gly-Gly pH 7.8  
15 mM MgSO4  
4 mM EGTA  
HANKS I buffer 8 g NaCl  
0.4 g KCl  
3.57 g Hepes 
0.06 g KH2PO4  
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0.06 g Na2HPO4 x 2 H2O  
add 1L Distilled H2O  
2.5 mM EGTA  
0.1% Glucose  
pH 7.4 
HANKS II buffer 8 g NaCl  
0.4 g KCl  
3.57 g Hepes  
0.06 g KH2PO4  
0.06 g Na2HPO4 x 2 H2O  
add 1L Distilled H2O  
3 mg/ml Collagenase CLSII 5 
mM CaCl2  
0.1% Glucose  
pH 7.4 
LB medium  
 
10 g/l Trypton  
5 g/l Yeast extract  
10 g/l NaCl  
pH 7.0  
Oil Red O stock solution  
 
0.7 g Oil Red O  
200 ml Isopropanol  
Stirred overnight, sterile 
filtrated  
Luciferase Harvest Buffer  
 
100% Gly-Gly buffer;  
1% Triton X-100  
1 mM DTT  
Luciferase Assay Buffer  
 
20 mM K3PO4 pH 7.8  
80% (v/v) Gly-Gly buffer  
1.6 mM DTT  
2mM ATP  
Luciferase Luciferin Buffer  
 
1 mM Luciferin  
10 mM DTT in Gly-Gly buffer  
Oil Red O working solution  
 
6 parts Oil Red O stock 
solution  
4 parts H2O  
ONPG buffer  
 
0.1 M NaP pH 7.5  
1 mM MgCl2  
10 mM KCl  
1 mg/ml ONPG  
100 mM ß-mercaptoethanol 
(added freshly)  
Orange G loading dye (6x)  
 
10 mM EDTA  
70% Glycerol  
A pinch Orange G  
PBS (10x) 1.4 M NaCl  
27 mM KCl  
100 mM Na2HPO4  
8 mM KH2PO4  
pH 6.8 
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7.2 Oligonucleotides 
All oligonucleotides possessed a G/C content between 40% and 60% and were approximately 20-
30bp in length.  
Restriction sites for specific enzymes were added to the cloning primers in 5’→3’ orientation, 
allowing directed insertion into a specific target vector. Six thymidine residues were added to the 5’ 
ends of the restriction sites in order to facilitate cleavage. The primers were designed to hybridize 
at temperatures of approximately 60°C. 
 
Oligonucleotide Sequence 5’3´ 
TSC22D1 luc for 3 TTTTGCGGCCGCCACTCGAGCCAGCACCACCG 
TSC22D1 luc rev 3 TTTTAAGCTTTGGGGGACATGCGCAGAACG 
miTSC22D1 4.2  CTCACACGCTGTTCTCGCTTT 
Control miRNA AAATGTACTGCGCGTGGAGAC 
shTSC22D1 395 GCCATTTGATGTATGCGGTGA 
PBS-T  
 
1x PBS with 0.1 % Tween-20  
PBS-TOSH  
 
30.8 mM NaCl  
120.7 mM KCl  
8.1 mM Na2HPO4  
1.46 mM KH2PO4  
10 mM MgCl2  
pH 7.2, sterile filtrated  
Proteinase K lysis buffer  
 
10 mM Tris pH 8.0  
100 mM NaCl  
15 mM EDTA  
1 % SDS  
SDS gel fixation buffer  
 
25% Isopropanol  
10% Acetic acid  
SDS running buffer (10x)  
 
0.25 M Tris  
1.92 M Glycin  
1% SDS  
Supplement buffer  
 
1.5 M NaCl  
10 % NP-40  
TBE buffer (10x)  
 
100 mM Tris  
1 mM EDTA  
90 mM Boric acid  
pH 8.0  
TE buffer (10x)  
 
1 mM EDTA  
10 mM Tris HCl  
pH 8.0  
Transfer buffer  
 
25 mM Tris  
192 mM Glycin  
20% Methanol  
0.01% SDS  
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Control shRNA GATCTGATCGACACTGTAATG  
 
7.3 Antibodies 
Primary Antibody Dilution Isotype Distributor 
Actin 1:1000 Mouse Santa Cruz #A5441 
ApoB 1:1000 Rabbit Santa Cruz, Sc-11795 
Akt 1:1000 Rabbit Cell Signaling, 9272 
phophoAkt 1:1000 Rabbit Cell Signaling, 9271 
Flag M2 1:1000 Mouse Sigma, #A8592 
Foxo 1:1000 Rabbit Cell Signaling, 9454 
phosphoFoxo 1:1000 Rabbit Cell Signaling, 9465 
VCP 1:10000 Mouse Abcam #ab11433 
 
TSC22D1 antibody was generated from Eurogentec in rabbit and was used as 1:200 dilution from 
serum.  
Secondary Antibody  Dilution  Isotype  Distributor 
Anti-mouse IgG-HRP 1:5000 Goat BioRad, Munich 
Anti-rabbit, IgG-HRP 1:5000 Goat BioRad, Munich 
Anti-goat, IgG-HRP 1:10000 Donkey Sigma, #sc2020 
 
7.4 Kits 
Kit  Distributor  
BLOCK-iTTM U6 RNAi Entry Vector Kit Invitrogen, Karlsruhe 
BLOCK-iTTM Adenoviral RNAi Expression System Invitrogen, Karlsruhe 
BLOCK-iTTM Pol II miR RNAi Expression Vector Kit Invitrogen, Karlsruhe 
Cholesterol determination Kit Randox, Crumlin, UK 
Enhanced Chemiluminescence (ECL) Kit  Amersham Biosciences, Freiburg  
First Strand cDNA Synthesis Kit  Fermentas, St. Leon-Rot  
Ketone bodies Determination Kit Wako, Neuss 
NEFA – C Determination Kit  Wako, Neuss  
Phusion Polymerase Kit Finnzymes, Vantaa  
Platinum® Quantitative PCR Supermix Invitrogen, Karlsruhe 
PureLink HiPure Plasmid FP Maxiprep Kit  Invitrogen, Karlsruhe  
Qiaprep Plasmid Miniprep Kit  Qiagen, Hilden  
Qiaquick Gel Extraction Kit  Qiagen, Hilden  
QIAGEN Plasmid Mega Kit Qiagen, Hilden 
Qiaquick PCR Purification Kit  Qiagen, Hilden  
RNeasy RNA Extraction Kit Qiagen, Hilden 
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TGF-beta 1 Quantikine ELISA Kit  R&D Systems 
TN T T7/T3 Coupled Reticulocyte Lysate System Promega, Mannheim 
Triglycerides Determination Kit  Sigma-Aldich Chemicals GmbH, Steinheim  
Triglycerides Liquicolour Human GmbH Wiesbaden  
 
7.5 Software  
Sofware Distributor 
AxioVS40x64 V4.8.3.0 Carl Zeiss, Göttingen 
BLAST  http://www.ncbi.nlm.nih.gov 
Cell Profiler http://www.cellprofiler.org 
Endnote Thomson, Carlsbad, USA 
Geneious Auckland, New Zealand 
GraphPad GraphPad Software Inc., La Jolla, USA 
Illustrator Adobe, San Jose, USA 
ImageJ Wayne Rasband, NIH, USA  
Image Lab Bio-Rad Laboratories 
Microsoft Office Microsoft, Unterschleißheim  
Photoshop Adobe, San Jose, USA 
Pubmed http://www.pubmedcentral.nih.gov 
Quantity One Bio-Rad, Munich 
StepOne Plus Applied Biosystems, Darmstadt System Software 
 
7.6 Consumables 
Consumable  Distributor 
1-stack cell culture dishes Sigma, Munich 
10-stack cell culture dishes  Sigma, Munich 
12-well tissue culture dishes Corning Inc., NY, USA 
6 well tissue culture dishes Falcon, Gräfeling-Lochham 
96 well MicroAmp plates Applied Biosystems 
96-well Microtiter® luminescense plates  Nunc, Wiesbaden 
Amersham HybondTM-P GE Healthcare, Freiburg 
Cell scrapers (Costar)  Corning Inc., NY, USA 
Centrifuge tubes (35 ml) Beckmann, Munich 
Cover slips Carl Roth GmbH, Karlsruhe 
Cryo tubes (2 ml) Cryo tubes (2 ml) 
Dialysis tubing Carl Roth GmbH, Karlsruhe 
Disposable scalpels Feather, Cuome, JP 
DNase / RNase free water  Invitrogen, Karlsruhe 
Filters (0.22 μm) Millipore, Eschborn 
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Filters (0.45 μm Millipore, Eschborn 
Gel staining boxes (Mini) Carl Roth GmbH, Karlsruhe 
Gloves (Gentle Skin) Meditrade, Kiefersfelden 
Gloves (Safe Skin Purple Nitrile) Kimberly Clark, BE 
Hyperfilm ECL  Amersham, Freiburg  
Immobilized streptavidin beads Pierce Biotech., Rockford, USA 
Micro test tubes (1.5 ml, 2 ml) Steinbrenner, Wiesenbach 
Mouth protection Meditrade, Kiefersfelden 
Nitrocellulose membrane Schleicher and Schüll, Dassel 
Parafilm Pechinery Inc., Wisconsin, USA  
Pasteur pipettes Brand, Wertheim 
PCR tubes (200 μl) Eppendorf, Hamburg  
Petri dishes Greiner, Kremsmünster, AU 
Pipette tips (0.1 – 1000 μl) Starlab, Helsinki, FI 
Pipette tips (0.1 – 1000 μl) (Tip One Filter Tips) Starlab, Helsinki, FI 
Polyallomer tubes (25mm x 89 mm) Beckmann, Munich 
Polyallomer tubes Beckmann, Munich 
Rabbit IgG-agarose Sigma, Munich 
Safelock micro test tubes (1.5 ml and 2 ml) Eppendorf, Hamburg 
Saran cling film Dow Chem. Co., Schwalbenbach 
Serological pipettes (5 ml, 10 ml, 25 ml, 50 ml) BD Biosciences, San Jose, USA 
Syringes (10 ml Luer Lock) Terumo, Leuven 
Syringes (50 ml) Terumo, Leuven 
Test tubes (15 ml and 50 ml) Falcon, Gräfeling-Lochham 
Tissue culture dishes (10 cm and 15 cm) Falcon, Gräfeling-Lochham 
Vivaspin Concentrator Vivaspin Concentrator 
Whatman paper Whatman Int., UK 
7.7 Chemicals and Reagents 
Chemical/Reagent Distributor 
Acetic acid (99%)  Sigma, Munich  
Acetone Sigma, Munich  
Acrylamide-bisacrylamide Solution (37.5 : 1) Carl Roth GmbH, Karlsruhe 
Adenosine triphosphate (ATP) Sigma, Munich 
Agarose Sigma, Munich 
Ammonium persulfate (APS) Carl Roth GmbH, Karlsruhe 
Antibiotics Sigma, Munich 
Bovine serum albumin (BSA) Sigma, Munich 
Bromophenol blue Sigma, Munich 
Chloroform  DKFZ 
Collagenase Type ll Sigma, Munich 
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Desoxynucleotides (dATP, dCTP, dGTP, dTTP) Roche, Mannheim 
Dexamethasone Sigma, Munich  
DMSO (Dimethyl sulfoxide) Sigma, Munich  
DOTAP Liposomal Transfection Reagent Sigma, Munich  
DTT (Dithiothreitol) Sigma, Munich 
Dulbecco’s modified Eagle’s medium (DMEM) Invitrogen, Karlsruhe 
EDTA (Ethylenediaminetetraacetic acid) Sigma, Munich 
EGTA (Ethylenglycoltetraacetic acid) Sigma, Munich 
Ethanol (99%) DKFZ 
Ethidium bromide Carl Roth GmbH, Karlsruhe 
Fetal calf serum (FCS) Invitrogen, Karlsruhe 
Formaldehyde DKFZ 
Forskolin  Sigma, Munich 
Gene Ruler 1kb DNA Fermentas, St. Leon Rot 
Glucose Sigma, Munich 
Glutathione sepharose Amersham, Darmstadt 
Glycerol Baker, Deventer, NL 
Gly-Gly Sigma-Aldrich, Munich 
Hepes Roth, Karlsruhe 
Hydrochloric acid (HCl) 37% Acros Organics, New Jersey, USA 
Hyperfilm ECL Western Blotting Detection 
Reagents  
Amersham, Freiburg 
Igepal (Nonidet NP40) Sigma, Munich 
IBMX Sigma, Munich 
Insulin human (recombinant yeast) Sigma, Munich 
Isopropyl-β-D-thio-galactopyranoside (IPTG) Sigma-Aldrich, Munich 
Isopropanol Sigma, Munich 
LB-Agar Carl Roth GmbH, Karlsruhe 
LB-Medium Carl Roth GmbH, Karlsruhe 
Lipofectamine2000 Reagent Invitrogen, Karlsruhe 
Loading dye solution (6x) Fermentas, St. Leon Rot 
Luciferin Sigma, Munich 
Magnesium chloride (MgCl2) Merck, Darmstadt 
Magnesium sulfate (MgSO4) Sigma, Munich 
Methanol (100%) Merck, Darmstadt 
Methionine (35S radiolabelled) Perkin Elmer, Rodgau 
Milk powder Rapilait Migros, Lörrach, CH 
Non-essential amino acids Invitrogen, Karlsruhe 
Oil Red O Sigma, Munich 
o-Nitrophenyl-β-D-galactopyranosid (ONPG) Sigma, Munich 
optiMEM Invitrogen, Karlsruhe 
Orange G Sigma, Munich 
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Page Ruler Prestained Protein Ladder Fermentas, St. Leon Rot 
Penicillin / Streptomycin (P/S)  Invitrogen, Karlsruhe 
Phosphatase Inhibitor Cocktail Sigma, Munich  
Platinum qPCR SuperMix Invitrogen, Karlsruhe 
Ponceau-S Solution Sigma, Munich  
Potassium chloride (KCl) Sigma, Munich 
Proteinase inhibitor cocktail Roche, Penzberg 
Qiazol Lysis Reagent Qiagen, Hilden 
RiboLock Ribonuclease Inhibitor Fermentas, St. Leon Rot 
Sodium chloride (NaCl) Invitrogen, Karlsruhe 
Sodium dodecyl sulfate (SDS) Gerbu, Biotechnik GmbH, Gaiberg 
Sodium fluoride (NaF) Sigma, Munich 
Sodium hydroxide (NaOH) Sigma, Munich 
Sodium orthovandate Sigma, Munich 
N,N,N’,N’-Tetramethylenediamine (TEMED) Carl Roth GmbH, Karlsruhe 
Tripotassium phosphate (K3PO4) Merck, Darmstadt 
Tris base Sigma, Munich  
Triton X-100 Sigma, Munich 
Trypsin-EDTA solution Invitrogen, Karlsruhe 
Tween-20 Sigma, Munich 
Urea  Sigma, Munich 
β-Mercaptoethanol (98%) Sigma, Munich 
Williams Medium E  Sigma, Munich 
 
7.8 Instruments 
Instrument Distributor 
Analytical scales Satorius, Göttingen 
Bacterial shaker Infors AG, Böttmingen, CH 
Centrifuge (2K15) Sigma, Munich 
Centrifuge (Biofuge fresco) Heraeus, Hanau 
Centrifuge (Biofuge pico Heraeus, Hanau 
Centrifuge (Function Line) Heraeus, Hanau  
Centrifuge (Micro 22R)  Hettich GmbH & Co, Tuttlingen 
Centrifuge (Super T21)  Heraeus Sorvall, Langenselbold 
ChemiDoc BioRad, Munich 
CO2-incubator Sanyo, Munich 
CO2-incubator (Forma Scientific) Labotect, Göttingen 
CO2-incubator (Forma Scientific) Labotect, Göttingen 
Countess Cell counter Invitrogen, Karlsruhe 
Electrophoresis chamber Steinbrenner, Wiesenbach 
Material 
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Electrophoresis power supply (Power Pack Basic) BioRad, Munich 
Electrophoresis power supply (Power Pack HC) BioRad, Munich 
Film cassette Amersham, Freiburg 
Film developer Amersham, Freiburg 
Freezer, -20°C  Liebherr, Biberach 
Freezer, -80°C (Hera Freeze) Heraeus, Heilbronn 
Fridge, 4°C Liebherr, Biberach  
Gel imager Intas, Göttingen 
Heat block (Thermostat Plus) Eppendorf, Hamburg  
Horizontal shaker (Duomax 1030) Heidolph, Kehlheim 
Hotplate / stirrer VWR, Darmstadt 
Incubator (Function Line) Heraeus, Hanau 
Microscope (Axio Imager M2) Carl Zeiss, Göttingen 
Microwave Bosch, Stuttgart 
Multistep pipette Eppendorf, Hamburg 
Neubauer counting chamber Carl Roth GmbH, Karlsruhe 
Nitrogen tank Thermo Electron corp., Erlangen 
pH-meter VWR, Darmstadt 
Photometer (NanoDrop ND-1000) Peqlab Biotechnology, Erlangen 
Pipettes (2 μl, 10 μl, 20 μl, 100 μl, 200 μl, 1000 μl) Gilson, Middleton, USA 
Pipettes (20 μl, 200 μl, 1000 μl) Eppendorf, Hamburg 
Real time PCR System StepOne Plus Applied Biosystems, Darmstadt 
Rotating wheel Neolab, Heidelberg 
Scale Kern und Sohn GmbH, Balingen 
Scale (BL 1500 S) Satorius, Göttingen 
Scanner Epson, Meerbusch 
SDS electrophoresis chambers BioRad, Munich 
Sonicator BioruptorTM Diagenode, Liège, Belgium 
Stand Carl Roth GmbH, Karlsruhe 
Sterile benches (Class II type A/B3) Sterilgard, Sanford, USA 
Tabletop centrifuges (Mini Spin Plus) Eppendorf, Hamburg 
Thermocycler (PTC-200) Biozym, Oldendorf 
Tissue Lyser Qiagen, Hilden 
Ultracentrifuge (Sorvall WX Ultra 80) Thermo Scientific, Osterode 
Vacuum pump Neolab, Heidelberg 
Vortex mixer (REAX 2000) Heidolph, Kehlheim 
Water bath Neolab, Heidelberg 
Western Blot Chamber BioRad, Munich 
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8 Glossary  
AAV Adeno-associated virus 
ABC ATP binding cassette 
Abd Abdominal 
ACLY ATP citrate lyase 
ANGPTL Angiopoietin related 
Apo Apoliporotein 
ATP Adenosine triphosphate 
BMI Body mass index 
Bp Base pairs 
C Celsius 
C26 Colon 26 
CD Cluster of Differentiation 
CE Cholester-ester 
CETP Cholesterylester transfer protein 
CIDE cell death–inducing DNA fragmentation factor-α-like effector 
CMV Cytolomegavirus 
CNP C-type natriuretic peptide 
CVD Cardiovascular Disease 
Cyp7 Cholesterol 7 alpha-hydroxylase 
DBD DNA binding domain 
DGAT Diglyceride acyltransferase 
DMEM Dulbeccos’s modified eagle medium 
DNA Deoxyribonucleic acid  
dNTP deoxyribonucleotide triphosphates 
ECL Enhanced chemiluminescence 
EGFP Enhanced green fluorescent protein 
ELISA Enzyme-linked immunosorbent assay   
ER Estrogen receptor 
FA Fatty acids 
FABP Fatty acid binding protein 
FASN Fatty acid synthase 
FCS Fetal calf serum 
Fig Figure 
FoxO1 Forkhead box protein O1 
Glossary 
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FPLC Fast protein liquid chromatography 
GC Gastrocnemius muscle 
GPS2 G protein pathway suppressor 2 
GR Glucocorticoid 
GSEA Gene set enrichment analysis 
GST Glutathion-S-Transferase 
h Hour 
HDAC Histone Deacetylase 
HDL High density lipoprotein 
HFD High fat diet 
HL Hepatic lipase 
HRP Horseradish peroxidase 
IDL Intermediate density lipoprotein 
Ing Inguinal  
LB Ludmilla Broth 
LBD Ligand binding domain 
LCAT Lecithin cholesterol aclytransferase 
LDL Low density lipoprotein 
LDLR LDL receptor 
LFD Low fat diet 
LPIN Lipin 
LPL Lipoprotein lipase 
LRP LDL receptor related protein 
LSR Lipolysis stimulated lipoprotein receptor 
LXR Liver X receptor 
MCD Methionine choline deficient diet 
Min Minute 
miRNA microRNA 
mRNA Messenger RNA 
MTTP Microsomal transfer protein 
NAA Non-essential amino acids 
NC Negative control 
NCoR Nuclear receptor co-repressor 
NEFA Non-esterified fatty acids 
NES Nuclear export signal 
Glossary  
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NR Nuclear receptor 
OE Overexpression 
ONPG o-Nitrophenyl-β-D-galactopyranosid 
PBS Phosphate buffered saline 
PGC PPARgamma co-activator 
PLIN Perilipin 
PLTP Phospholipid transfer protein 
PPAR peroxisome proliferator-activated receptors 
PVDF Polyvinylidenfluorid 
qPCR Quantitative polymerase chain reaction 
RCT Reverse cholesterol transport 
RIP Receptor interaction protein 
Rpm Rounds per minute 
RT Room temperature 
RXR Retinoid X receptor 
SCD1 Stearoyl-CoA desaturase 1 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
shRNA Short hairpin RNA 
SMRT Silencing mediator of retinoic acid and thyroid hormone receptor 
SR-B1 Scavenger receptor B1 
STZ Streptozotocin 
TBL1 Transducin beta like 1  
TBLR1 Transducin beta like 1 related 
TCID Tissue culture infection dose 
TG Triglyceride 
TGF Transforming growth factor beta 
TRIB Tribbles 
TSC22D1 Transforming growth factor beta1-stimulated clone 22 D1 
UV Ultra Violet 
VCP Valosin-containing protein 
VLDL Very low density lipoprotein 
WHO World health organization 
wt Wildtype 
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9 Figures and Tables  
9.1 Figures 
Fig 1: Emerging obesity. 3 
Fig 2: The metabolic syndrome. 5 
Fig 3: Schematic representation of the general structure of a lipoprotein 8 
Fig 4: Schematic representation of exogenous and endogenous lipid metabolism 10 
Fig 5: Schematic representation of HDL metabolism and reverse cholesterol transport in humans 12 
Fig 6: Schematic representation of nuclear receptor structure 14 
Fig 7: Schematic diagram of transcriptional repression or activation by nuclear receptors and co-
regulators 16 
Fig 8: TSC22D1 co-precipitates with TBL1 in Flag co-immunoprecipitation studies 20 
Fig 9: TSC22D1 expression is strongly downregulated by fasting. 21 
Fig 10: TSC22D1 expression is reduced in mice on methionine choline deficient diet. 22 
Fig 11: TSC22D1 expression correlates with the degree of cachexia in patients and mice. 23 
Fig 12: TSC22D1 expression is increased in mice on a high fat diet. 24 
Fig 13: TSC22D1 expression is increased in obese mice. 25 
Fig 14: TSC22D1 expression is reduced in old mice. 25 
Fig 15: TSC22D1 expression is induced by TGF-β1 stimulation. 26 
Fig 16: Cloning of adenoviral expression construct for TSC22D1 knockdown. 28 
Fig 17: ShRNA mediated knockdown of TSC22D1. 29 
Fig 18: Body, liver and abdominal fat weight are not affected by TSC22D1 knockdown. 30 
Fig 19: Glycogen and blood glucose are unaltered by TSC22D1 knockdown. 31 
Fig 20: Serum triglycerides are significantly reduced by TSC22D1 knockdown. 32 
Fig 21: TSC22D1 knockdown lowers circulating VLDL triglycerides and HDL cholesterol. 34 
Fig 22: LPL activity is not affected by TSC22D1 knockdown. 35 
Fig 23: TSC22D1 knockdown does not alter VLDL secretion by the liver. 35 
Fig 24: TSC22D1 knockdown increases VLDL triglyceride clearance. 36 
Fig 25: TSC22D1 knockdown does not alter pFoxo levels. 37 
Fig 26: TSC22D1 knockdown results in decreased expression of key genes involved in cholesterol 
metabolism. 39 
Fig 27: Hepatic overexpression of TSC22D1 in fasted and refed mice. 41 
Fig 28: Body, liver and abdominal fat weight are not affected by TSC22D1 overexpression 42 
Fig 29: Glycogen and blood glucose are unaltered by TSC22D1 overexpression. 43 
Fig 30: Serum parameters are unchanged by TSC22D1 overexpression 44 
Fig 31: TSC22D1 overexpression increases circulating VLDL triglycerides and HDL cholesterol. 45 
Fig 32: TSC22D1 overexpression induces FSP27 and ABCG1 expression. 46 
Fig 33: Cloning of AAV miRNA expression construct for long term TSC22D1 knockdown 47 
Fig 34: AAV mediated TSC22D1 knockdown. 48 
Fig 35: Chronic TSC22D1 knockdown reduces liver weight. 49 
Fig 36: Serum ketone bodies are reduced by long term TSC22D1 knockdown. 50 
Fig 37: Long term TSC22D1 knockdown lowers circulating HDL cholesterol. 50 
Fig 38: Chronic TSC22D1 knockdown alters expression of cholesterol metabolism genes. 51 
Fig 39: Gene expression profiling of C57BL/6J mice treated with control or TSC22D1 AAV. 53 
Fig 40: TSC22D1 knockdown reduces ApoA1 expression. 53 
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Fig 41: AAV mediated TSC22D1 knockdown. 54 
Fig 42: No change of body weight, blood glucose or liver weight by TSC22D1 knockdown. 55 
Fig 43: No change in circulating TGs by TSC22D1 knockdown in ob/ob mice. 56 
Fig 44: TSC22D1 knockdown in ob/ob mice lowers circulating HDL cholesterol. 57 
Fig 45: TSC22D1 knockdown reduces expression of cholesterol metabolism genes. 58 
Fig 46: Altered cholesterol metabolism by reduced TSC22D1 expression. 62 
Fig 47: Putative TSC22D1 action on nuclear receptor LXR. 67 
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11 Appendix 
11.1 The role of HIPK2 in liver metabolism 
Initially, the role of the serine/threonine kinase homeodomain-interacting protein kinase 2 (HIPK2) 
in liver metabolism was investigated for this thesis. In course of the work we unexpectedly, 
encountered several technical problems which lead to the decision to halt this project. The work 
was continued with the studies described in the main body of the thesis. In the following the main 
results obtained from the HIPK2 project will be presented.  
11.2 Gene expression analysis for HIPK2 
To assess if HIPK2 expression is deregulated in mouse models of metabolic stress and disease 
conditions, liver samples were taken and analyzed in regard to HIPK2 expression.  
11.2.1 HIPK2 expression is not changed in the New Zealand Obese mouse model 
The New Zealand Obese (NZO) mouse represents a polygenic model of diabetes. To determine if 
HIPK2 expression is influenced by the obese phenotype, hepatic RNA was isolated and HIPK2 mRNA 
expression was analyzed. A difference in HIPK2 expression between NZO and the respective control 
strain New Zealand Black (NZB) could not be detected (Fig A1). 
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Fig A1: HIPK2 expression is not changed diabetic New Zealand Obese (NZO) mice. Liver mRNA levels of HIPK2 
in lean New Zealand Black (NZB) and diabetic New Zealand Obese (NZO) were determined by qPCR. (n=6), 
(means ± SEM). 
 
11.2.2 HIPK2 expression is not changed in mice fed a high fat diet 
By feeding mice a high fat diet over the course of several weeks the onset of obesity can be 
modeled. In this experiment mice were fed either a high fat diet containing 60% energy from fat or 
a control low fat diet containing 10% energy from fat over a 9 week period. Hepatic HIPK2 
expression levels were determined (Fig A2). HIPK2 expression was slightly but not significantly lower 
in mice fed the high fat diet.  
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Fig A2: HIPK2 expression is not changed by high fat diet. Liver mRNA levels of HIPK2 in mice fed either a high 
fat diet (HFD) or a control low fat diet (LFD) were determined by qPCR. (n=3), (means ± SEM). 
 
11.2.3 HIPK2 expression is not changed in mice fed a methionine and choline deficient 
diet 
Mice fed with a diet lacking methionine and choline (MCD), encounter dramatic weight loss and 
develop severe hepatic steatosis and have low serum TG levels. To determine if HIPK2 expression is 
altered by this conditions hepatic RNA was isolated and HIPK2 mRNA expression was analyzed. A 
difference in HIPK2 expression between mice fed MCD diet or mice fed a control diet (CD) could not 
be detected (Fig A3). 
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Fig A3: HIPK2 expression is not changed by methionine choline deficient diet. Liver mRNA levels of HIPK2 in 
mice fed a methionine choline deficient diet (MCD) or a control diet (CD) were determined by qPCR. (n=3), 
(means ± SEM). 
 
11.2.4 HIPK2 expression is reduced upon fasting 
To test if HIPK2 expression is regulated in response to nutritional restriction, mice were fasted for 
24 hours. After starvation, one group of animals was sacrificed immediately and the other mice 
were fed for 4 hours, 6 hours or 24 hours. Hepatic HIPK2 mRNA expression was determined by 
quantitative PCR (Fig A4). HIPK2 levels were significantly reduced (~70%) in livers of mice after 24h 
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of fasting compared to mice which had been refed for 24 hours. Also 4 hours after refeeding HIPK2 
expression was still significantly lower.  
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Fig A4: HIPK2 expression is downregulated by fasting. Liver mRNA levels of HIPK2 in mice fasted for 24 hours 
and either directly sacrificed or refed for 4 hours, 6 hours or 24 hours were determined by qPCR. (n=5), (means 
± SEM). (**) indicates significance p≤0.01  
 
11.2.5 HIPK2 levels are increased in lipopolysaccharide-induced sepsis 
Injection of bacterial lipopolysaccharides (LPS) into mice stimulates an acute septic shock and leads 
to systemic inflammation and increased lipolysis. Mice were starved over night and subsequently 
injected intraperitoneally with either LPS at a dose of 20 mg/kg body weight or with PBS as a 
control. 8 hours after injection, mice were sacrificed. HIPK2 levels were more than 2-fold higher in 
LPS injected mice, compared to PBS injected mice (Fig A5). 
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Fig A5: HIPK2 expression is upregulated by LPS treatment. Liver mRNA levels of HIPK2 in mice injected with 
LPS or PBS injected control mice were determined by qPCR. (n=6), (means ± SEM). (***) indicates significance 
p≤0.001  
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11.3 Hepatic HIPK2 manipulation in vivo 
In order to investigate the role of hepatic HIPK2 in an in vivo setting an adenovirus expressing a 
short hairpin RNA (shRNA) against HIPK2 was cloned and produced.  
11.3.1 Adenovirus expressing HIPK2-specific shRNA reduces HIPK2 mRNA levels in 
HEPA1c1 cells 
Prior to in vivo use, the generated adenovirus expressing shRNA specifically targeting HIPK2 was 
tested in HEPA1c1 cells. For this purpose, cells were infected with different doses (MOI) of either 
HIPK2-specific or a scrambled shRNA as control. The knockdown efficiency was assessed by qPCR. 
HIPK2 mRNA levels could be ~80% downregulated with a virus dose of 25 MOI or higher (Fig A6). 
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Fig A6: Adenovirus expressing HIPK2-specific shRNA reduces HIPK2 mRNA levels in HEPA1c1 cells. 
Hepa1c1 cells were left uninfected or were transduced with control or shHIPK2. Cells were harvested 
after 24h and HIPK2 mRNA levels determined by qPCR. (n=3), (means ± SEM).  
 
11.3.2 Negative control adenovirus significantly reduces HIPK2 gene expression 
In order to investigate the function of hepatic HIPK2 in an in vivo setting 10 week old C57BL/6J mice 
were injected via the tail vein with 1x109, 2.5x109 or 5x109 viral particles expressing either a 
scrambled shRNA sequence or HIPK2 targeting sequence or phosphate buffered saline (PBS). Mice 
were given free access to food and considered random fed. Seven days after injection the animals 
were sacrificed. Liver was collected and shock frozen, additionally, serum was taken for further 
analysis. HIPK2 knockdown efficiency was assessed at mRNA level by qPCR (Fig A7). HIPK2 specific 
shRNA reduced HIPK2 expression levels by 60-80% compared to the PBS control in a dose 
dependent manner. Unexpectedly, HIPK2 gene expression was up to 80% reduced by the negative 
control virus as well. Thus, the adenovirus system could not be used for HIPK2 in vivo studies. The 
obtained samples were analyzed for changes in serum triglyceride, non-esterified fatty acid or 
ketone bodies. No differenced were seen between the groups (data not shown).  
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Fig A7: Negative control adenovirus reduces expression of hepatic HIPK2. C57BL/6J mice were injected via 
the tail vein with 1x109, 2.5x109 or 5x109 viral particles expressing either a scrambled shRNA sequence or 
HIPK2 targeting sequence or phosphate buffered saline (PBS). Hepatic HIPK2 mRNA levels were determined by 
qPCR. (n=3-4), (means ± SEM).  
11.3.3 SiRNA mediated hepatic HIPK2 kockdown 
As adenoviral mediated shRNA delivery could not be used as a method for HIPK2 knockdown, we 
tested the application of siRNAs in vivo. For that purpose, 10 week old C57BL/6J mice were injected 
intravenously with 7 mg/kg body weight siRNA targeting HIPK2, a scrambled control or PBS. Mice 
were given free access to food and considered random fed. Two, five and seven days after injection 
a group of animals were sacrificed. Liver was collected and shock frozen, additionally, serum was 
taken for further analysis. Hepatic HIPK2 mRNA levels were determined by qPCR. SiRNAs targeting 
HIPK2 could reduce HIPK2 expression by 60-70%, two and five days after transfection (Fig A8). The 
knockdown was however lost on day 7 as compared to the negative controls. Here, the negative 
control did not affect HIPK2 expression. The obtained samples were analyzed for changes in serum 
triglyceride, non-esterified fatty acid or ketone bodies. No differenced were seen between the 
groups (data not shown). Also abdominal adipose tissue, inguinal adipose tissue, kidney and 
intestine were analyzed for changes in HIPK2 gene expression. No differences were detected (data 
not shown).  
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Fig A8: SiRNA mediated hepatic HIPK2 knockdown. 10 week old C57BL/6J mice were injected intravenously 
with 7 mg/kg body weight siRNA targeting HIPK2, a scrambled control or PBS. Day of sacrifice after injection is 
indicated. Hepatic HIPK2 mRNA levels were determined by qPCR. (n=3), (means ± SEM).  
 
11.4 Concluding remarks 
Unexpectedly, treatment of C57BL/6 mice with negative control adenovirus resulted 
downregulation of HIPK2 gene expression that was nearly as strong as seen for the HIPK2 specific 
shRNA, when compared to PBS injected animals. Application of siRNA could specifically 
downregulate HIPK2 expression for up to 5 days, but the effect was gone on day 7, which only 
provides a very limited time frame for in vivo experiments. A further problem that occurred was 
that HIPK2 protein levels could not be detected in the liver with all available antibodies. Even a 
specifically generated antibody (Vera Greiner, Hoffman Lab), failed to detect endogenous HIPK2. 
Consequently, we decided to stop the study about HIPK2 function in liver. 
 
11.5 Materials and Methods 
In the following only material and methods that are not listed in the main body of the thesis will be 
named.  
 
11.5.1 Methods 
SiRNA injections 
For siRNA studies Silencer®siRNA from life technologies was used. SiRNA was mixed with 
Invivofectamine®2.0 Reagent from life technologies according to the manufactures protocol. Mice 
were intravenously injected with 7 mg/kg body weight siRNA or PBS. The animals were housed 
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according to international standard conditions with a 12 hrs dark, 12 hrs light cycle and regular 
unrestricted diet.  
 
11.5.2 Material 
SiRNA 
Sequence siHIPK2: 5’3’ GGAAGGGAGUGACAUGUUAUU 
As negative control siRNA #1 from life technologies was usedd 
 
shRNA 
Sequence shHIPK2: 5’3’ GGACACATAGTTGTAACATCA 
Sequence negative control: 5’3’ GATCTGATCGACACTGTAATG 
  
 
